






247 Pharmacotherapy Considerations in CKD Patients With 
COVID-19, A Narrative Review
Dashti-Khavidaki S, Khalili H, Nourian A
Dialysis
256 Effects of Carvedilol on Cardiovascular Events and 
Mortality in Hemodialysis Patients, A Systematic Review 
and Meta-Analysis
Tan Z, Ke G, Huang J, Yang D, Pi M, Li L, Liu X, Tao S, 
Chen L, Liang G, Liu S
ORIGINAL PAPER
Kidney Disease
267 Clinical and Radiologic Characteristics of COVID-19 in 
Patients With CKD
Abrishami A, Khalili N, Dalili N, Khaleghnejad Tabari R, 
Farjad R, Samavat S, Neyriz Naghadehi A, Haghighatkhah H, 
Nafar M, Sanei-Taheri M
278 Urinary System and Renal Involvement in Children With 
Cystic Fibrosis
Esfandiar N, Khanbabaee G, Riazi Kermani K
Dialysis
282 High Neutrophil/Lymphocyte Ratio as an Independent 
Risk Factor for the First Occurrence of Stroke in 
Peritoneal Dialysis Patients
Guo G, Zeng Y, Chen Q, Zhan X, Long H, Peng F, Zhang F, 
Feng X, Zhou Q, Wu X, Peng X, ETNA, Lai X, Zhang Y, 
Wang Z, Wen Y, Liang J
290 The Effects of Nano-curcumin on Metabolic Status in 
Patients With Diabetes on Hemodialysis, a Randomized, 
Double Blind, Placebo-controlled Trial
Aghadavod E, Bahmani F
Transplantation
300 The  Added Value of Trabecular Bone Score in Fracture 
Risk Assessment of Kidney Transplant Recipients
Malakoutian T, Mirzaei A, Shiroudbakhshi A, Amini Kadijani A, 
Tehrani-Banihashemi A, Zabihiyeganeh M
BRIEF COMMUNICATION
Kidney Disease
308 The Prevalence of Renal Scars Among Infants Under 
One-year Old With a First UTI With or Without VUR in 
Qom, Iran, 2017
Akhavan Sepahi M, Toloii F, Arsang Jang S, Hoseini BL
CASE REPORT
Kidney Disease
312 Proteinuria in Two Sisters With Beaulieu-Boycott-Innes 
Syndrome, A Case Report
Hassanvand Amouzadeh M, Akhavan Sepahi M, Abasi E
Dialysis
315 Peritoneal Dialysis in Extremely Obese Patient From 
Palestine, A Case Report
Hamdan Z, Tarabeih M, Jebrin K, Khazneh E, Abusalameh E, 
Nuairat H, Sawalmeh O
Transplantation
318 Late Acute Cellular Rejection After Anakinra Treatment in 
a Kidney Transplant Patient, Is It a Coincidence?
Haci Yeter H, Yetkin N, Faruk Akcay O, Derici U, Arinsoy T
LETTER
321 Surveillance and Isolation Based Strategies to Prevent 
COVID-19 in a Dialysis Center of Tehran, a Customized 
Approach
Najafi MT, Abbasi MR, Dehghan Manshadi SA, 
Rahimzadeh S, Shojamoradi MH
323 Comment: Newly Diagnosed Glomerulonephritis During 
COVID-19 Infection Undergoing Immunosuppression 
Therapy, a Case Report
Mubarak M, Tolouian R, Kowalewska J, Nasri H
326 Response to Comment on; Newly Diagnosed 
Glomerulonephritis During COVID-19 Infection 
Undergoing Immunosuppression Therapy, a Case Report
Moradi H, Naeimi A, Moeinzadeh F
APPENDIX
329 Erratum
IIIIranian Journal of Kidney Diseases | Volume 14 | Number 4 | July 2020
INSTRUCTIONS TO AUTHORS
The IJKD publishes manuscripts on nephrology, dialysis, 
and transplantation. Original research papers, case 
reports, and letters to the editor are considered for 
publication, all of which undergo extensive peer review 
prior to their acceptance. Review articles and Editorials 
are invited, but unsolicited reviews can be proposed to 
the editors by sending the title for initial consideration. 
Primarily, they are reviewed by the editors and biostatistical 
advisors. If extensive revision is not required, peer review 
will be done by at least 2 experts in the field. Otherwise 
the author(s) have to revise their manuscripts before the 
peer review process. Based on the comments of reviewers 
and the responses or revisions of the author(s), the 
Editorial Board either accepts or rejects the manuscripts. 
Reviewers’ and authors’ identities are kept confidential, 
and the existence of a submitted manuscript is not revealed 
to anyone other than the reviewers and editorial team. 
Submission of Manuscripts
Manuscripts along with a covering letter and the signed 
Authors’ Agreement Form (available from www.ijkd.org) 
should be submitted to the Editor-in-Chief of the IJKD 
via the online submission system. 
Electronic submission. The online submission is 
available on the journal’s web site (www.ijkd.org) and is 
the only way of manuscript submission.
Preparation of Manuscripts
General Instructions. Manuscripts should follow 
the stylistic conventions set forth in the American 
Medical Association Manual of Style, 10th edition. The 
Editors have the right to make editorial corrections and 
additional changes with the knowledge and approval of 
corresponding author. The preferred word processing 
format for the manuscript file is Microsoft Word. The main 
manuscript should carry the title page, abstract, main 
text, references, figures legends, and tables of the paper. 
Figures, including diagrams, photographs, etc, should 
be supplied separately and submitted as supplementary 
files. Please do not attach figures in the digital format of 
the main manuscript. 
Manuscripts should be double-spaced, with 2.5-cm 
margins on all sides of the paper. All abbreviations must 
be spelled out the first time they are used, followed by the 
abbreviated form in parentheses. Units of measurement 
must be complied with the International System of Units 
(SI). 
Original Research Papers. Original papers should be 
arranged as: Title Page, Abstract, Introduction, Methods, 
Results, Discussion, Conclusion, Acknowledgements, 
References, Tables, and Legends. The title page must 
include the following: title; full first name; surname; 
affiliations of each contributor; each author’s highest 
academic degree; the name, full postal address, telefax/
Summarized Version*
   April 2009
telephone numbers of the contributor who will deal with 
correspondence; keywords; and the total number of pages 
and figures being submitted. A structured abstract (with 
the subheadings Introduction, Materials and Methods, 
Results, and Conclusion) should appear on the second 
page of the manuscript and should not exceed 250 words. 
The main text (excluding the abstract and references) 
should not exceed 3000 words.
Case Reports. Case reports should be arranged as 
follows: Title Page, Abstract (nonstructured, not exceeding 
150 words), Introduction, Case Report, Discussion, 
References, and Legends. The length should not exceed 
700 words. 
Brief Communications. Original research papers can also 
be published in a brief format. Submitted papers that are 
of interest but are not acceptable as a full-length original 
contribution are offered by the editor to be published in 
this section. Also, the authors can primarily submit their 
papers for consideration of publication in this section. 
An unstructured abstract not longer than 150 words is 
required for this section. The body of the manuscript should 
not exceed 1500 words, and no heading or subheading 
should be used. Tables and/or Figures should be limited 
to 2 ones and references to 15 in maximum.
Letters to the Editors. Correspondence will be considered 
for publication if it contains constructive criticism on 
previously published articles in the IJKD, the authors of 
which will have the right of reply. Also, reports of limited 
research or clinical experiences can be submitted in the 
form of a letter. The length should not exceed 700 words.
PhotoNephrology. Photonephrology is a section for 
publishing interesting images of medical conditions. Any 
kind of images (pictures, radiological images, pathologic 
images, etc) that show a typical, unique, or rarely seen 
variety of a condition related to nephrology, or those with a 
highly educational value can be submitted to this section. 
However, the section is not a place for case reports. 
Only high-quality images that are not submitted or 
published elsewhere will be considered for publication. 
To submit an image, please send the materials via 
e-mail (info@ijkd.org). A maximum of 4 images can be 
submitted. A short title and accompanied by a legend of 
no more than 200 words is required. A short description 
of the case and images, as well as a brief discussion on 
the images should be provided in the text. No more than 
2 references can provided for the text. For photographs 
of an identifiable patient, a written consent is required. 
No more than 3 authors can be listed for this section. 
Fillers. Fillers are materials, including text and image, 
to be published in the blank spaces of the journal. The 
subject is not restricted, but those related directly or 
indirectly to medicine are preferred. Quotations, interesting 
instructions to authors
IV Iranian Journal of Kidney Diseases | Volume 14 | Number 4 | July 2020
pictures, historical notes, and notice on events are some 
examples. Please contact the editorial office via e-mail 
(info@ijkd.org) to send fillers.
References. Our reference style requirements are 
in accordance with the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals by the 
International Committee of Medical Journal Editors 
(ICMJE updated October 2008, available from: http://
www.icmje.org/). Number references in the order in which 
they appear in the text; do not alphabetize. In text, tables, 
and legends, identify references with superscript Arabic 
numerals in parentheses. 
Note: List all authors when there are 6 or fewer; when 
there are 7 or more, list the first 3, followed by “et al”
Samples:
Articles in journals
Raaijmakers R, Schroder C, Monnens L, Cornelissen 
E, Warris A. Fungal peritonitis in children on peritoneal 
dialysis. Pediatr Nephrol. 2007;22:288-93.
More than 6 authors
Piraino B, Bailie GR, Bernardini J, et al. Peritoneal 
dialysis-related infections recommendations. Perit Dial 
Int. 2005;25:107-31.
Books and other monographs
Brady HR, Clarkson MR, Lieberthal W. Acute renal 
failure. In: Brenner BM, Livine SA, editors. Benner 
& Rector’s the kidney. 7th ed. Philadelphia: WB 
Saunders; 2004. p. 1215-75.
For samples of reference citation formats, authors should 
consult National Library of Medicine web site: 
http://www.nlm.nih.gov/bsd/uniform_requirements.html
Keywords. Between 3 and 10 key words for indexing 
should be typed at the bottom of the title page for each 
manuscript. These words should be identical to the 
medical subject headings (MeSH) that appear in the Index 
Medicus of the National Library of Medicine.
Figures and Tables. Figures and tables should be kept to 
a necessary minimum and their information should not be 
duplicated in the text. Figures must be supplied either as 
JPEG or TIFF. Do not embed the figures in the manuscript 
file. Tables should be typed on separate sheets of the 
manuscript file, be numbered (with Arabic numbers), and 
have a title. Include double-spaced legends (maximum 
length, 60 words) on separate pages. Computer-generated 
images and photographs must have acceptable quality 
(at 300 dpi or higher). 
Covering Letter. All manuscripts must be accompanied 
by a covering letter signed by all authors. The name, 
address, telephone number, fax number, and E-mail 
address of the corresponding author must be provided. 
Previous publications or presentations of the manuscript 
or its parts, conflict of interests, and financial supports, if 
any, should be addressed in the covering letter. 
Ethical Requirements and Authors’ Responsibility 
Author(s) should certify that neither this manuscript nor one 
with substantially similar content under their authorship 
has been published or being considered for publication 
elsewhere in any language, except as described in the 
covering letter. 
The IJKD follows the latest definition for authorship 
provided by the Uniform Requirements for Manuscripts 
Submitted to Biomedical Journals. All authors should have 
a substantial contribution to the manuscript and take public 
responsibility for its contents. All persons designated as 
authors are assumed to qualify for authorship and all 
those who qualify are listed. The corresponding author 
takes responsibility for the integrity of the work as a whole, 
from inception to published article. In the event that an 
author is added or removed from the list of authors, written 
acceptance, signed by all authors, must be submitted to 
the editorial office. 
Any financial interests, direct or indirect, in connection 
with the author(s) manuscript must be disclosed in the 
covering letter. Furthermore, sources of financial support 
of the project are named in the covering letter as well as 
the Acknowledgements.
If the work involves experimentation on living animals, 
the author(s) must provide evidence that the study was 
performed in accordance with local ethical guidelines. If the 
study involves human beings, the author(s) must include a 
statement that the study was approved by the local ethical 
committee and that informed consent was obtained from 
the study participants. For those investigators who do 
not have formal ethics review committees, the principles 
outlined in the Declaration of Helsinki should be followed.
Al l  relevant permissions to ci te the unpubl ished 
observations of others must be obtained by the manuscript 
author(s). The names and initials of these persons must 
be cited in the text, and permission from the original 
author(s) must be obtained. Permission also must be 
obtained to reproduce or adapt any figures or tables that 
have been published previously. 
Copyright
The Iranian Society of Nephrology is the copyright owner of 
the material published in the IJKD. However, all published 
works are open access and are immediately available 
without cost to anyone at the journal’s web site. The users 
are free to use of the work, subject to proper attribution 
of authorship and ownership of the rights. Authors may 
use their material in presentations and subsequent 
publications they write or edit themselves, provided that 
the IJKD is notified in writing and is acknowledged as the 
original publication. All authors should read the Authors’ 
Agreement Form carefully and submit a completed and 
signed copy of it along with their manuscript (available 
from http://www.ijkd.org).
*Note: For a complete version of the instructions, see the IJKD’s 
web site.





Author(s) of the abovementioned manuscript have read the following statements and agree with them by signing this form. If 
the manuscript is not published in either print or electronic versions of the Iranian Journal of Kidney Diseases (IJKD) within 12 months of 
acceptance (or as otherwise agreed), this agreement shall automatically terminate.
Statement of Authorship
This statement acknowledges that each undersigned author has made a substantial contribution to the manuscript and is willing to take 
public responsibility for its contents. Author(s) attest that all persons designated as authors qualify for authorship and all those who qualify 
are listed. The corresponding author takes responsibility for the integrity of the work as a whole, from inception to published article. The 
IJKD follows the latest definition provided by the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.
icmje.org): “Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis 
and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version 
to be published. Authors should meet conditions 1, 2, and 3.”
All others who contributed to the work but are not authors (if any) are named in the Acknowledgements of the manuscript.
Ethical Requirements
Author(s) herein attest that all human and/or animal studies undertaken as part of research from which this manuscript is derived, are in 
compliance with the regulations of their institution(s) and generally accepted guidelines governing such work. Author(s) warrant that this 
manuscript contains no violation of any existing copyright or other third party right or any material of an obscene, indecent, libellous, or 
otherwise unlawful nature and that to the best of their knowledge the manuscript does not infringe the rights of others.
Copyright
Upon publication, author(s) agree that the Iranian Society of Nephrology is the copyright owner of the material published in the IJKD. 
However, in accordance with Bethesda Statement on Open Access Publishing, all works published in the IJKD are open access and 
are available to anyone on the web site of the journal without cost. The users are free to use the work, subject to proper attribution of 
authorship and ownership of the rights. Authors may use their material in presentations and subsequent publications they write or edit 
themselves, provided that the IJKD is referenced in writing and is acknowledged as the original publication. 
Conflict of Interest and Financial Supports
Author(s) warrant that any financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in 
connection with this manuscript have been disclosed in the covering letter. Furthermore, sources of financial support of the project are 
named in the covering letter as well as the Acknowledgements.
Previous Publications
Author(s) certify that neither this manuscript nor one with substantially similar content under their authorship has been published or being 
considered for publication elsewhere in any language, except as described in the covering letter. They also certify that any previous 
presentations of this paper in meetings are mentioned in the covering letter.
Names of all authors in order in which they appear in the Article:































 Annual (6 issues)              
                                                           
 Single Copy    
                                                           
 You may fill this form and send it together with the bank receipt of the subscription fee. 
 Subscription Fees: Annual (6 issues): US$ 100                
  Single issue: US$ 20
 Subscription Fees for customers in Iran: Annual (6 issues): 50 000 Rls    




Editorial Office: Apt 12, No 63, Shaheed Tousi St, Dr Gharib St, Keshavarz Blvd, Tehran, Iran 
Postal Code: 1419783311
Tel: +98 21 6691 2653   Fax: +98 21 6691 2653   www.ijkd.org    info@ijkd.org
KIDNEY DISEASES






Pharmacotherapy Considerations in CKD Patients With 
COVID-19, A Narrative Review 
Simin Dashti-Khavidaki, Hossein Khalili, Anahid Nourian
Treatment of coronavirus disease 2019 (COVID-19) among patients 
with CKD requires special pharmacotherapy considerations that 
are reviewed here.
Literature review was done for several pharmacotherapy aspects 
in CKD patients including selection and modification of COVID-19 
treatment, drug interactions, nephrotoxicity of drugs that are used 
for treatment of COVID-19 and potential risks/benefits of routine 
medications of CKD patients during COVID-19 pandemic.
CKD patients should be treated according to local or national 
COVID-19 protocols as other patients. But, there is no data on 
using remdesivir in patients with severe CKD. Oseltamivir and 
ribavirin require dose modification in patients with moderate 
to severe CKD. Nephrolithiasis, CKD, and acute interstitial 
nephritis have been reported with protease inhibitors. Acute 
kidney injury has been reported with remdesivir in patients with 
severe COVID-19. Pharmacokinetic-enhanced protease inhibitors 
increase the concentration of some drugs such as statins, cinacalcet, 
steroids, calcineurin inhibitors (CNIs). Some hypothetical benefits 
and harms have been suggested for statins and renin-angiotensin-
aldosterone system inhibitors in COVID-19 patients. Continuing 
guideline-directed administration of these drugs is recommended. 
Among different immunomodulating/immunosuppressive drugs, 
hydroxychloroquine and CNIs are the safest ones during COVID-19. 
Antimetabolites are suggested to be withheld during moderate to 
severe COVID-19. Fluid therapy and anticoagulant prophylaxis/
treatment need special attention in CKD patients with COVID-19.
CKD patients with COVID-19 are treated as other patients, with 
some dose modifications if needed. Be mindful for management of 
drug interactions as well as modification of immunosuppressive 
drugs in patients with moderate to severe COVID-19. 
IJKD 2020;14:247-55
www.ijkd.org
Faculty of Pharmacy, Tehran 
University of Medical Sciences, 
Tehran, Iran
Keywords. CKD, COVID-19, 
pharmacotherapy, SARS-CoV-2
INTRODUCTION
New coronavirus pandemic named coronavirus 
disease 2019 (COVID-19) causes by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2).1 
Patients with diabetes mellitus, hypertension, and 
cardiovascular diseases have been introduced as 
high risk patients for COVID-19.2 Diabetes and 
hypertension are common causes of chronic kidney 
disease (CKD).3 Hence, it is expected that patients 
with CKD be at increased risk for COVID-19. 
Treatment of COVID-19 among CKD patients 
requires special pharmacotherapy considerations 
that have been reviewed here in several aspects 
including modification of COVID-19 treatment 
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regimen for patients with impaired kidney 
function, management of drug interactions in these 
patients due to common polypharmacy among 
patients with CKD, attention to nephrotoxicity of 
COVID-19 treatment regimen and possible need 
for modification of commonly used drugs among 
CKD patients. Pharmacotherapy considerations 
in kidney transplant patients are not discussed 
here.
RISK FOR COVID-19 AMONG CKD PATIENTS
There is no exact data on the incidence of CKD 
as comorbidity among patients with COVID-19. A 
survey on 1099 patients with laboratory-confirmed 
COVID-19 from 552 hospitals in 30 provinces, China 
revealed that only 0.7% of the patients had pre-
existing CKD disease.2 Despite this low reported 
rate of CKD among patients with COVID-19, a 
meta-analysis on 4 studies consisting 1389 patients 
showed significant association between CKD and 
severe COVID-19 (OR = 3.03, 95% CI: 1.09 to 8.47).4 
Angiotensin converting enzyme (ACE) 2 that is 
the functional receptor for SARS-CoV-2 and its 
cellular invasion is expressed in podocytes and 
proximal convoluted tubules, therefore, kidney is 
expected to be an important organ for SARS-CoV-2 
induced cytopathic and inflammatory damage.5,6 
But, the rate of acute kidney injury (AKI) is not 
so high in hospitalized patients with COVID-19. 
In a report on 1099 patients from China, AKI 
happened in 0.5% of hospitalized patients.2 A 
systematic review and meta-analysis on 19 studies 
consisting 660 patients with COVID-9 showed 
that 7.9% of patients experienced AKI.7 Another 
retrospective, observational, multicenter study on 
193 patients with laboratory-proven COVID-19 in 
China showed that at hospital admission 59% of 
the patients had proteinuria, 44% had hematuria, 
14% had increased blood urea nitrogen (BUN), 
and 10% showed elevated serum creatinine 
concentration. Since previous medical histories 
of the patients were not exactly available, all of 
these findings cannot be readily diagnosed as 
AKI due to COVID-19; however, a multivariate 
analysis revealed that proteinuria, hematuria, and 
elevated BUN and creatinine concentrations were 
significantly correlated with death in patients with 
COVID-19.8 AKI has been reported as a lethal 
complication among patients with COVID-19 in 
another survey as well.9 
TREATMENT OF COVID-19 IN CKD PATIENTS
There is no specific pharmacologic treatment 
for SARS-CoV-2. Several antimicrobial and 
anti-inflammatory/adjuvant drugs are being 
used under clinical trial or compassionate use 
protocols. These drugs have been chosen based 
on in vitro activity against SARS-CoV-2 or other 
members of coronavirus family and/or some 
limited clinical experiences. These drugs include 
chloroquine/hydroxychloroquine, remdesivir, 
p r o t e a s e  i n h i b i t o r s  ( l o p i n a v i r / r i t o n a v i r , 
atazanavir, darunavir/cobicistat), favipiravir, 
arbidol (umifenovir), oseltamivir, azithromycin, 
sofosbuvir, tocilizumab, interferon (alpha and 
beta) ,  and intravenous immunoglobulin.10 
Patients with creatinine clearance of less than 
50 (NCT04292899) or 30 mL/min (NCT04257656, 
NCT04280705, NCT04323761) have been excluded 
from remdesivir clinical trials in patients with 
COVID-19.11 Tocilizumab has not been studies in 
patients with creatinine clearance of less than 30 
mL/min.12 Other drugs are not contraindicated 
in patients with underlying kidney disease but 
some of them needs dose modification based on 
the level of kidney function.12 Therefore, patients 
with underlying kidney diseases can be treated 
according to local or national COVID-19 protocols 
as other patients; but, more data is needed before 
using remdesivir and tocilizumab in patients with 
severe CKD.
DOSE ADJUSTMENT OF COVID-19 
TREATMENT REGIMEN IN CKD PATIENTS
Lopinavir/ritonavir, atazanavir, darunavir/
cobicistat, arbidol, sofosbuvir, and azithromycin 
do not require dose adjustment in patients 
with CKD.12,13 Fifty percent dose reduction has 
been suggested for hydroxycholoquine in lupus 
nephritis patients with creatinine clearance of 
less than 30 mL/min.12,14 Half routine dose of 
chloroquine has been suggested for patients 
with creatinine clearance of less than 10 mL/
min and those on maintenance hemodialysis 
or peritoneal dialysis.12 Dose modification of 
hydroxychloroquine has been proposed for patients 
who are taking these drugs chronically12,14 and may 
not be extrapolated to short-course treatment of 
COVID-19.
Oseltamivir dose has to be reduced from 75 
mg twice daily to 30 mg twice daily in patients 
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with creatinine clearance of less than 60 mL/min 
and to 30 mg/d in CKD patients with creatinine 
clearance of less than 30 mL/min. For patients on 
intermittent maintenance hemodialysis doses of 
75 mg and 30 mg after each dialysis session have 
been proposed for dialysis with high-flux and 
low-flux membranes, respectively. For patients 
on continuous ambulatory peritoneal dialysis it 
has been postulated that a single 30 mg dose is 
sufficient for a 5-day treatment course.12 
Remdesivir had not been previously approved 
by US food and drug administration (FDA) 
or European Medical Agency (EMA) for any 
indication. It is administered intravenously with 
a dose of 200 mg in the first day and then 100 mg 
daily for 9 days under clinical trial or compassionate 
protocols. Patients with creatinine clearance of 
less than 50 (NCT04292730, NCT04292899) or 
30 mL/min (NCT04323761, NCT04252664) have 
been excluded from remdesivir clinical trials in 
patients with COVID-19. Therefore, no data would 
be available for remdesivir in patients with severe 
CKD.11,15 
Favipiravir has been approved for treatment of 
influenza in Japan. It has not been approved by 
US FDA or EMA for any indication. So, enough 
data on its dose adjustment in CKD patients is 
not available. At least three clinical trials have 
been submitted for using favipiravir in COVID-19. 
Different doses have been applied e.g. 1600 mg 
twice daily for the first day of treatment, followed 
by 600 mg twice daily thereafter usually for 1 week 
(NCT04310228, NCT04333589) or 2400-2400-1200 
mg for the first day, 8 hours apart followed by 1200 
mg twice daily from the second day of treatment 
(NCT04303299). These studies have not excluded 
CKD patients from the study with these favipiravir 
doses. Only one of them excluded patients with 
unstable kidney function (NCT04333589) (probably 
AKI not CKD).11 
Ribavirin was used in the regimen of COVID-19 
at the beginning of SARS-CoV-2 outbreak; however, 
it is not used in newer COVID-19 regimens. It has 
been used with doses of 1000 to 1200 mg twice daily 
or 600 to 800 mg three times a day. Dose reductions 
of 50% and 75% have been proposed for patients 
with creatinine clearance between 30 to 50 mL/min 
and less than 30 mL/min, respectively in patients 
with SARS.16 Tocilizumab has been approved for 
rheumatoid arteritis and cytokine release syndrome. 
It has not been studied in patients with creatinine 
clearance of less than 30 mL/min.12
NEPHROTOXICITY OF DRUGS THAT ARE 
USED FOR TREATMENT OF COVID-19
Some drugs that are used in COVID-19 treatment 
regimen (such as remdesivir, favipiravir, arbidol) 
have not been approved previously by US FDA 
or EMA, so; there is no data on their potential 
nephorotoxicity. Chloroquine/hydroxychloroquine, 
azithromycin, oseltamivir, and interferons have no 
considerable nephrotoxicity.12
Ritonavir boosted protease inhibitors such as 
lopinavir/ritonavir and atazanavir/ritonavir have 
been associated with increased risk of CKD in less 
than 1% of patients taking these drugs. This side 
effect has been seen in the median time of 4.5 
years (inter-quartile range (IQR) 2.7 to 6.1 years) 
of follow-up.17 Atazanavir can cause crystalluria/
urolithiasis in a median time of 24.5 months (IQR 
14.7 to 34.6 months) after commencement.18 In 
addition, acute interstitial nephritis has been 
reported with atazanavir.19 However, short duration 
of administration of these drugs for treatment of 
COVID-19 decreases the risk of renal side effects 
of these protease inhibitors.
Sofosbuvir may induce AKI in the form of acute 
interstitial nephritis with varying incidence of 
1 to 15%. The median time of 9 weeks from the 
beginning of sofosbuvir to AKI occurence has been 
reported.20 Therefore, short treatment period of 
COVID-19 eliminates the concern of sofosbuvir 
induced acute interstitial nephritis. 
AKI has been reported as a major side effect of 
remdesivir among patients with severe COVID-19. 
This adverse effect has been mostly seen in patients 
under invasive mechanical ventilation.21 
Nephrolithiasis has been reported in less 
than 2% of the patients taking tocil izumb, 
however; most of the patients with this side 
effect were those with rheumatoid arteritis 
who were taking methotrexate concomitantly. 
Methotrexate has been well known for inducing 
nephrolithiasis.12
Acute kidney injury has been reported in less 
than 1% of patients who receive intravenous 
immunoglobulin. In patients with underlying kidney 
dysfunction the infusion rate and concentration of 
the intravenous immunoglobulin solution have to 
be reduced.12
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MANAGEMENT OF INTERACTION BETWEEN 
ROUTINE DRUGS OF THE CKD PATIENTS 
WITH COVID-19 TREATMENT REGIMEN
Some protease inhibitors (e.g.  lopinavvir, 
darunavir) and their pharmacokinetic enhancers 
(ritonavir and cobicistat) are potent inhibitors of 
both cytochrome (CYP) 450 3A isoenzymes and 
P-glycoprotein efflux pump. These two systems 
play major roles in the metabolism and cellular 
distribution of several drugs; some of them are 
widely used by CKD patients.12,22 
Cinacalcet 
Cinacalect is metabolized by CYP450 3A. 
Cinacalcet concentration and exposure increase 
in patients taking lopinavir/ritonavir, atazanavir/
ritonavir or darunavir/cobicistat. Although, serum 
level of parathyroid hormone may not change 
rapidly during only several days coadministration 
of cinacalcet with these ritonavir/ cobicistat 
-boosted protease inhibitors, rapid presenting side 
effects of cinacalcet such as hypocalcemia and 
hypomagnesemia may develop. These electrolyte 
abnormalities intensify the QT prolongation 
adverse effect of lopinavir/ritonavir or atazanivir/
ritonavir especially if these antiviral drugs are 
used in a regimen containing chloroquine/
hydroxychloroquine as well.12,22 
Statin 
Many patients with nephrotic syndrome take 
statins. CKD patients with different types of 
cardiovascular diseases also receive statins.3 
Most statins are metabolized by CYP450 3A and 
their exposure increases if coadministered with 
pharmacokinetic-enhanced protease inhibitors. 
Coadministration of simvastatin or lovastatin with 
ritonavir/cobicistat boosted protease inhibitors 
should be avoided. Due to increased systemic 
exposure to atorvastatin and rosuvastatin by about 
490% and 108%, respectively when coadministered 
with pharmacokinetic-boosted protease inhibitors; 
maximum daily doses of 20 mg for atorvastatin 
and 10 to 20 mg for rosuvastatin have been 
proposed in patients taking these two drug classes 
concomitantly. Systemic exposure to pitavastatin 
and pravastatin increases by about 30% if taken 
with protease inhibitors. No dose adjustment was 
recommended for these two statins in combination 
with pharmacokinetic-enhanced protease inhibitors. 
It is prudent to monitor patients taking statins 
in combination with ritonavit/cobicistat-boosted 
protease inhibitors  regarding myopathies , 
creatine phosphokinase elevation and possibly 
rhabdomyolysis and AKI. Keep in mind that 
these signs and symptoms are common between 
COVID-19 and statin toxicity.12,22,23 
Corticosteroids 
P a t i e n t s  w i t h  g l o m u r e l u n e p h r i t i s  o r 
vasculituies are usually treated with intravenous 
methylprednisolone pulse and oral prednisone/
prednisolone. Pharmacokinetic-boosted protease 
inhibitors increase steroid exposure and adverse 
effects.12,22 
Calcineurin Inhibitors 
Pharmacokinetic-boosted protease inhibitors 
impede metabolism of calcineurin inhibitors (CNIs). 
A significant decline of 80% to 95% in cyclosporine 
dose or dose reduction of tacrolimus to about 1mg 
weekly and close blood concentrations monitoring 
of  CNIs  are  recommended.  Chloroquine/
hydroxychloroquine also can increase CNIs blood 
concentration by inhibiting CNIs metabolism. In 
contrast, tocilizumab decreases CNIs concentrations 
by inducing CYP450 3A.12,22 
Azathioprine 
Hematologic toxicities of azathioprine may 
be enhanced in combination with chloroquine/
hydroxychloroquine. Ribavirin can interfere with 
azathioprine metabolism and increase myelotoxic 
metabolites of azathioprine. Ribavirin has its 
own hematologic toxicity as well that exacerbate 
cytopenia in patients treating with these two drugs 
concomitantly. Enhanced myelotoxicity may also 
happen in coadministration of azathioprine with 
tocilizumab or interferons.12,22 Patients should be 
monitored for blood cells counts.
Mycophenolate Mofetil/Sodium 
M y c o p h e n o l a t e 1 2  a n d  C O V I D - 1 9 2 h a v e 
hematologic side effects in common. Although 
chloroquine/hydroxychloroquine has hematologic 
side effects12 and despite long term use of 
mycophenolate and hydroxychloroquine in 
patients with lupus nephritis,13 no interaction 
has been reported between these two drugs in 
the literature.12,22
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HYPOTHETICAL BENEFITS/HARMS OF SOME 




SARS-CoV-2  uses  ACE2 as  a  funct ional 
receptor for cell entry. ACE2-bound SARS-CoV-2 
internalization causes ACE2 down-regulation 
and subsequent overexpression of angiotensin II 
(AngII) and AT1 receptor in the lung and heart 
and damages to these tissues. Based on above 
findings, some researchers hypothesized that ACE 
inhibitors or angiotensin receptor blockers (ARBs) 
could be possible options to reduce SARS-CoV-2 
induced lung injury.24 This hypothesis has not 
been assessed in experimental or clinical studies. 
While ACE2 down-regulation by the virus may 
promote AngII and AT1 receptor expression, using 
ACE inhibitors and ARBs also increase AngII 
expression by several times. In addition, ACE2 
is not inhibited by ACE inhibitors.25 Therefore, 
using renin-angiotensin system inhibitors to 
prevent or treat COVID-19 may provide more 
ACE2 available for SARS-CoV-2 spike protein to 
bind and invade the lung and cardiac cells. Some 
investigators concern regarding harmful effects 
of these drugs in COVID-19 patients because of 
increased ACE2 levels in the lungs and heart by 
these drugs.26 There is no scientific evidence to 
support this suggestion as well. Taken together, 
at this time it is recommended not initiating ACE 
inhibitors or ARBs to prevent or treat COVID-19. 
Several specialty societies recommend continuing 
these drugs during COVID-19 outbreak in patients 
who were taking them due to definite cardio- and 
nephroprotective indications such as history of 
myocardial infarction, heart failure, hypertension 
or proteinuria.27 Another aspect that should be 
taken into account is AKI as a severe complication 
among patients with COVID-19. It may be at 
least partly due to high expression of ACE2 in 
podocytes and proximal convoluted tubules that 
make kidney as an important organ for SARS-
CoV-2 induced cytopathic and inflammatory 
damage.5 ACE inhibitors and ARBs may also 
cause AKI especially during initiation and dose 
escalation. Dose adjustment or even temporary 
discontinuation of ACE inhibitors/ARBs may be 
required in patients with severe AKI and subsequent 
hyperkalemia.28 
Statins
Some human and animal studies revealed 
lung injury improvement by statins due to 
anti-inflammatory effects of these drugs.29,30 In 
contrast, a retrospective study on the efficacy 
of rosuvastatin against infection-induced ARDS 
showed higher mortality in statin treated patients 
possibly because of increased IL-18.31 During 
current COVID-19 pandemic some US hospitals 
included statin in their treatment regimen32 and 
some suggested their use.33,34 On the other hand, 
some others worry about statin-induced increase 
IL-18 level and worsening of SARS-CoV-2 induced 
ARDS and mortality.35 
Large number of CKD patients suffers diabetes 
or cardiovascular diseases and should receive 
statin. Therefore, guideline-directed continuations 
of statin therapy among COVID-19 patients with 
history of atherosclerotic cardiovascular disease 
or diabetes and guidance-directed initiation of 
statin in patients with COVID-19 who show 
acute cardiac injury have been recommended. 
But, staring statin for management of COVID-19 
infection outside clinical trial protocols is not 
suggested.23 
FLUID THERAPY IN CKD PATIENTS WITH 
COVID-19
In the absence of shock, conservative fluid 
management is recommended in COVID-19 patients 
with severe acute respiratory infection or acute 
respiratory distress syndrome (ARDS). Excessive 
fluid administration may worsen oxygenation in 
these patients. For patients in septic shock, bolus 
dose of 250 to 500 mL crystalloid solutions over 15 
to 30 minutes is recommended. Additional fluid 
should be administered after assessment for signs 
of overload.36 
MODIFICATION OF IMMUNOSUPPRESSIVE/
IMMUNOMODULATORY DRUGS IN CKD 
PATIENTS WITH COVID-19
Hydroxychloroquine 
Almost all patients with lupus nephritis are treated 
with hydroxychloroquine.14 Hydroxychloroquine 
has been used in COVID-19 treatment regimens 
as well.10 So, CKD patients who are treated 
with hydroxychloroquine should continue this 
drug during COVID-19 pandemic and infection 
episode.
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Corticosteroids
L a r g e  n u m b e r  o f  C K D  p a t i e n t s  w i t h 
glomerulonephritis or vasculitis takes maintenance 
oral prednisolone/prednisone and during disease 
flare receives intravenous steroid pulse.3,14 Steroids 
may prolong viral shedding, therefore, are not 
recommended for the treatment of patients with 
mild to moderate COVID-19 unless other indication 
such as exacerbation of asthma or obstructive 
pulmonary disease is present. Steroids are used for 
treating severe COVID-19 patients with septic shock 
or ARDS.36 Some experts propose administering 
least effective maintenance dose of prednisolone/
prednisone during COVID-19 pandemic in CKD 
patients who were already treating with these 
drugs. Increased steroid dose or changing oral 
steroid to intravenous one during severe COVID-19 
infection and ARDS is recommended in kidney 
disease patients on chronic steroid therapy.37 
CNIs 
Some in vitro antiviral activities have been 
reported for cyclosporine against some members 
of coronavirus family.10,38 Considering risks of 
the flare of underlying kidney disease, it seems 
prudent to continue CNIs especially cyclosporine 
with the lowest effective dose.37 Balancing the 
risk of flare of the underlying kidney disease and 
severity of COVID-19 infection, one may consider 
switching from other immunosuppressive drugs 
to cyclosporine if there is efficacy for cyclosporine 
in that situation. However, AKI is a complication 
that may be seen with both COVID-192 and CNIs.39 
Mycophenolate / Azathiopurine
The results regarding antiviral effects of 
mycophenolate are conflicting.38,40 Fatal outcome has 
been reported with this drug during previous viral 
outbreaks.38 On the other hand, mycophenolate has 
adverse hematologic effects including leukopenia 
and thrombocytopenia that may exacerbate 
hematologic complications of COVID-19.2,38 Since 
available data shows no higher incidence of 
COVID-19 among CKD patients compared with 
other populations, it seems logical to continue 
mycophenolate in CKD patients taking this drug 
for glomerulonephritis or vasculitis diseases. In 
patients with severe COVID-19, it is suggested 
to stop antimetabolites including mycophenolate 
and azathioprine.37 
Cyclophosphamide / Rituximab
ERA/EDTA recommends postponing the 
administration of maintenance cyctotoxic drugs/
rituximab in patients with glomerulonephritis 
or vasculitis, however, disease flare may be 
detrimental.37
ANTICOAGULATION IN CKD PATIENTS 
WITH COVID-19
Patients with severe COVID-19 are at increased 
risk for thrombosis because of inflammation, 
immobility, hypoxia-induced thrombosis, and 
possibly invasion of the virus into the endothelial 
cells.41 In a retrospective study on 449 patients 
with severe COVID-19, 28-day mortality was 
compared between patients who received and 
not received prophylactic doses of unfractionated 
(UFH) or low molecular weight heparin (LMWH). 
In general, mortality did not differ between these 
two groups of the patients. But, in patients with 
sepsis induced coagulopathy score42 of more 
than 4 or D-dimer of more than 6 times of upper 
normal limit, 28-day mortality was significantly 
lower in heparin product users.43 In addition to 
anticoagulation effects, heparin derivatives possess 
anti-inflammatory effect44 that may be of benefit in 
COVID-19 patients who fulfill criteria for receiving 
prophylactic or treatment doses of heparins. World 
health organization recommends thromboembolism 
prophylaxis using LMWH (preferred) or UFH 
for critically ill patients with COVID-19 with no 
contraindication for heparin administration.36 
Based on available data, International Society 
of Thrombosis and Haemostasis (ISTH) has 
recommended the prophylactic dose of LMWH 
for every patient with COVID-19 who requires 
hospitalization. ISHT considered only active 
bleeding and platelet count of less than 25 × 109 /L 
as contraindications for LMWH administration.45 
CKD is a double-edged sword situation for 
thrombosis and hemorrhagic events.46 Due to renal 
elimination of LMWH, unfractionated heparin is 
usually preferred in CKD patients with creatinine 
clearance of less than 30 mL/min or those who 
experience AKI during infection episode. However, 
dose reduction to 1 mg/kg/d for treatment and 20 
to 30 mg/d for thrombosis prophylaxis has also 
been proposed for enoxaparin in CKD patients 
with creatinine clearance of less than 30 mL/
min.12,46 ISTH did not exclude patients with severe 
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CKD from its recommendation for thrombosis 
prophylaxis using LMWH and only recommended 
patient and laboratory monitoring.45
CONCLUSION
CKD patients should be treated according to local 
or national COVID-19 protocols as other patients. 
Due to lack of data in patients with severe CKD, 
remdesivir and tocilizumab are not suggested 
in patients with severe CKD. Oseltamivir and 
ribavirin require dose modification in patients 
with moderate to severe CKD. 
Nephrolithiasis, CKD and acute interstitial 
nephritis have been infrequently reported with 
some protease inhibitors; however, due to the short 
period of COVID-19 treatment, there is no concern 
for these renal side effects. Pharmacokinetic-boosted 
protease inhibitors increase the concentration of 
some drugs such as statins, cinacalcet, steroids, 
and CNIs that are frequently used in patients 
with kidney diseases. The dose of these drugs 
should be reduced and their side effects be 
monitored. Some hypothetical benefits and harms 
have been proposed for statins and inhibitors of 
renin-angiotensin-aldosterone system in patients 
with COVID-19. Specialty societies recommend 
continuing these drugs in CKD patients who were 
already taking them during COVID-19 infection. 
They also recommend guideline-directed starting 
of these drugs in patients with COVID-19; however 
their side effects that are in common with clinical/
laboratory characteristics of COVID-19 (such as AKI 
or myopathy) should be kept in mind. CKD patients 
who are taking hydroxychloroquine should continue 
this drug during COVID-19 pandemic and infection. 
Among different immunosuppressive drugs, CNIs 
are the safest ones during COVID-19 pandemic and 
infection. Antimetabolites are recommended to be 
withheld during moderate to severe COVID-19 
infection. Some specialty societies recommend 
postponing administration of cytotoxic drugs and 
rituximab. But, clinicians should be mindful for the 
risk of underlying disease flare. Fluid therapy in 
hospitalized CKD patients with COVID-19 should be 
done conservatively. Fluid resuscitation in patients 
with shock should be done with small bolus of 
crystalloid solutions. Excessive fluid administration 
deteriorates oxygenation and increases the risk of 
ARDS. Prophylactic anticoagulation with heparin 
derivatives is recommended in CKD patients 
with COVID-19 who are admitted in the hospital. 
Report and studies on the efficacy and safety 
of drugs that are used in COVID-19 treatment 
regimen in CKD patients are emergently needed. 
Appropriate modification of immunosuppressive 
drugs requires sharing experiences of different 
hospitals worldwide. 
CONFLICT OF INTEREST
Authors declare no competing interest.
FUNDING
There is no funding support.
AUTHORS CONTRIBUTIONS
SDK contributed in conceptualization, literature 
review, data gathering and interpretation, 
manuscript writing, drafting, and finalization.
HK contributed in literature review, data 
gathering and interpretat ion,  supervision, 
manuscript writing, drafting and finalization.
AN contributed in l i terature review and 
manuscript drafting.
REFERENCES
1. World Health Organization. https://www.who.int/
emergencies/diseases/novel-coronavirus-2019. Accessed 
20 March 2020.
2. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 
coronavirus disease 2019 in China. N Engl J Med. 2020; 
382: 1708-1720.
3. KDIGO 2012 clinical practice guideline for the evaluation 
and management of chronic kidney disease. Kidney Int 
Suppl. 2013; 3(1):1-150.
4. Henry BM, Lippi G. Chronic kidney disease is associated 
with severe choronavirus disease 2019 (COVID-9) 
infection. Int Urol Nephrol. 2020; 52(6):1193-1194.
5. Pan X, Xu D, Zhang H, et al. Identification of a potential 
mechanisms of acute kidney injury during the COVID-19 
outbreak: a study based on single-cell transcriptome 
analysis. Intensive Care Med. 2020; 46(6):1114-1116.
6. Diao B, Wang C, Wang R, et al. Human kidney is a target 
for novel severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection. medRxiv. 2020.
7. Rodriguez-Moralesa AJ, Cardona-Ospinaa JA, Gutiérrez-
Ocampoa E, et al. Clinical laboratory and imaging features 
of COVID-19: a systematic review and metaanalysis. 
Travel Med Infect Dis. 2020; 34:101623
8. Li Z, Wu M, Yao J, et al. Caution of kidney dysfunction of 
COVID-19 patients. medRxiv. 2020. 
9. Cheng Y, Luo R, Wang K, et al. Kidney disease is 
associated with in-hospital death of patients with 
COVID-19. Kidney Int. 2020; 97(5):829-838.
10. Li G, De Clercq E. Therapeutic options for the 2019 novel 
Pharmacotherapy in CKD Patients with COVID-19—Dashti et al
254 Iranian Journal of Kidney Diseases | Volume 14 | Number 4 | July 2020
coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020. 9: 
149-150.
11. www.clinicaltrial.gov. Accessed date: 11 May 2020.
12. Drug’s monograph. Lexicomp. April 2020.
13. Instructions for the medical use of arbidol. Good Earth 
Medicine LLC. Bellingham, WA 98225. http://good-earth- 
medicine.com. Accessed date 4 April 2020.
14. Fanouriakis A, Kostopoulou M, Cheema K, et al. 
2019 Update of the Joint European League Against 
Rheumatism and European Renal Association–European 
Dialysis and Transplant Association (EULAR/ERA–EDTA) 
recommendations for the management of lupus nephritis. 
Ann Rheum Dis. 2020; 79(6):713-723.
15. Center for Disease Control and Prevention. https://www.
cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.
html. Accessed date: 4 April 2020.
16. Koren G, King S, Knowles S, Phillips E. Ribavirin in the 
treatment of SARS: A new trick for an old drug? CMAJ 
Can Med Assoc J. 2003;168(10):289–1292.
17. Ryom I, Mocroft A, Krik O, et al. Association between 
antiretroviral exposure and renal impairment among HIV-
positive persons with normal baseline renal function: the 
D:A:D study. J Infect Dis. 2013; 207:1359-1369.
18. Hamada Y, Nishijima T, Watanabe K, et al. High incidence 
of renal stone among HIV-infected patients on ritonavir-
boosted atazanavir than in those receiving other protease 
inhibitor containing antiretroviral therapy. Clin Infect Dis. 
2012; 55: 1262-1269.
19. Brewster UC, Perazella MA. Acute interstitial nephritis 
associated with atazanavir, a new protease inhibitor. Am J 
Kidney Dis. 2004; 44: e81-84.
20. Dashti-Khavidak S, Khalili H, Nasiri-Toosi M. Potential 
nephrotoxicity of sofosbuvir-based treatment in patients 
infected with hepatitis C virus: a review on incidence, type 
and risk factors. Expert Rev Clin Pharmacol. 2018; 11(5): 
252-259.
21. Grein J, Ohmagari N, Shin D, et al. Compassionate use of 
remdesivir for patients with severe COVID-19. New Engl J 
Med. 2020; 382(24): 2327-2336.
22. Liverpool COVID-19 drug interactions. http://www.covid19-
druginteractions.org/. Accessed 9 May 2020. 
23. Dashti-Khavidaki S, Khalili H. Considerations for statins 
therapy in patients with COVID-19. Pharmacotherapy. 
2020; 40(5): 484-486.
24. Gurwitz D. Angiotensin receptor blockers as tentative 
SARS-CoV-2 therapeutics. Drug Dev Res.2020. 
25. Hilal-Dandan R. Renin and angiotensin. In: Brunton LL, 
Halal-Dandan R, Knollmann BC, editors. Goodman and 
Gilman’s: The pharmacological basis of therapeutics. 13th 
edn. New York: McGrawHill; 2018. pp.482-499.
26. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and 
the cardiovascular system. Nat Rev Cardiol. 2020; 
17(5):259-260.
27. Vaduganthan M, Vardeny O, Michel T, McMurray JJV, 
Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone 
system inhibitors in patients with COVID-19. N Engl J 
Med. 2020; 382(17):1653-1659.
28. Clark AL, Kalra PR, Petrie MC, Mark PB, Tomlinson 
LA, Tomson CRV. Change in renal function associated 
with drug treatment in heart failure: national guidance. 
Heart.2019; 105: 904-910.
29. Shyamsundar M, McKeown STW, O’Kane CM, et al. 
Simvastatin decreases lipopoly-saccharide-induced 
pulmonary inflammation in healthy volunteers. Am J 
Respir Crit Care Med. 2019; 179:1107–1114. 
30. Chen W, Sharma R, Rizzo AN, Siegler JH, Garcia JG, 
Jacobson JR. Role of claudin-5 in the attenuation of 
murine acute lung injury by simvastatin. Am J Respir Cell 
Mol Biol. 2014; 50:328 –336.
31. Rogers A, Guan J, Trtchounian A, et al. Association 
of elevated plasma interleukin-18 level with increased 
mortality in a clinical trial of statin treatment for acute 
respiratory distress syndrome. Crit Care Med. 2019; 47: 
1089-1096.
32. Massachusetts General Hospital COVID-19 Treatment 




33. Fedson, DS, Opal SM, Rordamc OM. Hiding in plain sight: 
an approach to treating patients with severe COVID-19 
infection. mBio. 2020; 11 (2): e00398-20. 
34. Castiglione V, Chiriacó M, Emdin M, Taddei S, Vergaro 
G. Statin therapy in COVID-19 infection. Eur Heart J. 
Cardiovasc Pharmacother. 2020. 
35. Goldstein MR, Poland GA, Graeber CW. Are certain drugs 
associated with enhanced mortality in COVID-19. QJM. 
2020; 113(7):509-510.
36. Clinical management of severe acute respiratory infection 
(SARI) when COVID-19 disease is suspected. World 
Health Organization.13 March 2020.WHO reference 




date: 1 May 2020.
37. ERA/EDTA recommendation. Available at: https://www.
era-edta.org/en/covid-19-news-and-information/#toggle-
id-8. Accessed date: 1 May 2020. 
38. Mo Y, Fisher D. A review of treatment modalities for Middle 
East Respiratory Syndrome. J Antimicrob Chemother . 
2016;71(12): 3340-3350.
39. Nankivell BJ, P,Ng CH, O,Connell PJ, Chapman JR. 
Calcineurin inhibitor nephrotoxicity through the lens of 
longitudinal histology: comparison of cyclosporine and 
tacrolimus eras. Transplantation. 2016; 100(8): 1723-
1731.
40. Shen L, Niu J, Wang C, et al. High-throughput screening 
and identification of potent broad-spectrum inhibitors of 
Coronaviruses. J Virol. 2019; 93(12): e00023-19. 
41. Luo W, Yu H, Gou J, Li X, Sun Y, Li J, Liu L. Clinical 
pathology of critical patient with novel coronavirus 
pneumonia (COVID-19). Pathology and Pathobiology. 
2020. Preprint 2020020407.
42. Iba T, Levy JH, Warkentin TE, et al. Diagnosis and 
management of sepsis-induced coagulopathy and 
disseminated intravascular coagulation. J Thromb 
Haemost. 2019; 17(11): 1989-1994. 
Pharmacotherapy in CKD Patients with COVID-19—Dashti et al
255Iranian Journal of Kidney Diseases | Volume 14 | Number 4 | July 2020
43. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. 
Anticoagulant treatment is associated with decreased 
mortality in severe coronavirus disease 2019 patients with 
coagulopathy. J Thromb Haemost. 2020; 18(5):1094-1099.
44. Porterucha TJ, Libby P, Goldhaber SZ. More than an 
anticoagulant: do heparins have direct anti-inflammatory 
effects? Thromb Haemost. 2017; 117(3): 437-444. 
45. Thachil J, Tang N, Gando S, et al. ISTH interim guidance 
on recognition and management of coagulopathy in 
COVID-19. J Thromb Haemost. 2020; 18(5):1023-1026.
46. Hughes S, Szeki I, Nash MJ, Thochil J. Anticoagulation in 
chronic kidney disease patients-the practical aspects. Clin 
Kidney J. 2014; 7: 442-449.
Correspondence to:
Simin Dashti-Khavidaki, MD
Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran 
University of Medical Sciences, P.O. Box: 1417614411, Tehran, 
Iran
Tel: 0098 21 6695 4709












Effects of Carvedilol on Cardiovascular Events and Mortality in 
Hemodialysis Patients, A Systematic Review and Meta-Analysis
Zhouke Tan,1 Guibao Ke,2,3 Junlin Huang,4 Die Yang,5 
Mingjing Pi,6 Li Li,6 Xiaolin Liu,7 Shaohua Tao,8 Lvlin Chen,8 
Guobiao Liang,9 Shuangxin Liu2,3
Carvedilol, the third generation of vasodilators; serves as the 
blocker of non-selective beta-adrenergic receptor and alpha1 
adrenergic receptor. It could protect the cardiovascular system of 
patients receiving dialysis treatment. However, current clinical 
trials discussing the therapeutic benefit of carvedilol on patients 
receiving dialysis treatment remain inconsistent. Consequently, we 
decided to perform a meta-analysis to evaluate the clinical efficacy 
of carvedilol on patients receiving dialysis treatment.
A search was conducted using EMBASE, Pubmed, Cochrane Central 
Register of Controlled Trials, Wanfang database, Chinese National 
Knowledge Infrastructure (CNKI), and VIP information database 
up to February 2020. We research publications (include English 
and Chinese language) that discuss the effects of carvedilol on 
cardiovascular events, all-cause mortality, hospitalizations or left 
ventricular ejection fraction (LVEF) in dialysis population. 
Our analysis included 4 randomized control trials and 2 observational 
studies. We discussed the therapeutical effects of carvedilol on 
all-cause mortality, cardiovascular events, hospitalizations, and 
LVEF of patients receiving dialysis treatment. Totally, this analysis 
reported 2998 hemodialysis (HD) patients. We found a significant 
association between carvedilol and reduced incidence of all-cause 
mortality, cardiovascular events and hospitalizations in HD patients. 
In addition, carvedilol significantly improves LVEF (n = 241; 
WMD = 6.95; 95% CI, 0.54 to 13.36; I2 = 90%) in HD population.
Our systematic review and meta-analysis demonstrates that 
carvedilol is associated with a reduced incidence of cardiovascular 
events, all-cause mortality and hospitalizations in patients on HD. 
Besides; carvedilol significantly improves LVEF in HD population. 
Nevertheless, high-quality and well-powered evidence is still needed, 
so as to further confirm the impacts of carvedilol on HD patients.
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INTRODUCTION
Cardiovascular events is the major killer of 
Hemodialysis (HD) patients because of the following 
reasons.1-3 First, approximately 80% of HD patients 
have one or more types of cardiac diseases,4 which 
increases the possibility of cardiovascular events. 
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The mortality rate of chronic kidney disease (CKD) 
patients receiving dialysis is 6.1 to 7.8 times higher 
than the general population. Second, intermittent 
HD sessions expose patients to a high variability 
in hemodynamics, heart rate and electrolytes, 
which also increase the risk of cardiovascular 
events and mortality. Third, over activated 
sympathetic nervous system in HD patients can 
trigger cardiovascular events.5-7 Finally, due to the 
lack of evidence-based drug therapy strategies and 
the complex pathophysiology in dialysis patients, 
cardiovascular events remains a big challenge to 
improve the survival rate of patients receiving 
dialysis.8 Carvedilol, the blocker of non-selective 
beta-adrenergic receptor and alpha1 adrenergic 
receptor; offers multiple favorable effects such 
as antioxidant, antiapoptotic, and antiarrhythmic 
actions.9-11 Thus, it may theoretically play a unique 
cardiovascular protective role in the patients 
receiving dialysis. However, only a clinical trial 
demonstrated that carvedilol improved survival 
rate of chronic dialysis patients with severe heart 
failure,12 while other studies failed to demonstrate 
that carvedilol could help improve the survival 
rate13,14 in the dialysis population. Considering 
the fact that the effect of carvedilol on dialysis 
patients still remains controversial, we thus aimed 
to perform a meta-analysis to evaluate the effects 
of carvedilol on patients requiring dialysis.
MATERIALS AND METHODS
We perform the systematic review and meta-
analysis in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement. Ethical approval is not 
required because this meta-analysis does not 
directly involve any patient.
Data Sources and Search Strategy
A search was conducted using EMBASE, Pubmed, 
Cochrane Central Register of Controlled Trials, 
Wanfang database, Chinese National Knowledge 
Infrastructure (CNKI), and VIP information database 
up to February 2020. We research publications 
(include English and Chinese language) that discuss 
the effects of carvedilol on cardiovascular events, all-
cause mortality, hospitalizations or left ventricular 
ejection fraction (LVEF) in dialysis population. The 
search strategy comprised a combination of free 
text terms and MeSH terms, primarily including: 
“Carvedilol”, “Hemodialysis”, “Hemodialyses”, 
“Dialysis”, and “Renal Replacement Therapy”. 
We also reviewed the reference lists in order to 
search additional relevant studies.
Inclusion and Exclusion Criteria 
Inclusion criteria was considered: a) participants: 
adult HD patients, b) study design: randomized 
controlled trial and observational studies, c) 
outcomes:  cardiovascular events,  al l-cause 
mortality, and hospitalizations, d) intervention: 
the intervention group received standard care + 
carvedilol treatment, while the comparison group 
received standard care + placebo therapy or only 
standard care. 
Exclusion criteria was considered: abstracts, 
reviews, duplicate publications,  editorials, 
comments, case reports, publications without 
available data, and cell or animal experiments.
Data Extraction and Study Quality Assessment
Data from the included studies were extracted 
and recorded independently by two authors (D.Y. 
and J.H.) and disagreements were resolved by 
consensus. The following information recorded 
in each included study were extracted for both 
RCTs and observational studies: first author, year 
of publication, study design, dosage of carvedilol, 
sample size, follow-up, cardiovascular events, all-
cause mortality, hospitalizations, mean and SD of 
LVEF (if the LVEF data was presented as mean and 
SE, it was converted to mean and SD). For RCTs, 
two reviewers (L.L. and M.P.) evaluated risk of bias 
of studies with the Cochrane collaboration risk of 
bias (ROB) tool.15 For observational studies, the 
Newcastle-Ottawa Scale16 was used to assess the 
quality of our included studies by the reviewers 
(L.L. and M.P.). Conflicts were resolved by the 
third reviewer (G.K.).
Statistical Analysis
We used the risk ratio (RR) and weighted mean 
difference (WMD) to compare dichotomous and 
continuous variables respectively. All results were 
reported with a 95% confidence intervals (CIs). 
Heterogeneity among studies was assessed using 
the I2 statistics (I2 > 50% suggested substantial 
heterogeneity). We used fixed effects or random 
effects model because it takes into account the 
heterogeneity across studies. Pre-stratified subgroup 
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analysis was performed to investigate possible 
sources of heterogeneity, including study design. 
The presence of publication bias was also evaluated 
with Egger’s tests and funnel plots. If the all-causes 
mortality were present merely in figures, two authors 
(L.L. and G.K.) would use Engauge Digitizer 10.8 to 
collect data from the statistical graphs independently. 
Then, the mean values of all-cause mortality would 
be used to perform meta-analysis.17 All analyses 
were performed using RevMan 5.3 and Stata 12.0. 
We considered P < .05 as statistically significant.
RESULTS
Search Results
In total, our comprehensive search yielded 248 
articles. First, 36 duplicate articles were excluded 
and 212 articles were remained for screening. Then, 
we excluded 167 of the 212 articles after examining 
the title and abstract in more detail. We scrutinized 
the full texts of the remaining 45 studies, of which 
39 were excluded, due to a lack of necessary data 
related to our study. Eventually, after a careful 
selection based on our above-mentioned inclusion 
criteria, 6 studies (Figure 1) with a total of 2998 
participants were included in this meta-analysis 
(4 RCTs7,12,14,18 and 2 observational studies13,19). 
Study Characteristics
The main characteristics of the 6 studies included 
are shown in Table 1 and 2. Patients in these 6 studies 
had a long-term HD history. The intervention groups 
received standard care + carvedilol treatment, 
while the control groups received standard care + 
placebo therapy or only standard care. All LVEF 
measurements were estimated by echocardiogram. 
The author’s judgments over the risk of bias for 
each included study were shown in Supplementary 





according to title or abstract
39 studies without complete
data excluded according to
reading the full article
45 articles assessed for
eligibility
212 records assessed after
similar and reduplicate
studies removed









VIP information database (n=13).
Figure 1. It shows flow diagram illustrating the selection of studies for this meta-analysis.
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studies were at low risk.
Association of Carvedilol Therapy with All-
cause Mortality 
In the pooled analysis of 6 studies (n = 2998), 
compared with the patients with no carvedilol 
treatment, carvedilol reduced all-cause mortality in 
HD patients (RR = 0.79, 95% CI: 0.74 to 0.84; P < .01 
in the fixed effects model, Figure 2a). There was 
no heterogeneity among studies (P > .05, I2 = 0%). 
Besides, subgroup analysis also showed that the 
results of 4 RCTs and 2 observational studies were 
consistent.
Association of Carvedilol Therapy with 
Cardiovascular Events 
Meta-analysis of 5 studies (n = 290, 4 RCTs and 
1 observational study) showed a significant decline 
in cardiovascular events of patients who received 
carvedilol treatment (RR = 0.51, 95% CI: 0.35 to 
0.75; P < .01 in the fixed effects model, Figure 2b). 
Heterogeneity was detected among studies (P > .05, 
I2 = 34%). Since we only use one observational 
study, we did not perform subgroup-analysis. 
Association of Carvedilol Therapy with 
Hospitalizations 
Meta-analysis of 3 RCTs (n = 183) showed a 
noticeable reduction in hospitalizations with 
carvedilol treatment (RR = 0.68, 95% CI: 0.49 to 
0.93; P < .05 in the fixed effects model, Figure 2c). 
Heterogeneity was found among studies (p = 0.2, 
I2 = 39%). 
Association of Carvedilol Therapy with LVEF 
Change
Meta-analysis of 4 studies (n = 241, 3 RCTs, 1 
observational study) showed carvedilol significantly 
improves LVEF (WMD = 6.95, 95% CI: 0.54 to 13.36; 
P < .05 in the random effects model, Figure 2d) in 
HD patients. However, heterogeneity was detected 
among studies (P < .01, I2 = 90%). Similarly, since 
Study
All-cause Mortality Cardiovascular Events Hospitalizations LVEF
Carvedilol Placebo Carvedilol Placebo Carvedilol Placebo Carvedilol Placebo
Cice et al, 2003 30 (52%) 41 (73%) 17 (29%) 39 (70%) 20 (34%) 33 (59%) 37 [10] 24 [10]
Kojima et al, 2007 0 0 0 0 0 0 63.5 [5.4] 66.4 [5.1]
Tang et al, 2008 0 0 2 (11%) 1 (6%) Unclear Unclear 46.8 [5.4] 38.8 [5.3]
Roberts et al, 2016 1 (4%) 0 1 (4%) 3 (13%) 14 (54%) 14 (61%) Unclear Unclear
Ma et al, 2018 5 (36%) 19 (36%) 3 (21%) 10 (17%) Unclear Unclear 68.6 [8.0] 59.2 [9.7]
Tang et al, 2016 555 (55%) 1190 (70%) Unclear Unclear Unclear Unclear Unclear Unclear
Table 2. All-cause Mortality, Cardiovascular Events, Hospitalizations, and LVEF in Studies Using Carvedilol















Free of Other 
Bias
Cice 2003 Yes Unclear Unclear Yes Yes Yes
Kojima 2007 Yes Unclear Unclear Yes Yes Yes
Roberts 2016 Yes Unclear Unclear Yes Yes Yes
Tang 2008 Yes Unclear Unclear Yes Yes Yes
Supplementary Table 1. Risk of bias assessment quality of included RCTs
Note: Risk of bias was assessed with use of the Cochrane risk-of-bias tool. The overall risk of bias of a study was considered “high” if more than 
1 item was rated as “high risk” or if fewer than 2 items were rated as “low risk”; The overall risk of bias of a study was considered “moderate” if 2 




















MA 2018 * * * - ** * * * 8
Tang 2016 * * * * ** * * * 9
Supplementary Table 2. Risk of Bias in Observational Studies Using Newcastle-Ottawa Scale
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we only use one observational study, we did not 
perform subgroup-analysis. 
Publication Bias
The potential publication bias was detected 
by Egger’s test and funnel plots (Figure 3a and 
3b). We found no publication bias for carvedilol 
on all-cause mortality (Egger’s test, P > .05) and 
cardiovascular events (Egger’s test, P > .05). Besides, 
apart from all-cause mortality and cardiovascular 
events, we do not draw the funnel plots for other 
parameters in this meta-analysis, due to the small 
size of these parameters in our included studies.
DISCUSSION
To the best of our knowledge, the present research 
is the first meta-analysis that evaluated the clinical 
efficacy of carvedilol on HD patients. Our analysis 
included 4 RCTs and 2 observational studies, 
reporting 2998 HD patients. First, Carvedilol was 
associated with a 49% reduction in cardiovascular 
events, a 21% reduction in all-cause mortality and 
a 32% reduction in hospitalizations in HD patients. 
Besides, carvedilol significantly improves LVEF 
in HD population. Our research outcome could 
help update the information over the unique role 
of carvedilol in protecting patients receiving HD.
Approximately 80% of HD patients have one or 
more types of cardiac disease.4 Also, intermittent 
HD sessions (usually three times a week) expose 
patients to a high variability in hemodynamics, heart 
rate and electrolytes. What’s more, overactivated 
sympathetic nervous system in HD patients 
further triggers off cardiovascular events.5-7 Given 
the high incidence of cardiovascular events, HD 
patients may benefit from -blockers therapy,20,21 
especially the carvedilol, which is widely used in 
patients with heart failure (HF),22,23 chemotherapy-
induced cardiotoxicity,24 arterial stiffness,25 left 
ventricular function dysfunction,26 acute coronary 
syndrome,27 and hypertension28. However, few 
high-quality and well-powered studies have 
evaluated cardiovascular therapy’s effects on HD 
patients. Most studies have excluded patients with 
advanced CKD due to the risk of side effects, such 
as hyperkalemia, hypotension, fluid overload, 
anemia and so forth.29-32 Wali et al. reported a 
meta-analysis on RCTs addressing the efficacy 
and safety of carvedilol in HF treatment on CKD 
patients.33 They suggested that treatment with 
carvedilol in CKD patients reduced the relative risks 
for all-cause, cardiovascular, and HF mortality in 
HF patients with CKD.33 However, their finding 
did not determine whether carvedilol therapy 
could benefit advanced CKD or HD patients. Our 
meta-analysis filled such a gap by including data 
of 2998 HD patients and extracted from six studies. 
The pooled result suggested that carvedilol might 
play a unique cardiovascular protective role in the 
patients receiving dialysis. 
First, our analysis focused on the association 
of carvedilol therapy with mortality rate, in that 
(d)
Figure 2. It demonstrates forest plots for all-cause mortality, cardiovascular events, hospitalizations, and LVEF outcomes; respectively: 
carvedilol associated with reduced all-cause mortality (a), cardiovascular events (b), and hospitalizations (c) in HD patients. 
Furthermore, carvedilol significantly improves LVEF (d) in dialysis population (LVEF, left ventricular ejection fraction; HD, hemodialysis).
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mortality rate is one important clinical index, and 
mortality rates are high for HD patients. For HD 
patients initiating their renal replacement therapy 
within 3 years, the mortality rate almost reached 
50%.34 In addition, we also discussed the association 
of carvedilol therapy with Cardiovascular events, 
because Cardiovascular events is the leading killer 
of HD patients.2,3,35 Moreover, we continued to 
analyze the association between carvedilol therapy 
and LVEF, as LVEF is the most frequently used 
parameter to define left ventricular systolic (dys-) 
function36 and is strongly associated with the 
increased mortality rate in CKD patients.37,38 Volume 
overload, chronic pressure and non-hemodynamic, 
such as oxidative stress and abnormal renin-
angiotensin-aldosterone system (RAAS) activation, 
lead to the development of left ventricular systolic 
and diastolic dysfunction39 of CKD patients. Our 
meta-analysis showed that carvedilol significantly 
improves LVEF in HD population, and thus was 
Figure 3. It shows publication bias assessment by funnel plot for all-cause mortality (a) and cardiovascular events(b).
(a)
(b)
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consistent with the findings which showed that 
carvedilol was associated with a 49% reduction in 
cardiovascular events, a 21% reduction in all-cause 
mortality, and a 32% reduction in hospitalization 
of HD patients. 
In sum, carvedilol is associated with a reduced 
possibility of cardiovascular events, all-cause 
mortality and hospitalizations in patients receiving 
HD. Besides; carvedilol significantly improves 
LVEF in dialysis population. Carvedilol can 
block sympathetic neural and RAAS activation, 
antioxidant, antiapoptotic, antiarrhythmic actions 
and so forth. Hence, it can provide a potential 
protective mechanism for HD patients.
Limitations of this systematic review and meta-
analysis are as follows. Firstly, we were unable 
to minimize the heterogeneity’s impacts through 
stratified analyses or subgroup, especially in LVEF 
comparisons, because of the limited number of 
included studies. The random effects model might 
reduce the effect of heterogeneity, but does not 
minimize it. Secondly, the included RCTs have 
a relatively small sample size and a short-term 
follow-up, which may lack strong persuasiveness. 
Thirdly, because of the limited number of studies 
(such as metoprolol, nebivolol, and bisoprolol), 
we could just quantitatively assess the effects of 
carvedilol. Hence, further clinical trials are needed 
to test the effects of other beta-blockers. Fourthly, 
different doses, different lengths of intervention time 
in each study might cause a potential bias. Also, 
different experiments had different designs, and 
the condition of patients also differed. Moreover, 
the small number of included studies could afford 
modest ability to detect the presence of publication 
bias.40 Thus, high-quality and well-powered 
evidence is needed for future study. 
CONCLUSION
The results of this meta-analysis support the 
argument that treatment with carvedilol can reduce 
rates of cardiovascular events, all-cause mortality 
and hospitalization in HD patients. Besides, 
carvedilol significantly improves LVEF in HD 
population. Nevertheless, high-quality and well-
powered evidence is still needed to confirm the 
therapeutic impacts of carvedilol on HD patients.
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Clinical and Radiologic Characteristics of COVID-19 in 
Patients With CKD 
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Introduction. In this study, we aimed to evaluate the presentation 
and outcome of COVID-19 in patients with chronic kidney disease 
(CKD).
Methods. We included 43 patients with a past history of CKD 
and confirmed diagnosis of COVID-19. Patients were evaluated 
for demographic characteristics, clinical and laboratory data and 
findings of initial chest computed tomography (CT) and were 
followed until either death or discharge occurred. Then, study 
variables were compared based on final outcome and stage of CKD.
Results. Mean age ± SD of patients was 60.65 ± 14.36 years; 65.1% 
were male. Five of 43 patients (11.6%) died on follow-up and the 
rest were discharged. Disease outcome did not differ across CKD 
stages (P > .05). More than half of the patients (58.1%) presented 
with severe disease on admission. Clinical symptoms were similar 
to those of non-CKD individuals. Mean duration of hospitalization 
was higher in those who died, although not significant (16.6 ± 8.38 
vs. 11 ± 6.26, P > .05). The only hematologic parameter that 
significantly differed between survivors and non-survivors was 
lactase dehydrogenase level (P < .05). Ground-glass opacification 
and reticular pattern were the most frequent patterns on CT and 
pleural effusion existed in about one-fifth of all patients. A greater 
lower zone score was noted in deceased patients (P < .05). 
Conclusion. Patients with CKD are vulnerable to a more severe 
form of COVID-19 and experience a higher mortality rate than 
the general population; however, higher CKD stage is not related 
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INTRODUCTION
In December 2019, an outbreak of pneumonia 
caused by a novel beta-coronavirus, currently 
named as the “severe acute respiratory syndrome 
coronavirus 2” (SARS-CoV-2) ,  occurred in 
Wuhan, China. The disease caused by this virus 
was subsequently named Coronavirus Disease 
2019 (COVID-19).1 The most common clinical 
presentations of COVID-19 include fever, cough, 
dyspnea, and fatigue along with ground glass 
opacification (GGO) on chest computed tomography 
(CT) imaging.2,3 Although the majority of patients 
with COVID-19 develop mild form of the disease, 
specific patient populations are at a risk of severe 
disease and require more attention. According 
to published studies, patients with underlying 
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conditions such as diabetes, cardiovascular disease, 
liver cirrhosis, and chronic kidney disease (CKD) 
are not only at a higher risk of infection, but also 
prone to a more serious outcome once infected. 
These patients are more likely to progress to forms 
of disease requiring admission to intensive care unit, 
mechanical ventilation or death.4,5 Of note, patients 
with CKD are most likely to suffer from other 
concurrent comorbidities, such as hypertension, 
diabetes, and cardiovascular diseases. 
Hence, it is likely that patients with CKD, in 
particular those on dialysis, will be at an excessive 
risk by the current COVID-19 pandemic5 and as the 
crisis tends to remain, increased emphasis should 
be given to understanding disease presentation in 
high-risk subgroups for better patient management. 
While there is relatively extensive data regarding 
acute kidney injury triggered by COVID-19,6,7 only 
few studies have investigated the characteristics 
of COVID-19 in patients with pre-existing kidney 
failure. Thus, in this study, we aimed to evaluate 
the clinical, laboratory and imaging findings, as 
well as disease outcome of a series of CKD patients 
with confirmed diagnosis of SARS-CoV-2 infection. 
MATERIALS AND METHODS
Study Population And Design
This was a single-center study conducted on 43 
consecutive patients with confirmed COVID-19 
who were admitted from 20 February, 2020 to 
15 April, 2020 to our academic tertiary hospital. 
Figure 1 shows the flowchart for patient enrollment. 
Inclusion criteria were as follows: 1) confirmed 
diagnosis of COVID-19 through real-time reverse 
transcriptase polymerase chain reaction (RT-PCR) 
assay with samples obtained from nasopharyngeal 
swab; 2) chest CT images suggestive for COVID-19 
pneumonia; 3) confirmed diagnosis of CKD based 
on Kidney disease: Improving Global Outcomes 
(KDIGO) CKD Work Group (2012) classification;8 
and 4) age older than 18 years old. All patients 
were receiving standard therapy for CKD based on 
national and international guidelines. On admission, 
patients’ information regarding demographic data, 
past medical history, and presenting signs and 
symptoms was obtained through a pre-designed 
questionnaire filled by an independant investigator. 
Also, vital signs including patients’ pulse rate 
and oxygen saturation (SpO2) were measured by 
a fingertip pulse oximeter and respiratory rate 
was measured by counting chest movements in 
one minute. Furthermore, the imaging findings of 
patients’ initial chest CT were recorded. According 
to diagnosis guidelines of COVID-19 in Iran, all 
patients had undergone at least one low-dose CT 
scan at admission as part of their initial work-up.9 
302 adult patients with suspected COVID-19
98 adult patients suspected of COVID-19 with
CKD stage II*-V
204 patients did not meet criteria for CKD
based on KDIGO guideline:
•158 patients with a GFR ≥ 90
(ml/min/1.73 m2)
•46 patients with a GFR between 60-89
(ml/min/1.73 m2) and no concurrent
comorbidities or systemic diseases
43 adult CKD patients with confirmed COVID-
19 and suggestive chest involvement on CT
55 patients did not meet inclusion criteria:
•36 patients who did not test positive for
SARS-CoV-2 RT-PCR
•19 patients without suggestive chest
involvement on CT
Figure 1. It shows flowchart of patient enrollment.
*G2 category with concurrent comorbidity/systemic disease
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All patients were followed until one of the study 
endpoints (determined as either death or complete 
recovery and discharge) were reached. Estimated 
glomerular filtration rate (eGFR) was calculated 
for each case according to the Modification of Diet 
in Renal Disease (MDRD) equation.10 According 
to the interim guideline of the WHO, published 
on 13 March, 2020, severe disease was defined 
as fever or suspected respiratory infection, plus 
either respiratory rate > 30 breaths/min; severe 
11 
Lymphocytopenia was considered as absolute 
lymphocyte count < 1× 109, thrombocytopenia as 
platelet count < 150 × 109, neutrophilia as absolute 
neutrophil count > 7.5 × 109, and eosinopenia 
as < 0.01 × 109 in per liter of blood. 
Ethical Considerations 
The study protocol was approved by the ethics 
committee of our institutional review board. 
Informed consent was obtained from all patients 
prior to enrollment and all personal data was 
anonymized. All procedures performed in this study 
was in accordance with 1964 Helsinki declaration 
and its later amendments.
Chest CT Imaging 
As part of national COVID-19 guidelines, all 
patients underwent non-contrast chest CT scan with 
a low-dose protocol.18 All CT scans were performed 
using a 64-slice scanner (Siemens sensation; 
Siemens Healthineers, Erlangen, Germany) in 
a supine position during end-inspiration. For 
every patient, a low-dose CT protocol with the 
following scanning parameters was performed: 
gantry rotation time of 0.5 seconds, 0.625 mm 
× 64-detector array, pitch of 1.4, table speed of 
45.2 mm/rotation, 20 mAs, 120 kVp, and a 300 
× 300 matrix. CARE Dose4D; CARE kV scanning 
parameters were off. For the purpose of sagittal and 
coronal image reconstruction, 1 mm slice thickness 
and 1 mm reconstruction intervals were used. All 
of the machine surfaces were disinfected with 
ethanol and didecyldimethylammonium chloride 
(DDAC). After every CT, passive air ventilation 
was performed for at least 30 minutes. 
DICOM data were transferred onto a picture 
archiving and communicating system (PACS) and 
two expert radiologists with 9 and 18 years of 
experience interpreted the images. Both radiologists 
were blinded to the lab data, clinical features, and 
patients’ diagnosis. A final CT score was reached 
by consensus of the two radiologists. The opinion 
of a third radiologist was used to resolve dual-
reader disagreements. All the CT scans were 
reviewed in axial, sagittal and coronal planes. In 
patients with more than one CT scan at admission, 
only the initial CT was evaluated. For classifying 
lung zone involvement, three zones were defined 
as follows: upper zone: above the carina region; 
middle zone: the area between the carina and 
inferior pulmonary vein; and lower zone: below the 
inferior pulmonary vein.2 Predominant pattern of 
involvement was assessed and classified as GGO, 
consolidation, reticular or mixed. In addition, lesion 
distribution (peripheral, central or diffuse) and 
predominant zonal involvement (upper, middle, 
lower or diffuse) were recorded. In addition, the 
presence of other imaging features including crazy-
paving, reverse halo sign, airway thickening, dilated 
vessels, airway dilatation, air bronchogram and 
lymphadenopathy (defined as a lymph node with 
a short-axis diameter > 10 mm) was assessed. The 
percentage of lung involvement was scored using 
the following system: 0: no involvement, 1: < 25%, 
2: 26% to 50%, 3: 51% to 75%, and 4: > 75%.26 The 
scores of each specific zone (upper, middle, and 
lower) of both lungs were summed up to calculate 
the zonal score (maximum score = 8) and the total 
score was calculated by summing scores of the upper, 
middle, and lower zones (maximum score = 24). 
Laboratory Procedures
At admission, nasopharyngeal swab samples 
were taken from all patients with suspected 
SARS-CoV-2 infection and RT-PCR (DAAN gene 
Co Ltd device) was performed for every patient. 
Laboratory tests including biochemistry, complete 
blood count (CBC) and indices such as neutrophil/
lymphocyte ratio (NLR) and platelet/ lymphocyte 
ratio (PLR) ratios, and inflammatory markers such 
as C-reactive protein (CRP) were recorded. CRP 
levels were measured using the Rondox essay kit 
with immunoturbidimetric techniques. To evaluate 
CBC, NLR and PLR, venous blood samples were 
collected in potassiumethylene diamine tetraacetic 
acid tubes (dipotassium EDTA tubes) and the 
Sysmex-XE 2000i automated blood cell analyzer 
(Sysmex, Kobe, Japan) was used to for measurement 
within an hour. This is the standard duration time 
Characteristics of COVID-19 in patients with CKD—Abrishami et al
270 Iranian Journal of Kidney Diseases | Volume 14 | Number 4 | July 2020
for our laboratory, since it prevents EDTA-induced 
swelling.
Statistical Analysis
Continuous variables are reported as mean 
(± SD) and categorical variables are expressed as 
frequency (percentage). Variables were compared 
across outcome groups (death vs discharge) and 
also CKD stages. Normality assumptions were 
tested using the Shapiro-Wilk test. Student t-test 
was used for comparison of continuous data and 
Chi-square or Fischer’s exact test was applied 
to compare categorical variables. All statistical 
analyses were performed by SPSS version 23 (IBM 




Table 1 shows demographic characteristics of 
patients at baseline. The mean age ± SD of patients 
was 60.65 ± 14.36 years (range: 27 to 87); 65.1% 
were male. Age and sex were equally distributed 
across the two groups of outcome (P > .05, P > .05; 
respectively). The most frequent CKD stage was 
stage IIIa and the least common was stage IV. Of 
the five patients with ESRD, three were already 
on dialysis and in the other two cases; dialysis 
was initiated for the first time after SARS-CoV-2 
infection. Majority of patients (n = 32, 74.4%) had 
a positive history of cardiovascular diseases.
Clinical and Laboratory Findings
Table 2 shows clinical and laboratory data of 
patients at the time of admission. Of the total 43 
patients, 5 (11.6%) died on follow-up; including four 
patients with an estimated GFR < 60 cc/min/ 1.73m2 
and one patient with stage II CKD. The rest of the 
cases (88.4%) were discharged. Disease outcome was 
not significantly different across different stages of 
CKD (P > .05). On admission, severe disease had 
developed in 58.1% of the patients. Mean duration 
of hospitalization was 11.65 ± 6.67 (range: 2 to 
33), which was not significantly different across 
outcome groups (P > .05, P > .05; respectively, 
Table 2). Overall, the most common clinical 
presentation was dyspnea (65.1%), followed by 
cough (60.5%). Mean respiratory rate, temperature, 
and oxygen saturation did not vary significantly 
between those who died and those who were 
discharged (Table 2). Leukopenia, leukocytosis, 
and thrombocytopenia were observed in 7 (16.3%), 
4 (9.3%), and 12 (27.9%) patients; respectively. 
The mean lymphocyte, neutrophil and eosinophil 
count was 1.29 ± 0.57 × 109 /L, 4.56 ± 2.81 × 109 
/L, 0.083 ± 0.065 × 109 /L which did not display 
a significant difference between the two groups 
of outcome. Evaluation of serum biochemistry 
revealed that mean serum C-reactive protein and 
lactase dehydrogenase (LDH) level were higher 
Variables Total Patients(n = 43) 
Discharged
(n = 38) 
Death
(n = 5) P





38 to 76 > .05
Sex
Male 28 (65.1) 23 (60.5) 5 (100)
> .05
Female 15 (34.9) 15 (39.5) -
Comorbidities
IHD 14 (32.6) 11 (28.9) 3 (60)
> .05
HTN 18 (41.9) 16 (42.1) 2 (40)
Diabetes Mellitus 16 (37.2) 15 (39.5) 1 (20)
Asthma 1 ( 2.3) 1 (2.6) -
CKD stage
II 10 (23.3) 10 (26.6) -
> .05
IIIa 19 (44.2) 17 (44.7) 2 (40)
IIIb 7 (16.30) 5 (13.2) 2 (40)
IV 2 (4.7) 2 (5.3) -
V 5 (11.6) 4 (10.5) 1 (20) 
Table 1. Comparison of Patients’ Baseline Characteristics Based on Final Disease Outcome.
Continuous variables are reported as mean ± SD and range. Categorical variables are reported as n (%). P values are calculated by 2 test, 
Fisher’s exact test, or Student t-test.
Abbreviations: IHD, ischemic heart disease; HTN, hypertension; CKD, chronic kidney disease.
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Variables Total Patients(n = 43) 
Discharged
(n = 38) 
Death
(n = 5) P
Clinical Presentation
Dyspnea 28 (65.1) 25 (65.8) 3 (60)
> .05
Fever 21 (48.8) 19 (50) 2 (40)
Cough 26 (60.5) 23 (60.5) 3 (60)
Sore Throat 5 (11.6) 4 (10.5) 1 (20)
Chilling Sensation 9 (20.9) 9 (23.7) -
Headache 4 (9.3) 3 (7.8) 1 (20)
Myalgia 14 (32.6) 13 (34.2) 1 (20)
Nausea 6 (14) 5 (13.1) 1 (20)
Abdominal Pain 6 (14) 5 (13.1) 1 (20)
Diarrhea 4 (9.3) 3 (7.8) 1 (20) 





7 to 29 > .05





68 to 96 > .05





12 to 24 > .05





35 to 38.3 > .05
Leukocyte Count
< 4 × 109 /L 7 (16.3) 6 (15.8) 1 (20)
> .05× 109 /L 32 (74.4) 28 (73.6) 4 (80)
> 4 × 109 /L 4 (9.3) 4 (10.6) -
Platelet count
< 150 × 109 /L 12 (27.9) 10 (26.3) 2 (40)
> .05150-450 × 109 /L 29 (67.4) 26 (68.2) 3 (60)
> 450 × 109 /L 2 (4.7) 2 (5.2) -





9 to 15.3 > .05
Differential Count
Neutrophilia 4 (9.3) 4 (10.5) -
> .05Lymphocytopenia 23 (53.5) 20 (52.6) 3 (60)
Eosinopenia 3 (7) 3 (7.9) -
NLR 4.03 ± 2.99 4.11 ± 3.15 3.36 ± 0.93 > .05
PLR 179.57 ± 73.52 184.5 ± 74.4 142.7 ± 60.44 > .05
NLR*CRP 174.8 ± 199.1 176.5 ± 210.6 160.1 ± 28.0 > .05





1.26 to 6.24 > .05





43 to 163 > .05





33 to 69 > .05





82 to 531 > .05





430 to 1413 < .05





7.8 to 9.3 > .05





2.3 to 5.1 > .05





1.7 to 2.1 > .05





17 to 70 > .05
Table 2. Comparison of Patients’ Baseline Clinical Presentation and Laboratory Findings Based on Final Disease Outcome
Continuous variables are reported as mean ± standard deviation and range. Categorical variables are reported as n (%). P values are calculated 
by 2 test, Fisher’s exact test, or Mann-Whitney U test.
Abbreviations: NLR, Neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CRP, C-reactive protein; BUN, blood urea nitrogen.
Characteristics of COVID-19 in patients with CKD—Abrishami et al
272 Iranian Journal of Kidney Diseases | Volume 14 | Number 4 | July 2020
than normal in all patients. Also, baseline LDH 
level was significantly higher in patients who had 
experienced death (P < .05). Blood urea nitrogen and 
serum creatinine showed borderline significance 
in regards to disease outcome. 
Imaging Findings
Table 3 shows chest CT findings of patients 
Variables Total Patients(n = 43) 
Discharged
(n = 38) 
Death
(n = 5) P





0 to 5 > .05





4 to 7 > .05





4 to 8 < .05





8 to 19 > .05
Pattern of Involvement
Ground Glass Opacification 15 (34.9) 12 (31.5) 3 (60)
> .05
Consolidation 4 (9.3) 3 (7.9) 1 (20)
Reticular 7 (16.3) 7 (18) -
Mixed 4 (9.3) 3 (7.9) 1 (20) 
Lesion Distribution
Axial
Central 2 (4.7) 2 (5.2) -
> .05Peripheral 35 (87.4) 32 (84.2) 3 (60)
Diffuse 6 (14) 4 (10.5) 2 (40)
Craniocaudal
Upper 3 (7) 3 (7.8) -
> .05
Middle 8 (18.6) 8 (21) -
Lower 20 (46.5) 18 (47.4) 2 (40)
Diffuse 12 (27.9) 9 (23.7) 3 (60)
Anteroposterior
Anterior 2 (4.7) 2 (5.2) 2 (40)
> .05Posterior 29 (67.4) 29 (76.3) -
Diffuse 12 (27.9) 9 (23.7) 3 (60)
Lung Involvement
Bilateral 40 (93) 35 (92.1) 5 (100)
> .05
Unilateral 3 (7) 3 (7.9) -
Other Imaging Features
Pleural Effusion 9 (20.9) 8 (21) 1 (20)
> .05
Pericardial Effusion 6 (14) 6 (15.8) -
Emphysema 1 (2.3) 1 (2.6) -
Fibrosis 1 (2.3) 1 (2.6) -
Bronchiectasis 1 (2.3) 1 (2.6) -
Bronchial Wall Thickening 37 (86) 32 (84.2) 5 (100)
Crazy-paving Pattern 7 (16.3) 6 (15.8) 1 (20)
Reversed-halo Sign - - -
Dilated Vessel 32 (74.4) 27 (71) 5 (100)
Airway Dilatation 18 (41.9) 17 (44.7) 1 (20)
Air Bronchogram 13 (30.2) 12 (31.5) 1 (20)
Cavitation - - -
Interseptal Thickening 4 (9.3) 4 (10.5) -
Cyst 3 (7) 3 (7.8) -
Lymphadenopathy 3 (7) 3 (7.8) -
Table 3. Comparison of Patients’ Initial Chest CT Findings Based on Final Disease Outcome
Continuous variables are reported as mean ± standard deviation and range. Categorical variables are reported as n (%). P-values are calculated 
by 2 test, Fisher’s exact test, or Student t-test.
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in detail. As shown, the mean ± SD score of the 
upper zone, middle zone, and lower zone were 
2.63 ± 1.77, 3.98 ± 2.12, and 4.3 ± 2.31; respectively. 
The total lung score was 10.91 ± 5.67, which was not 
different across outcome groups (P > .05); however, 
in patients who died, lower zone score was higher 
(P < .05). We observed bilateral involvement in 93% 
of patients. Interestingly, bilateral lung involvement 
was seen in all patients who eventually experienced 
COVID-19-related mortality. The most common 
pattern of involvement was GGO followed by 
reticular pattern. Lesions were mainly distributed 
in the posterior and lower parts of the lungs. 
Moreover, these lesions were commonly found 
in the periphery of lungs. Among other imaging 
features, vessel dilatation was a frequent finding, 
observed in approximately 75% of patients. Also, 
we observed that airway thickening and vessel 
dilatation existed in all patients who had expired. 
Pleural effusion was seen in approximately one-
fifth of patients and pericardial effusion was seen 
in 14% of our patients (Figure 2).
Comparison of Clinical, Laboratory, and CT 
Findings Based on CKD Stage
As shown in Table 4, patients with ESRD 
experienced the longest duration of hospitalization, 
however; when comparing across groups, no 
statistically significant different was seen. Mean 
oxygen saturation also did not vary in patients 
with different stages of CKD. Evaluation of 
biochemical parameters revealed that leukocyte 
count is associated with borderline difference across 
CKD stages (P > .05); however, this difference was 
not observed in platelet count and level of serum 
hemoglobin. 
As shown by the total lung score, the extent of 
lung involvement did not differ across patients 
with different stage of CKD (P > .05, Table 4). 
However, the presence of consolidation and GGO 
was significantly different across CKD groups 
(P < .05). Although lymphadenopathy was more 
commonly observed in patients with a higher GFR 
(P < .05), the presence of other imaging features 
did not vary significantly between patients with 
different CKD stages.
DISCUSSION
Many recent studies have emphasized the role 
of SARS-CoV-2 infection in inducing acute kidney 
damage but evidence regarding the characteristics 
of COVID-19 infection in patients with a history of 
chronic renal disease is sparse.6,7 Besides, no study 
has specifically investigated disease outcome in 
these patients based on stage of CKD. The results 
of our study showed that more than half of patients 
with CKD developed severe form of COVID-19. 
However, lower GFR and subsequently, higher 
stage of CKD, was not associated with a poorer 
prognosis and outcome.
To date, several risk factors have been proposed 
to increase the chance of developing progressive 
COVID-19 disease, among them the presence of 
co-existing morbidities. Recent reports have stated 
that CKD is significantly associated with increased 
COVID-19 severity and mortality.5,12 Our results 
Figure 2. A) A 55-year-old male patient with a history of underlying chronic kidney disease (GFR = 9.1, stage V) presented with dry 
cough and dyspnea which had started since 5 days ago. Initial computed tomography (CT) imaging showed bilateral moderate pleural 
effusion predominantly in right side, ground glass opacity and area of consolidation in middle zones. B) CT imaging obtained 22 days 
later show bilateral mild pleural effusion and complete lesion absorption. The patient was discharged after 7 days.
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approved this finding, showing that the risk of 
developing severe disease is twice as higher as 
compared with the general patient population.13,14 
Also, mortality rate was considerably higher (11.6%) 
in our patients than the rate reported for the general 
population.13-5 The comorbidities associated with 
increased odds of COVID-19-related death are 
prevalent in patients with CKD. A large study in 
China estimated mortality rate of COVID-19 to be 
10.5% in patients with cardiovascular diseases.16 
In our cohort of patients, more than 75% of cases 
had a positive history of cardiovascular diseases, 
possibly justifying the high mortality rate that 
was observed.
Our patients mostly manifested with dyspnea 
and cough, which is similar to that of non-CKD 
patients.3,17 In contrast to other studies, we did 
not find a significantly worse outcome in the 
elderly.17-9 A recent study on kidney transplant 
patients reported fever in 80% of cases, however; 
we observed fever in less than half of our patients. 
Furthermore, in the mentioned study, patients 
who required hospitalization were more likely to 
have reported dyspnea.20 However, the result of 
our study failed to show any relationship between 
disease presentation and final outcome.
We observed a borderline significant difference 
in patients’ outcome based on serum creatinine 
and BUN level. In a recent study, it was reported 
that elevated levels of BUN and serum creatinine 
are significantly associated with the death of 
patients with COVID-19.6 In anothor study, these 
factors were found to be predictive of in-hospital 
death.7 Despite this, our study did not display a 
difference in disease severity, outcome, or duration 
of hospitalization as the level of GFR decreased. 
In this study, the only biochemical factor which 
demonstrated a significant relationship with 
outcome was level of LDH. This finding had 
previously been reported by several studies.3,21-3 
CRP was elevated in 69.7% of our patients, which 
was very close to the rate (60.7%) reported by Guan 
and his colleagues,3 however it was not predictive 
of disease outcome. 
Normal white blood cell count was a more 
frequent finding in our series of patients compared 
with leukopenia, which is consistent with the 
results of another study conducted on kidney 
transpalnt patients.24 Although we did not perform 
a subset analysis on lymphocyte count, a study on 
hemodyalis patients with COVID-19 pneumonia 
showed that T-cell count was significantly less as 
compared to non-hemodyalisis patients.5 
Lymphocytopenia has been addressed as a 
marker of diseaese severity in COVID-19.25 Despite 
the higher mortality rate obsereved in our study, 
lymphocytopenia existed in just a little more 
than half of our patients on admission, which is 
Variables Stage II(n = 10) 
Stage IIIa
(n = 19) 
Stage IIIb




(n = 5) P
Days of Hospitalization 13 ± 8.5 10.2 ± 6.2 10.6 ± 2.8 10.5 ± 2.1 15.4 ± 6.4 > .05
Oxygen Saturation, % 90.5 ± 5.1 88.6 ± 5.7 90.0 ± 4.7 92.0 ± 2.3 82.0 ± 12.7 > .05
Leukocyte Count, × 109 /L 5.32 ± 1.36 6.09 ± 3.64 5.25 ± 1.98 4.25 ± 0.07 9.06 ± 3.03 > .05
Platelet Count, × 109 /L 214.2 ± 78.6 206.3 ± 89.2 170.7 ± 96.7 134.5 ± 96.8 337.1 ± 181.2 > .05
Hemoglobin Level, g/dL 14.4 ± 2.6 13.7 ± 2.4 13.9 ± 3.93 12.0 ± 1.37 11.2 ± 3.3 > .05
Lymphopenia 7 (70) 8 (42.1) 2 (28.6) 2 (100) 4 (80) > .05
Neutrophilia - 2 (10.5) - - 2 (40) > .05
Eosinopenia - 1 (5.3) 1 (14.3) - 1 (20) > .05
NLR 3.07 ± 1.35 4.3 ± 3.9 4.3 ± 1.7 2.3 ± 0.1 5.2 ± 3.2 > .05
PLR 168.4 ± 64.5 175.9 ± 46.5 185.3 ± 94.3 147.4 ± 44.7 236.9 ± 128.1 > .05
NLR*CRP 138.5 ± 100.5 207.3 ± 274.1 181 ± 67.8 108.9 ± 73.1 114.1 ± 101.5 > .05
C-reactive Protein, mg/dL 38.4 ± 19.3 41.3 ± 22.8 39.3 ± 6.44 66.0 ± 15.3 29.0 ± 27.6 > .05
Lactase Dehydrogenase, IU/I 392.5 ± 75.5 330.3 ± 142.1 619.4 ± 484.5 450.0 ± 43.8 378.6 ± 78.3 > .05
Upper Zone Score 3.5 ± 1.9 2.8 ± 1.8 1.85 ± 0.89 2.0 ± 0.0 1.41 ± 1.67 > .05
Middle Zone Score 4.1 ± 2.6 4.6 ± 1.9 3.1 ± 2.1 2.5 ± 0.7 3.0 ± 2.0 > .05
Lower Zone Score 4.5 ± 2.75 5.1 ± 1.9 2.8 ± 2.4 4.5 ± 0.7 3 ± 2 > .05
Total Zone Score 12.1 ± 7.0 12.5 ± 5.0 7.8 ± 5.1 9 ± 1.4 7.9 ± 4.9 > .05
Table 4. Comparison of Clinical and Laboratory Data and CT Scores Based on CKD Stage
Continuous variables are reported as mean ± standard deviation and range. Categorical variables are reported as n (%). P values are calculated 
by 2 test, Fisher’s exact test, or Student t-test.
Abbreviations: NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CRP, C-reactive protein.
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lower than the rate reported for general patient 
population.18,21,25 Moreover, unlike other studies 
reporting NLR and PLR as important indicators 
of predicting disease progression,26-9 we did not 
observe such a finding in CKD patients. 
The CT imaging features of COVID-19 pneumonia 
resemble various other conditions such as organizing 
pneumonia or inflammatory lung processes.30,31 
Trujillo et al. recently evaluated kidney transplant 
patients infected with SARS-CoV-2, reporting no 
significant difference between imaging features 
of survivors and non-survivors.32 Our study also 
displayed the same results. However, we found 
that predominant radiologic patterns among CKD 
patients are slightly different to those of other 
patients. In this study, the most frequently observed 
patterns were GGO followed by reticular pattern, 
while in other studies, GGO and consolidation have 
been reported as the typical chest CT features of 
COVID-19 pneumonia.19,33 It has been reported that 
reticular pattern is a late finding; however, even 
in late stages, reticular pattern has been observed 
in 3% to 6% of the general population,34 which is 
considerably lower than the rate observed in our 
study. Another interesting finding was the high 
prevalence of vessel dilatation in the CT imaging of 
our patients, in particular those who died. Vascular 
enlargement has been reported to convey prognostic 
information, thus, this observation might be justified 
by the fact that our patients had presented with 
a more severe form of disease.35,36 Also, of note, 
pleural effusion was seen in more than one-fifth 
of our patients. Generally, the observation of 
pleural effusion in a patient with acute respiratory 
distress, especially in early stages, is not in favor 
of COVID-19 pneumonia and leads away from its 
diagnosis.37-9 However, based on the results of our 
study and also considering the fact that pleural 
effusion is a common complication in patients with 
impaired renal function, in particular in those with 
ESRD,40,41 the presence of pleural effusion should 
not exclude the possibility of COVID-19 diagnosis 
in this specific patient population. Other imaging 
findings were similar to studies investigating 
the general population; for example, our study 
demonstrated bilateral lung involvement, mainly 
in the peripheral posterior lobes and with lower 
lung zone predilection, which is consistent with 
the majority of published studies.42,43 Regarding 
CT score, lower zone score was found to be higher 
in patients who died, however, total CT score did 
not differ based on patients’ CKD stage or disease 
outcome. Therefore, we suggest that the extent of 
lower zone involvement could be considered as a 
marker of disease burden.
Our study had some limitations. First, the time 
from symptom onset to presentation was not 
evaluated in this study. Second, the sample size 
in our study was relatively small, which could 
possibly affect the reults. 
CONCLUSION
In conclusion, the results of this study showed 
that compared to the general population, patients 
with CKD are vulnerable to a more severe form of 
COVID-19 and experience a higher rate of death. 
Thus, the presence of CKD should be considered 
as an important factor in risk stratification of 
COVID-19 patients and imply the need for close 
monitoring and timely management of these 
patients. Nevertheless, higher stage of CKD is 
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Urinary System and Renal Involvement in Children With 
Cystic Fibrosis
Nasrin Esfandiar,1 Ghamartaj Khanbabaee,2 
Khadijeh Riazi Kermani3 
Introduction. A few data on the prevalence of renal involvement 
in cystic fibrosis and its spectrum in childhood is available. In 
the present study, we conducted a prospective study on children 
who had cystic fibrosis and evaluated their renal involvement. 
In fact, the aim of the study was to provide data on the clinical 
consequences of proper identification of kidney disease in a group 
of children with cystic fibrosis. 
Methods. This prospective study was conducted on 55 consecutive 
patients with previous diagnosis of cystic fibrosis during a three-
year period and at least 3 months to over 5 years or more follow-up. 
The inclusion criteria was the diagnosis of cystic fibrosis which 
was made by clinical presentation of cystic fibrosis and laboratory 
results. Initially, patients’ medical records were reviewed and 
relevant data were collected. A 24-hour urine collection (or a 
random urine sampling in very young infants) was used to assess 
crystalluria and renal function was evaluated by blood sampling. 
Results. Totally, 55 patients with cystic fibrosis were admitted in 
two hospitals with the mean age of 8.22 ± 5.66 years. GFR totally 
reduced in 34.5%. The overall prevalence of hypercalciuria was 
estimated to be 60%, while hyperoxaluria, hypocitraturia, and 
hyperuricosuria in 41.8%, 24.5%, and 47.3%; respectively. 
Conclusion. Crystalluria is a common consequence of cystic 
fibrosis in childhood. The prevailing crystalluric finding includes 
hypercalciuria followed by hyperuricosuria, and hyperoxaluria. 
During disease GFR may be decreased due to several reasons such 
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INTRODUCTION
Recent evidences have emphasized the association 
between cystic fibrosis and appearance of kidney 
injuries especially among children.1,2 Following 
significant development in treatment of respiratory 
disorders and pancreatitis in cystic fibrosis, the life 
expectancy among patients has been considerably 
increased from 2 years to more than 30 years.3,4 
One of the main underlying factors affecting the 
progression as well as prognosis of the affected 
patients includes the presence of the CFTR gene 
polymorphism that encodes a polyprotein cystic 
fibrosis trans-membrane conductance regulator 
(CFTR), which functions as an ATP-responsive 
chloride channel in apical membrane of epithelial 
cells.5 Because this gene is abundantly findable 
in various segments of the nephron especially in 
proximal tubule, the inactivation of CFTR can lead 
to renal insufficiency presents with proteinuria as 
well as nephrocalcinosis and hypercalciuria.6 In this 
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regard, the overall prevalence of nephrocalcinosis 
and hypercalciuria is estimated to be 90% and 
30% of affected patients, respectively emphasizing 
high risk for renal impairment in cystic fibrosis 
patients.7 More interestingly, urolithiasis in these 
patients may result from hyperoxaluria originated 
from other clinical abnormal conditions such as fat 
malabsorption. Along with urolithiasis, patients 
with cystic fibrosis may be also found, but less 
commonly, with other renal disorders such as 
glomerulonephritis, and AA amyloidosis.8-10 Totally, 
renal involvement in cystic fibrosis should be 
considered as an emergence; however a few data 
on the prevalence of renal involvement and its 
spectrum in childhood is available. In the present 
study, we report a series of children who had cystic 
fibrosis and some degree of renal involvement. In 
fact, the aim of this study was to provide data on 
proper identification of kidney disease in a group 
of children with cystic fibrosis. 
MATERIALS AND METHODS
This prospective study was conducted on 55 
consecutive patients with final diagnosis of cystic 
fibrosis who referred to Masih Daneshvari and 
Mofid Children’s hospital in Tehran during 2012 to 
2015. In this study, the diagnosis of cystic fibrosis 
was made if there were clinical presentations in 
addition to chloride concentration more than 60 
mmol/L in sweet test according to the guidelines 
by the Gibson & Cooke methods in two separate 
tests.  In addition, we confirmed pancreatic 
malabsorption by quantification of elastase-1 
activity and fat droplet in stool sample. False 
positive cases such as anorexia nervosa, congenital 
adrenal hyperplasia,  adrenal insufficiency, 
glucose-6-phosphatase deficiency,  familial 
hypoparathyroidism, hypothyroidism, nephrogenic 
diabetes insipidus, pseudohypoaldosteronism, 
and Klinefelter syndrome were ruled out by 
history, physical examination, and appropriate 
laboratory tests. Initially, patients’ medical records 
were reviewed, and relevant data were collected 
regarding baseline characteristics, anthropometric 
parameters, blood pressure on admission, and 
laboratory indices. Also, kidney ultrasonography 
was done and findings were highlighted. A 24-hour 
urine collection (or a random urine sampling in 
very young infants) was done to assess crystalluria. 
The methods of measurement of crystals in urine 
was as following: peroxidase-TOOS [N-ethyl-N-
(2-hydroxy-3-sulfopropyl)-m-toluidine] method 
for uric acid, photometric method for calcium and 
citrate, colorimetric oxidase method for oxalate, and 
Jaffe’s reaction for creatinine. GFR was calculated 
using the Schwartz formula and serum creatinine 
was measured by Jaffe method: “GFR (mL/min/ 
1.73m2) = (K) (height in cm) / serum creatinine 
(mg/dL).11
In this formula, “K” coefficient in infants under 
one year of age with LBW and infants with birth 
weight above 2.5 Kg under one year is 0.35 and 
0.45, respectively. This number for young children 
and female patients in pubertal age is 0.55 and for 
male patients is 0.7.12,13
To assess the electrolyte abnormalities, their 
concentration was determined and venous blood 
gas analysis was done. The findings related to the 
CFTR mutation were also recorded if available. In 
ten cases genetic study confirmed the diagnosis.
Results were presented as mean ± SD for 
quantitative variables and were summarized by 
absolute frequencies and percentages for categorical 
variables. For the statistical analysis, the statistical 
software SPSS version 16 for windows was used.
RESULTS
Within three years of study, 55 patients with 
cystic fibrosis were admitted to these two hospitals 
with the mean age of 8.22 ± 5.66 years (ranged 4 
months to 22 years). Follow up duration was five 
years. Even in some cases the follow up period 
was longer. Patients were visited on a monthly 
basis or every two months averagely. Cases with 
exacerbation or worsening of their condition were 
hospitalized. Treatments included antibiotics based 
on patients age and cultured microbial species. 
Nebulized treatments which were used were as 
following: inhaled antibiotics, hypertonic saline, and 
in some cases recombinant DNAase. Appropriate 
supplements, vitamins and diet were prescribed 
for CF patients. Physiotherapy was done and based 
on the patients’ condition, traditional methods or 
appropriate devices were used. During admission, 
psychologic or psychiatric consultation might 
have been required. Appropriate vaccination was 
considered. We took patients’ or parents’ consent 
in advance. The study was approved by ethics 
committee of SBMU (The registration number is: 
IR.SBMU.MSP.REC.1397.559). Among patients, 
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52.7% were male (with a mean age of 7.20 ± 5.34 
years) and 47.3% were female (with the mean age 
of 9.55 ± 5.81 years). The blood pressure was in 
the normal range in all subjects with no evidences 
of hypertension. Hematuria was a prominent 
finding in 5 patients (9.1%). Urine culture was 
negative in all patients. One patient (1.8%) showed 
bilateral fullness in ultrasonography. None of the 
patients had electrolyte disturbances. The details 
on demographic data and laboratory indices 
are summarized in Table. The most common 
electrolyte abnormalities were hyponatremia and 
hypokalemia.Venous blood gas analysis showed 
normal condition in 28 patients, while 5 patients 
were diagnosed as respiratory acidosis, 10 patients 
as respiratory alkalosis, 5 patients as metabolic 
alkalosis, and 7 patients as a mixed blood gas 
abnormality. GFR totally reduced (according to 
patients’ age) in 14 patients (25.4%), while ranged 
60 to 89 in 23.6%, and 15 to 30 in only 1.8%. The 
status of crystalluria is shown in Figure. The overall 
prevalence of hypercalciuria was estimated to be 
60.0%, while hyperoxaluria, hypocitraturia, and 
hyperuricosuria diagnosed in 41.8%, 24.5%, and 
47.3%; respectively. Decreased urine output was 
found in only one patient (1.8%). 
DISCUSSION
Despite  low prevalence  of  symptomatic 
urolithiasis among patients with cystic fibrosis, 
the prevalence of hypercalciuria was shown to 
be notably high causing unexplained morbidities 
in these patients. It is thus mandatory to identify 
different aspects of renal involvement in the patients 
because of its adverse effect on life expectancy 
particularly among children due to their lower 
tolerability. In most studies the incidence and 
clinical status of renal involvement in cystic fibrosis 
Parameter Mean SD Minimum Maximum
Weight, kg 20.53 11.39 2.8 52.7
Height, cm 116.7 29.98 55 161
Percentage of FTT 63.63 (35 cases) - - -
Sweat Chloride, mmol/L 81.67 11.38 65 110
Urine Output, mL 1290.38 682.35 200 2700
Sodium, mEq/L 137.96 2.72 131 144
Potassium, mEq/L 4.24 0.45 3.1 5.5
Urea, mg/dL 18.34 6.33 4 34
Cr, mg/dL 0.65 0.15 0.3 0.9
Uric Acid, mg/dL 4.29 0.96 2.9 6.8
Calcium, mg/dL 8.87 0.59 7.6 10
Phosphorus, mg/dL 4.21 1.02 2.1 6.6
Alkaline Phosphatase 491.45 207.84 156 1124
Bicarbonate 24.98 24.56 16.6 44.4
PH 7.41 7.41 7.3 7.53
PCO2 37.05 11.04 22 76.2
Urine Calcium 11 197 92.84 55.03
Urine Uric Acid 384.84 252.77 59 1072
Urine Citrate 324.7 221.71 74 902
Urine Phosphorus, mg 512.8 323.96 132 1620
Urine Protein, mg 92.69 72.44 11 282
Urine Cr, mg 385.61 200.02 66 743
GFR, mL/min/ 1.73 m2 100.87 27.62 20.16 162
Details on Demographic Data and Laboratory Serum Indices in Children with Cystic Fibrosis
It shows frequency of crystalluria in children with cystic fibrosis.
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was based on histological assessments using renal 
biopsy. In one of the main studies by Abramowsky 
and Swinehart11 on autopsies from both pediatric 
and adult patients, the main histological findings 
were related to glomerulomegaly, a mesangiopathic 
lesion, and tubulointerstitial disease frequently 
associated with acute and chronic tubular injury 
that were significantly associated with the severity 
of renal dysfunction. In the present study and aided 
by laboratory findings and sonography assessment, 
we showed high prevalence of crystalluria especially 
hypercalciuria and hyperuricosuria in children 
with cystic fibrosis. In our study, the dominant 
crystalluric finding was hypercalciuria found in 
about two-third of patients, while hyperoxaluria 
or hyperuricosuria was found in less than half of 
them. In fact, it seems that the existence of exocrine 
pancreatic dysfunction as a major risk factor for 
enteric hyperoxaluria may be revealed in about half 
of our patients. In contrast with other reports that 
showed increased prevalence of calcium oxalate 
and medullary nephrocalcinosis,12 our results 
were negative. 
Regarding renal functional status, reduced GFR 
was found in about a quarter of the children that 
was significant. We estimated the GFR based on 
creatinine clearance; however we showed reduced 
urinary output only in 1.8% of the patients. It is now 
agreed that the estimation of GFR using creatinine 
is not a reliable estimation of renal function. In 
fact, the assessment of renal sclerotic lesions as a 
serious renal change following cystic fibrosis may 
not be followed by only GFR estimation based on 
creatinine. Because accurate assessment of renal 
sclerotic lesions is of great help for clinicians 
who care for these patients, employing suitable 
and more valid tools to assess these changes is 
essential particularly in those who require receiving 
nephrotoxic immunosuppressive agents; As a 
result, limitation of our study was that we could 
not use an accurate method for GFR measurement 
such as DTPA (diethylenetriamine pentaacetate). 
In  conclusion,  crystal lur ia  is  a  common 
consequence of cystic fibrosis in childhood. 
The prevailing crystalluric finding includes 
hypercalciuria followed by hyperuricosuria, 
and hyperoxaluria. Thus, assessing the risk of 
crystalluria and also determination of its main 
predictors is essential to prevent deleterious effects 
on renal function especially in affected children. 
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High Neutrophil/Lymphocyte Ratio as an Independent Risk 
Factor for the First Occurrence of Stroke in Peritoneal 
Dialysis Patients
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Introduction. Though neutrophil/lymphocyte ratio (NLR) level 
appears to be related with stroke events in general population, its 
relationship with stroke in peritoneal dialysis (PD) patients is still 
uncertain. This study aims to investigate the association between 
NLR and the first occurrence of stroke in PD patients.
Methods. In this retrospective cohort study, 1507 PD patients were 
enrolled from four centers in China and stratified into tertiles of NLR 
levels. The incidence of the first occurrence of stroke was analyzed 
by Kaplan-Meier cumulative incidence curve among different NLR 
tertiles, competing risk analysis was used to calculate the incidence 
of the first occurrence of stroke in the presence of competing risk of 
other events, multivariable COX regression analysis was performed to 
estimate the hazard ratios (HRs) for the first occurrence of stroke, as 
well as forest plot was utilized to describe the relationship between 
NLR and the first occurrence of stroke in different subgroups.
Results. During follow-up, 84 new-onset stroke events were recorded. 
Kaplan-Meier cumulative incidence curves showed significant 
differences in the incidence of the first occurrence of stroke among 
three groups (log-rank test: P < .001). In competing risk analysis, 
the cumulative incidence curves for tertiles of NLR levels were 
highly significant for the first occurrence of stroke (P < .001), but 
they were not statistically different for the occurrence of other 
events. Compared to the lowest tertile of NLR level, the highest 
tertile was associated with increased risk of the first occurrence of 
stroke in the adjusted Cox model (HR = 2.39, 95% CI: 1.37 to 4.15; 
P < .05). As for forest plot, there was no interaction in all subgroups.
Conclusion. High NLR was an independent risk factor for the first 
occurrence of stroke in PD patients.
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INTRODUCTION 
Stroke is the second leading cause of death 
worldwide and currently the leading cause of death in 
China, which contributes to a heavy disease burden.1-4 
It seems that people with chronic kidney diseases 
have the highest risk in suffering from subsequent 
cardiovascular disease (CVD).5,6 Moreover, CVD 
become the main causes of mortality in end-stage 
renal disease (ESRD) patients maintaining dialysis.7 
Stroke is one of the major causes of cardiovascular 
mortality in the group.8 What’s more, patients 
relying on maintenance dialysis with ESRD have 
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remarkably greater stroke incidence and higher 
mortality of stroke than non-dialysis patients do.9,10 
Therefore, reliable prognostic factors, which could 
help to estimate patients at high risk of stroke for 
ESRD population, are needed.
Neutrophil to lymphocyte ratio (NLR) as a 
novel index could be used to predict stroke and 
stroke prognosis.11 Fang YN et al. suggested NLR 
was one of the credible biomarkers, which had 
the advantage of predicting prognostic outcome 
among patients who had suffered acute ischemic 
stroke.12 Tao C et al. also found that increased level 
of NLR was associated with poor 90-day outcome 
independently after intracerebral hemorrhage, 
while NLR may serve as a novel inflammatory 
biomarker after intracerebral hemorrhage.13 
Since NLR has been associated with increased 
risk of stroke prognosis in non-dialysis patients, 
it may probably also predict the risk of stroke in 
PD patients. However, there is no published paper 
having indicated NLR level associates with the risk 
of stroke in PD patients. In this study, we aim to 
investigate the association of NLR and the first 
occurrence of stroke in PD patients.
MATERIALS AND METHODS
Participants
From January 1, 2010 to May 31, 2016, a total of 
1652 patients were recruited from four PD centers. 
Of them, 145 were excluded for the following 
reasons: age younger than 18 years or older than 
80 years (n = 34), PD was maintained for less 
than 3 months (n = 32), clinical evidence of active 
infection that happened in a month before returning 
to hospital (n = 37), history of hematological or 
autoimmune disease and taking glucocorticoid or 
immunosuppressive (n = 42). Above patients were 
excluded because those factors may influence NLR 
level. Finally, this study included 1507 patients. The 
Institutional Review Board of the four PD centers 
approved this retrospective study. Written informed 
consent was not required because we retrospectively 
collected available medical records in the hospital.
Baseline Investigations
Baseline demographic and clinical data were 
collected at the initiation of PD therapy. Biochemical 
parameters were collected 3 months after PD 
therapy was initiated. Patients who reported 
current use of insulin or oral hypoglycemic agents 
and/or who had a clinical diagnosis of type 1 or 
type 2 diabetes mellitus were considered to have 
diabetes mellitus.14 Hypertension was recorded if 
the patient took antihypertensive drugs or had 2 
mmHg. CVD was defined as including coronary 
heart disease, myocardial infarction, angioplasty, 
coronary artery bypass or heart failure. Stroke was 
defined as including cerebral infarction, intracerebral 
hemorrhage and subarachnoid hemorrhage.
Laboratory measurements were obtained using 
standard methods in the clinical laboratory. 
Total Kt/V were calculated using PD Adequest 
software 2.0 (Baxter, Deerfield, IL). Medicine use 
was recorded based on prescriptions. The patients 
returned to these centers for quarterly evaluation, 
and trained nurses interviewed the patients by 
telephone monthly to assess general conditions.
Study Outcome
The outcome was the first occurrence of stroke 
since PD therapy. Stroke was defined as including 
cerebral infarction, intracerebral hemorrhage, and 
subarachnoid hemorrhage. Trained nurses asking 
about previous medical events during monthly 
phone interviews identified strokes, and then 
experienced doctors confirmed the diagnosis of 
stroke again or via review of medical records. 
All patients were followed until death, transfer 
to hemodialysis therapy, kidney transplantation, 
transfer of care from four centers or censoring on 
May 31, 2017.
Statistical Analysis
Participants were divided into tertiles of NLR 
levels (tertile 1 [lowest], < 2.74; tertile 2 [middle], 
Summary statistics by tertile of NLR level were 
presented. Based on the results of the normality test, 
all continuous variables are skewed distribution. 
The values for skewed variables were described 
as median (25th to 75th percentile) and categorical 
data were given as frequency and percentages. 
Differences among the tertiles of NLR level were 
tested using 2 test for categorical variables, Mann-
Whitney U test for skewed continuous variables. 
A univariable logistic regression model was used 
to examine the association between patients’ 
characteristics and new-onset stroke events since 
PD therapy with lower category as reference, 
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and then a multivariable logistic regression was 
used to examine patients’ characteristics with 
predictive odds of the first occurrence of stroke, 
which adjusted for covariates with (P < .05 in 
univariable logistic analysis). Kaplan-Meier 
cumulative incidence curves were used to analyze 
the incidence of the first occurrence of stroke, and 
differences among distributions of incidence of 
new-onset stroke events were assessed by log-
rank test. Competing risk analysis was used on 
the first occurrence of stroke and other events, 
and differences were assessed by Gray’s test. 
Cox regression models were used to evaluate the 
relationship among the tertiles of NLR level with 
the first occurrence of stroke in PD patients, initially 
without adjustment and subsequently adjusting for 
several groups of covariates. The multivariable Cox 
regression model was constructed using eligible 
covariates that demonstrated significant or near-
significant association with the first occurrence 
of stroke (P < .05) on multivariable analysis or 
characteristics (P < 0.01) list in Table 1 or for 
Variables Total (n = 1507) Tertile 1 (n = 502) Tertile 2 (n = 509) Tertile 3 (n = 496) P
No. of C1/C2/C3/C4 316/794/36/361 124/249/9/120 130/249/7/123 62/296/20/118 < .001
No. of Men/Women 855/652 262/240 275/234 318/178 < .001
NLR 3.4 (2.5, 4.5) 2.2 (1.8, 2.5) 3.4 (3.0, 3.8) 5.4 (4.6,7.0) < .001
Demographics
Age, y 51 (41, 62) 49 (39, 61) 50 (41, 61) 53 (43,63) < .001
BMI, kg/m2 22.1 (20.0, 24.3) 22.0 (20.0, 24.2) 22.0 (20.1, 24.4) 22.1 (20.0,24.3) > .05
Comorbid
Systolic BP, mmHg 149 (132, 164) 146 (130, 160) 149 (134, 161) 150 (134,170) > .05
Diastolic BP, mmHg 87 (78, 95) 87 (78, 95) 87 (80,95) 87 (78,96) < .001
Hypertension, n (%) 990 (65.7) 312 (62.2) 321 (63.1) 357 (72.0) < .05
Diabetes Mellitus, n (%) 346 (23.0) 106 (21.1) 116 (22.8) 124 (25.0) > .05
Cardiovascular Disease, n (%) 136 (9.0) 47 (9.4) 44 (8.6) 45 (9.1) > .05
Stroke Disease, n (%) 80 (5.3) 22 (4.4) 26 (5.1) 32 (6.5) > .05
Laboratory Variables
Hemoglobin, g/L 87 (74, 100) 89 (76, 103) 88 (76, 101) 82 (70,95) < .05
Albumin, g/L 34.5 (31.1, 37.9) 34.9 (31.3, 38.4) 34.7 (31.3, 37.5) 34.2 (30.5,37.3) < .001
710.0 (544.0, 933.4) 699.5 (543.8, 899.5) 711.0 (541.9, 931.1) 729.5 (546.0,950.0) < .001
Urea nitrogen, mmol/L 20.47 (15.50, 26.85) 19.4 (15.1, 25.4) 20.2 (15.3, 26.4) 22.0 (16.4,29.3) < .001
Uric acid, mmol/L 428 (355, 509) 430 (356, 512) 427 (354, 504) 426 (358,502) < .05
FBG, mmol/L 4.7 (4.1, 5.5) 4.6 (4.1, 5.4) 4.7 (4.1, 5.5) 4.8 (4.1,5.7) < .001
Total Cholesterol, mmol/L 4.2 (3.5, 5.0) 4.3 (3.6, 5.1) 4.2 (3.5, 5.0) 4.1 (3.4,4.9) > .05
Total Triglycerides, mmol/L 1.3 (1.0, 1.8) 1.4 (1.0, 1.9) 1.4 (1.0, 1.9) 1.3 (0.9,1.7) > .05
Sodium, mmol/L 140.0 (138.0, 142.3) 140.7 (138.1, 142.5) 140.0 (138.0, 142.9) 140.0 (137.6,142.0) > .05
Chlorine, mmol/L 103.0 (99.3, 107.0) 103.2 (100.0, 107.0) 103.0 (99.3, 106.8) 102.8 (99.0,107.0) > .05
Calcium, mmol/L 2.0 (1.9, 2.2) 2.1 (1.9, 2.2) 2.1 (1.9, 2.2) 2.0 (1.8,2.1) > .05
Potassium, mmol/L 4.1 (3.6, 4.7) 4.2 (3.7, 4.8) 4.1 (3.6, 4.7) 4.1 (3.6,4.8) < .05
Phosphorus, mmol/L 1.7 (1.4, 2.0) 1.6 (1.4, 2.0) 1.6 (1.3, 2.0) 1.8 (1.4,2.1) < .001
Alkaline Phosphatase, U/L 73 (58, 94) 71 (56, 91) 73 (59, 91) 76 (60,99) < .001
Total Kt/V 2.3 (1.8, 2.6) 2.3 (1.8, 2.7) 2.4 (1.7, 2.6) 2.2 (1.8,2.6) > .05
RRF, mL/min 4.6 (2.1, 15.0) 4.4 (2.0, 13.4) 4.6 (2.2, 15.1) 4.7 (2.0,16.5) > .05
Treatments
CCB, n (%) 1108 (73.5) 371 (73.9) 371 (72.9) 366 (73.8) > .05
ACEI/ARB, n (%) 554 (36.8) 186 (37.1) 199 (39.1) 169 (34.1) > .05
Loop Diuretic, n (%) 101 (6.7) 33 (6.6) 30 (5.9) 38 (7.7) > .05
Insulin, n (%) 232 (15.4) 75 (14.9) 71 (13.9) 86 (17.3) > .05
Aspirin, n (%) 135 (9.0) 42 (8.4) 44 (8.6) 49 (9.9) > .05
Time, mo 30.6 (18.9, 46.9) 33.0 (20.1, 50.8) 32.6 (21.4, 47.3) 27.9 (16.3,41.5) < .001
Table 1. Demographic and Baseline Clinical Data for the Study Patients
Note: All continuous variables are skewed distribution, the values for continuous variables are given as median (P25, P75). Time refer to time 
from the onset of peritoneal dialysis to the first occurrence of stroke events.
Abbreviations: C1,center 1; C2,center 2; C3,center 3; C4,center 4; NLR, neutrophil lymphocyte ratio; BMI, body mass index; FBG, fasting 
blood-glucose; Kt/V, K (dialyzer clearance of urea), t (dialysis time), V (volume of distribution of urea); RRF, residual renal function; CCB, calcium 
channel blocker; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker.
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importance of clinical concern. Moreover, the 
interaction between subgroups variable of interest 
including sex, age, history of diabetes mellitus 
and NLR group were examined by performing 
a formal test of interaction. Forest plot was used 
to represent the relationship between NLR and 
new-onset stroke events in each subgroup. In Cox 
regression models, time at risk was from study 
entry until death, transferring to hemodialysis 
therapy, kidney transplantation, transferring care 
from our center, or the end of study on May 31, 
2017. For primary effects, P < .05 was considered 
statistically significant. Statistical analyses were 
performed using SPSS version 23 and R software 
(version R-3.6.1, www.r-project.org). 
RESULTS
Participants
Baseline demographic and clinical characteristics 
of the cohort were given in Table 1, divided 
according to tertiles of NLR levels. A total of 1507 
patients were enrolled in this study (median age, 
51 (41, 62) years; 56.7% men; 23.0% with diabetes; 
65.7% with hypertension), with a median follow-
up of 30.6 (maximum, 89.4) months. Median NLR 
value was 3.4 (2.5, 4.5) for all patients. In the whole 
process, 78 (5.2%) patients underwent kidney 
transplantation after a median of 20 months, 199 
(13.2%) were transferred to hemodialysis therapy 
for any reason after a median of 28 months, 20 
(1.3%) transferred to other center after a median 
of 36 months, and 25 (1.7%) lost to follow up. 
Stroke events were registered during follow-up. 
A total of 84 stroke events (5.6%) were recorded. 
(Figure 1).
NLR Associated with the First Occurrence of 
Stroke in PD Patients 
The significant risk factors for new-onset stroke 
events were given in Table 2 by adjusting for 
covariates (P < .05 univariable logistic regression). 
The first occurrence of stroke was associated with 
male, history of hypertension, stroke and CVD 
as well as higher FBG. Associations of NLR with 
new-onset stroke events with defined models (with 
the group 1 as the reference group) are listed in 
Table 3. Regardless of the adjustment method used, 
the highest tertile of NLR level was associated 
significantly with the first occurrence of stroke 
compared to the lowest tertile. 
In crude analysis, the Kaplan-Meier cumulative 
incidence curves showed there were significant 
differences in the incidence of new-onset stroke 
events among the tertiles of NLR level (log-rank 
test: P < .001, Figure 2). In competing risk analysis, 
cumulative incidence curves for each tertile of NLR 
level are highly significant for the first occurrence 
Risk Factors OR (95% CI) P
Univariable Logistic Regression
Sex (Female vs. Male) 0.45 (0.27 to 0.74) < .05
Diabetes Mellitus (Yes vs. No) 2.17 (1.38 to 3.44) < .05
Hypertension (Yes vs. No) 2.51 (1.42 to 4.43) < .05
History of Stroke Disease (Yes 
vs. No)
3.32 (1.72 to 6.41) < .001
Cardiovascular Disease (Yes 
vs. No)
2.78 (1.58 to 4.89) < .001
FBG (> 1-mmol/L) 1.12 (1.05 to 1.20) < .05
Use of ACEI/ARB (Yes vs. No) 1.69 (1.09 to 2.63) < .05
Use of Insulin (Yes vs. No) 1.92 (1.14 to 3.21) < .05
Multivariable Logistic Regression
Sex (Female vs. Male) 0.43 (0.26 to 0.71) < .05
Hypertension (Yes vs. No) 1.98 (1.10 to 3.56) < .05
History of Stroke Disease (Yes 
vs. No)
2.53 (1.29 to 4.99) < .05
Cardiovascular Disease (Yes 
vs. No)
1.95 (1.05 to 3.64) < .05
FBG (> 1-mmol/L) 1.09 (1.01 to 1.17) < .05
Table 2. Significant Risk Factors for the First Occurrence of 
Stroke
Note: Multivariable logistic regression adjusted for covariates 
(P < .05) list in univariable logistic regression. Abbreviations: OR, 
odds ratio; CI, confidence interval; FBG, fasting blood-glucose; ACEI, 




Exclude (n = 145)
Enrollment (n = 1507)
Stroke events (n = 84)
Follow up to
2017/05/31(n = 855)
Death (n = 246)
Transferred to HD (n = 199)
Renal transplantation (n = 78)
Transfer to other center (n = 20)
Lost to follow up (n = 25)
Exclude (n = 145)
Age < 18 years or > 80 years (n = 34)
PD less than three months (n = 32)
Active infection (n = 37)
Use glucocorticoids or 
immunosuppressants hematology or 
immune disease (n = 42)
Figure 1. It shows study algorithm, including patient enrollment 
and outcomes. (PD, peritoneal dialysis; HD, hemodialysis).
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of stroke (P < .001), but they are not statistically 
different for transfer to hemodialysis therapy 
(P > .05), kidney transplantation (P > .05), transfer 
to other center (P > .05), being lost to follow up 
(P > .05), and death (P > .05) (Figure 3).
NLR Associated with the First Occurrence of 
Stroke in Different Subgroups
We investigated the association between NLR 
and the first occurrence of stroke in different 
subgroups which we were interested in, including 
male or female, with or without diabetes, old age 
subgroups were analyzed by COX regression and 
represented as a forest plot. No interaction was 
found in all subgroups (Figure 4).
DISCUSSION
This retrospective cohort study indicated that 
the incidence of first occurrence of stroke was 
significantly higher in Tertile 3, while compared 
to Tertile 1. It indicated that elevated NLR was 
associated with new-onset stroke events risk 
in PD patients, after adjusting possibly related 
confounders. 
As is well-known, the relationship between 
chronic inflammation and CVD has been studied 
widely.15 Elevated WBC was reported to be 
related to CVD,16 in which neutrophils played a 
significant predictive role.17 NLR, as a simple ratio 
readily obtained from inexpensive blood routine 
examination, has been reported that its predictive 
value was higher than individual cell counts.15 
Tertile 2 (n = 509) Tertile 3 (n = 496) 
HR (95% CI) P HR (95% CI) P
Unadjusted 1.09 (0.57 to 2.07) > .05 3.15 (1.83 to 5.43) < .001
Model 1 1.03 (0.54 to 1.97) > .05 2.58 (1.49 to 4.46) < .05
Model 2 1.00 (0.53 to 1.91) > .05 2.55 (1.47 to 4.41) < .05
Model 3 0.99 (0.52 to 1.88) > .05 2.39 (1.37 to 4.15) < .05
Table 3. Relationship Between Tertiles of NLR and the First Occurrence of Stroke
Note: Reference group is Tertile 1.
Model 1: sex, age, BMI
Model 2: Model 1 plus comorbid conditions (diabetes mellitus, hypertension, stroke disease, cardiovascular disease) and medical history (aspirin)
Model 3: Model 2 plus albumin, creatinine, urea nitrogen, uric acid, FBG, total cholesterol, total triglycerides, phosphorus, alkaline phosphatase
Abbreviations: NLR, neutrophil lymphocyte ratio; BMI, body mass index; FBG, fasting blood glucose; HR, hazard ratio; CI, confidence interval.
Figure 2. It demonstrates cumulative incidence of the first occurrence of stroke in 1507 peritoneal dialysis patients by NLR. The curves 
were constructed using the Kaplan–Meier method and compared using the Mantel–Cox log-rank test. Patients in the highest tertile of 
NLR level showed higher incidence of the first occurrence of stroke.
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Figure 3. It shows estimated cumulative incidence curves with the first occurrence of stroke. The cumulative incidence curves for the 
tertiles of NLR level were highly significant for the first occurrence of stroke (P < .001), but they were not statistically different for transfer 
to hemodialysis therapy, kidney transplantation, transfer to other center, lost to follow up and death as competing events for each type of 
NLR level.
Figure 4. It demonstrates forest plot of relationship between NLR and the first occurrence of stroke in different subgroups. 
Note: The P1 value corresponded to the relationship between NLR and the first occurrence of stroke in different subgroups. The P2 
value corresponded to the interaction test between the NLR and the subgroups variable of interest. No interaction was observed for age, 
diabetes mellitus and sex in the first occurrence of stroke. Adjusted model: sex, age, BMI, history of diabetes mellitus, hypertension, 
stroke and cardiovascular disease, use of aspirin, albumin, creatinine, urea nitrogen, uric acid, FBG, total cholesterol, total triglycerides, 
Phosphorus, alkaline phosphatase (in particular, the adjustment model should exclude its own factors in different subgroups. For 
example, in the age subgroup, the adjustment model did not include age.) Abbreviations: NLR, Neutrophil / Lymphocyte ratio; HR, 
hazard ratio; CI, confidence interval.
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Plenty of studies have indicated that the occurrence, 
development and mortality of coronary heart 
disease could be predicted by increased NLR level 
independently.16,18-21 It has also been proved that 
NLR showed perfect predictive value in stroke,11 
which was relevant to the prognosis of cerebral 
hemorrhage and infarction.13,22 A large-scale 
retrospective cohort study enrolled 24708 generally 
healthy screened people, it was demonstrated that 
subjects with increased NLR tended to have elevated 
risk for the incidence of ischemic stroke.23 Luo P 
et al. reported that elevated NLR was positively 
related with cerebral hemorrhage incidence in T2DM 
patients.24 These two studies have confirmed that 
NLR was associated with the incidence of stroke 
in non-dialysis population. However, few study 
investigated the relationship between NLR and the 
occurrence of stroke in dialysis patients. 
So far, only one study25 explored the relationship 
of NLR level and the occurrence of cardiovascular 
events in incident dialysis patients. The prospective 
cohort study, which, enrolled 86 PD patients with 
median of NLR equal to 3.72 showed that elevated 
NLR was associated with increased risk of CVD 
events (3.02, 95% CI: 1.32 to 8.00; P < .05). However, 
the association between NLR and stroke events 
has not been investigated independently. And 
some problems in the study should be pointed out: 
Firstly, the number of patients they enrolled was 
small; Secondly, they did not exclude patients who 
suffered from those diseases which altered NLR; 
Thirdly, they included patients receiving different 
dialysis treatment, which might be influential in 
CVD events. Yet the potential role of NLR as a 
simple and easily obtained indicator needs to be 
confirmed by multicenter prospective studies with 
relatively scientific grouping methods in the future.
In our study, a total of 1507 PD patients were 
included and stratified into tertiles of NLR levels. 
Multivariable Cox regression analysis showed 
that NLR was significantly associated with the 
first occurrence of stroke. This conclusion was 
consistent with the previous study.23 Moreover, we 
investigated whether NLR independently predicted 
the new-onset stroke events in different subgroups. 
However, the result was negative.
Some strength could be found in our study. First, 
the number of patients we enrolled from multicenter 
was relatively large. Second, the association 
between NLR levels and the first occurrence of 
stroke were investigated independently for the 
first time in PD patients, instead of exploring the 
relationship between NLR and CVD events. Third, 
we finished a detailed evaluation and adjustment 
for stroke risk factors.
There were several limitations in this study. Firstly, 
because the patients were from four centers, some 
data was lack and not considered, such as CRP, 
smoking history and other confounding factors, 
which may influence the NLR value and statistical 
results. We should try to fill up previous flaw data 
through available information of patients and pay 
more attention to collecting new data carefully in 
the future. Secondly, our study was a retrospective 
cohort study rather than a prospective study. So, it 
is necessary to initiate a prospective study about the 
relationship between NLR and the new-onset stroke 
events in PD patients. Thirdly, all the parameters 
were measured on a single occasion at baseline and 
did not take into account changes over time. Some 
dynamic data of those patients should be included to 
strength the conclusion. Fourthly, in this study, we 
cannot analyze the association of NLR and the first 
occurrence of every type of stroke respectively, for 
not paying attention to registering the types of stroke 
when collecting data. In that case, the pathogenic 
hypothesis about NLR and the first occurrence of 
stroke in PD patients was not stated in this study.
CONCLUSION
In conclusion, our study demonstrated that 
high NLR is an independent risk factor for the 
first occurrence of stroke in PD patients. Although 
further study is needed, NLR could be considered 
as a useful and inexpensive marker for identifying 
higher risk for stroke in PD patients. 
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The Effects of Nano-curcumin on Metabolic Status in 
Patients With Diabetes on Hemodialysis, a Randomized, 
Double Blind, Placebo-controlled Trial
Rana Shafabakhsh,1 Zatollah Asemi,1 2 
Alireza Soleimani,3 Esmat Aghadavod,1 Fereshteh Bahmani1
Introduction. This study evaluated the effects of nano-curcumin 
intake on metabolic status in patients with diabetes on hemodialysis 
(HD).
Methods. This randomized, double-blind, placebo-controlled 
clinical trial was performed on 60 patients with diabetes on HD. 
Participants were randomly divided into two groups to take either 
80 mg/d nano-curcumin (n = 30) or placebo (n = 30) for 12 weeks. 
Results. Nano-curcumin significantly decreased fasting plasma 
glucose (  = -19.68 mg/dL, 95% CI: -33.48 to -5.88; P < .05) and 
serum insulin levels (  = -1.70 μIU/mL, 95% CI: -2.96 to -0.44; 
P < .05) when compared with patients who received placebo. Nano-
curcumin treatment was associated with a significant reduction in 
triglycerides (  = -16.13 mg/dL, 95% CI: -31.51 to -0.75; P < .05), 
VLDL-cholesterol (  = -3.22 mg/dL, 95% CI: -6.30 to -0.15; P < .05), 
total cholesterol (  = -17.83 mg/dL, 95% CI: -29.22 to -6.45; P < .05), 
LDL-cholesterol (  = -15.20 mg/dL, 95% CI: -25.53 to -4.87; P < .05), 
and total-cholesterol/HDL-cholesterol ratio (  = -1.15, 95% CI: 
-0.2.10 to -0.21; P < .05) when compared with the placebo. Nano-
curcumin also resulted in a significant reduction of serum high 
sensitivity CRP (  = -0.78 mg/L, 95% CI: -1.41 to -0.15; P < .05), 
and plasma malondialdehyde (  = -0.25 μmol/L, 95% CI: -0.45 to 
-0.04; P < .05); but also with a significant increase in plasma total 
antioxidant capacity (  = 52.43 mmol/L; 95% CI: 4.52 to 100.35; 
P < .05) and total nitrite levels (  = 3.62 μmol/L, 95% CI: 2.17 to 
5.08; P < .001) when compared with placebo. 
Conclusion. Nano-curcumin intake for 12 weeks had beneficial 
effects on metabolic profile in patients with diabetes on HD.
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Diabetes mellitus is one of the leading causes 
of chronic kidney disease (CKD) worldwide. 
Diabetic nephropathy (DN) is the most common 
risk factor for developing end-stage renal disease 
(ESRD). Approximately 95% of these patients are 
treated with hemodialysis (HD).1 Hyperglycemia 
is the primary cause for developing DN because it 
increases generation of reactive oxygen species and 
causes oxidative damage, which are more expressed 
in HD patients. In addition to oxidative stress, other 
factors such as malnutrition, inflammation, and the 
reduced production of nitric oxide (NO) promote 
endothelial dysfunction and atherosclerosis in these 
patients.2-4 Moreover, changes of lipoproteins, both 
quantitative and qualitative, are often found in 
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CKD patients and are more pronounced in end-
stage of the disease.5-7 However, diabetes per se, 
particularly type 2 diabetes mellitus (T2DM), is 
very often associated with atherogenic dyslipidemia 
which is characterized by hypertriglyceridemia, 
low HDL-cholesterol and moderately elevated or 
even normal LDL-cholesterol but LDL particles 
are small, dense and more atherogenic.8-10 CKD is 
associated in patients with diabetes with higher 
levels of plasma triglycerides and lower levels of 
HDL-cholesterol even among patients with good 
control of LDL- cholesterol.11
Curcumin is  the active compound of the 
traditional dietary and medicine plant named 
turmeric.12,13 Curcumin has a wide variety of 
pharmacological and biomedical effects in various 
conditions such as inflammatory diseases, metabolic 
syndrome, obesity, dyslipidemia, cardiovascular 
diseases, and cancer.14-16 This natural compound 
has attracted attention because of its beneficial 
properties in treatment of diabetes and its 
complications due to its hypoglycemic, lipid-
lowering, anti-inflammatory and antioxidant 
effects.17,18 Curcumin improves insulin resistance 
and glucose homeostasis by enhancing -cells 
function and insulin secretion affecting glycolysis, 
glyconeogenesis and lipids metabolism in liver.19 
Lipid-lowering effects of curcumin are due to its 
ability to increase the activity of lipoprotein lipase, 
to reduce lipid peroxidation, plasma total cholesterol 
and triglycerides concentrations and to elevate 
HDL-cholesterol levels.20,21 There are indications 
that curcumin can modulate the expression of some 
genes related to glucose and lipid metabolism 
such as peroxisome proliferator-activated receptor 
(PPAR- ) and LDL receptor (LDLR).22,23 
Despi te  o f  potent ia l  pos i t ive  e f fec t s  o f 
curcumin, its oral bioavailability is low. Nano 
formulated curcumin is a novel way to improve its 
bioavailability.24 Therefore, based upon reported 
beneficial effects of curcumin, we tried to evaluate 
the effects of Nano-curcumin intake on metabolic 
status in patients with diabetes mellitus on 
hemodialysis (HD).
MATERIALS AND METHODS
Trial Design and Participants
T h i s  s t u d y ,  r e g i s t e r e d  i n  t h e  I r a n i a n 
website for clinical trials (http://www.irct.ir: 
IRCT20150606022562N6), was a randomized, 
double-blind, placebo-controlled clinical trial 
performed on 60 patients with diabetes on HD; 
18 to 80 years old, which were referred to the 
Akhavan Clinic in Kashan, Iran, between December 
2018 and April 2019. All participants fulfilled The 
Declaration of Helsinki requirements and signed an 
informed consent. The ethics committee of Kashan 
University of Medical Sciences (KAUMS) approved 
this study. Patients involved with infectious, 
inflammatory and malignant diseases, those who 
were taking curcumin supplements, antioxidant 
and/or anti-inflammatory supplements within 
3 months before participation in the study, and 
subjects who were receiving immunosuppressive 
and antibiotics medications were not included in 
the study.
Study Design
Patients were asked to continue their routine 
physical activity, and not to take any anti-
inflammatory and antioxidant medications or 
supplements that might affect their nutritional 
status during the 12-week intervention. By asking 
participants to give back the medication containers 
we checked administration of curcumin and 
placebo during the study. All participants were 
reminded to take the supplement (or placebo) 
by sending a short SMS message every day. All 
partients completed both 3-day food records and 
physical activity records at weeks 0, 6, and 12 of the 
intervention. To obtain macro- and micro-nutrient 
intake composition of participants based on these 
3-day food records, Nutritionist IV software (First 
Databank, San Bruno, CA) modified for Iranian 
foods was used.
Intervention
Patients were randomized into two groups to 
take either nano-curcumin capsule (80 mg/d) or 
placebo (n = 30, each group) for 12 weeks. Nano-
curcumin and placebo capsules were purchased 
from Exir Nano Sina Company (Tehran, Iran). 
Nano-curcumin and placebo were similar in shape 
and package.
Assessment of Anthropometric Measures
Body weight and height were assessed after 
overnight fasting using the same digital scale (Seca, 
Hamburg, Germany) at baseline and after the 12-
week of intervention. Body mass index (BMI) was 
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calculated by weight and height measurements 
[weight (kg) / height (m2)].
Clinical Measurements
Assessment of Outcomes. Insulin resistance and 
insulin levels were considered as primary outcomes 
while serum lipoproteins, and biomarkers of 
inflammation and oxidative stress were considered 
as secondary outcomes. A 15 mL fasting blood 
sample was collected at baseline and at week 12 
after the intervention at Kashan reference laboratory 
and samples were centrifuged to separate serum. 
Then, the samples were stored at -80°C until 
analysis. Serum insulin and hs-CRP levels were 
quantified by using ELISA kit (DiaMetra, Milano, 
Italy and LDN, Nordhorn, Germany) with inter- 
and intra-assay coefficient variances (CVs) lower 
than 7%. The homeostasis model of assessment-
insulin resistance (HOMA-IR), and the quantitative 
insulin sensitivity check index (QUICKI) were 
determined according to the standard formula.25 
Enzymatic kits (Pars Azmun, Tehran, Iran) were 
used to quantify fasting plasma glucose (FPG), 
serum lipoproteins, creatinine and blood urea 
nitrogen (BUN) with inter- and intra-assay CVs 
less than 5%. Total nitrite was estimated using 
Griess method,26 total antioxidant capacity (TAC) 
by the method of ferric reducing antioxidant 
power developed by Benzie and Strain,27 total 
glutathione (GSH) using the method of Beutler et 
al.28 and malondialdehyde (MDA) concentrations 
were determined by the thiobarbituric acid reactive 
substances spectrophotometric test29 with inter- 
and intra-assay CVs lower than 5%. Systolic 
(SBP) and diastolic blood pressure (DBP) was 
measured using the same sphygmomanometer 
(ALPK2, Zhejiang, China). Blood pressure was 
measured between 08:00 and 09:00 AM by the 
same investigator each time.
Isolation of Lymphocytes
Lymphocytes were extracted from blood samples 
using 50% percoll (Sigma-Aldrich, Dorset, UK). 
Cell count and viability test were conducted using 
trypan blue, RNA and DNA extraction.
RNA Extraction and Real-time PCR (RT-PCR)
Gene expressions of  PPAR- ,  LDLR and 
transforming growth factor beta (TGF- ) were 
assessed by quantitative RT-PCR in peripheral 
blood mononuclear cells (PBMCs), using the 
LightCycler technology (Roche Diagnostics, 
Rotkreuz, Switzerland) with SYBR green detection 
and Amplicon Kit (Table 1). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) primers were 
used as a housekeeping gene. Primer Express 
Software (Applied Biosystems, Foster City, USA) 
and Beacon designer software (Takaposizt, Tehran, 
Iran) were used to design primers. Relative 
transcription levels were calculated using the 
method of Pffafi.
Sample Size
In this study, we used a randomized clinical 
trial sample size calculation formula where type 
one ( ) and type two errors ( ) were 0.05, and 
0.20 (power = 80%); respectively. According to 
our previously published trial,30 we used 0.170 
as the SD and 0.135 as the change in mean (d) 
of HOMA-IR as a primary outcome. Based on 
the formula, we needed 25 participants in each 
group. After allowing for 5 dropouts in each 
group, the final sample size was 30 persons in each 
group.















Table 1. Specific Primers Used for Real-time Quantitative PCR
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; LDLR, low-density lipoprotein receptor; PPAR- , peroxisome proliferator-activated 
receptor gamma; TGF- , transforming growth factor beta.
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Randomization
Computer-generated random numbers were used 
for randomization. The researchers and patients 
were not aware of randomization details until the 
final analyses were completed. The enrolling of 
participants, randomized, and allocating them to 
treatment or placebo were performed by trained 
staff at the dialysis clinic.
Statistical Methods
The Kolmogorov-Smirnov test was done to 
determine the normality of data. To detect the 
differences in anthropometric parameters, dietary 
intakes and gene expression between two groups, we 
used the independent-samples t-test. Paired-samples 
t-test was used to detect within-group changes. 
Multiple linear regression models were used to 
assess treatment effects on study outcomes. The 
effect sizes were presented as the mean differences 
with 95% confidence intervals. P values < .05 were 
considered statistically significant. All statistical 
analyses were done using the Statistical Package 
for Social Science version 18 (SPSS Inc., Chicago, 
Illinois, USA).
RESULTS
Four patients in the Nano-curcumin group and 
3 in the placebo group withdraw from the trial, 
due to personal reasons; thus 53 patients [nano-
curcumin (n = 26) and placebo (n = 27)] completed 
the study (Figure 1). The compliance rate was high, 
more than 90% of capsules were taken during the 
course of the trial in both groups. No side effects 
were reported following the consumption of 
Nano-curcumin in patients with diabetes on HD 
during the study.
Distribution of gender, mean age, height, baseline 
weight and BMI were not statistically different 
between the two groups (Table 2). 
Based on the 3-day dietary records obtained 
change in dietary macro- and micro-nutrient intake 
(data not shown).
Nano-curcumin significantly decreased FPG 
(  = -19.68 mg/dL, 95% CI: -33.48 to -5.88; P < .05) 
and serum insulin levels (  = -1.70 μIU/mL, 95% CI: 
Randomized (n=60)
Allocated to placebo (n=30)
Lost to follow-up (n=3)
Analyzed (n=27)
Allocated to intervention (n=30)
Lost to follow-up (n=4)
Analyzed (n=26)
Assessed for eligibility (n=64)
Excluded (n=4)






























Figure 1. It shows summary of patients’ flow diagram.
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-2.96 to -0.44; P < .05) when compared with placebo 
(Table 3). Nano-curcumin was also associated with 
a significant reduction in triglycerides (  = -16.13 
mg/dL, 95% CI: -31.51 to -0.75; P < .05), VLDL-
cholesterol (  = -3.22 mg/dL, 95% CI: -6.30 to 
-0.15; P < .05), total cholesterol (  = -17.83 mg/dL, 
95% CI: -29.22 to -6.45; P < .05), LDL-cholesterol 
(  = -15.20 mg/dL, 95% CI: -25.53 to -4.87; P < .05), 
and total-/HDL-cholesterol ratio (  = -1.15, 95% 
CI: -0.2.10 to -0.21; P < .05) when compared with 
placebo. Nano-curcumin significantly reduced 
serum hs-CRP (  = -0.78 mg/L, 95% CI: -1.41 to 
-0.15; P < .05) and plasma MDA (  = -0.25 μmol/L, 
95% CI: -0.45 to -0.04; P < .05); and significantly 
increased plasma TAC (  = 52.43 mmol/L, 95% 
CI: 4.52 to 100.35; P < .05), and total nitrite levels 
(  = 3.62 μmol/L, 95% CI: 2.17 to 5.08; P < .001) 
when were compared with the placebo. Nano-
curcumin intake did not change other metabolic 
parameters. 
Baseline levels of HDL-cholesterol (P < .05), 
total-/HDL-cholesterol ratio (P < .05), and creatinine 
(P < .05) were significantly different between the 
two groups. Therefore, we adjusted the analyses for 
the baseline levels. However, after this adjustment 
no significant changes in our findings occurred 
(data not shown).
Nano-curcumin intake upregulated gene 
expression of PPAR-  (P < .05) and LDLR (P < .05) 
in PBMCs of patients with diabetes on HD, when 
compared with placebo. Nano-curcumin did not 
affect gene expression of TGF-  (Figure 2).
DISCUSSION
In this study, we analyzed the effects of Nano-
curcumin intake on metabolic profiles in patients 
with diabetes on HD. We found that Nano-curcumin 
supplementation during 12 weeks in these patients 
had beneficial effects on FPG, insulin levels, 
HOMA-IR, triglycerides, VLDL-cholesterol, total 
cholesterol, LDL-cholesterol, total-/HDL-cholesterol 
ratio, hs-CRP, total nitrite levels, TAC and MDA, 
and gene expression of PPAR-  and LDLR, but did 
not affect other metabolic parameters and gene 
expression of TGF- . 
Effects on Glycemic Control and Serum Lipids 
Our findings indicated that nano-curcumin intake 
during 12 weeks significantly reduced FPG, insulin 
Placebo 
Group




(n = 26) 
P1
Gender (%) 
Males 15 (55.6) 17 (65.4) > .05†
Females 12 (44.4) 9 (34.6) 
Age, years 56.2 ± 9.8 58.3 ± 9.4 > .05
Height, cm 165.5 ± 7.2 167.5 ± 7.3 > .05
Weight at Baseline, kg 73.9 ± 10.7 78.6 ± 15.9 > .05
Weight at the End of 
Trial, kg
74.9 ± 10.8 77.8 ± 15.4 > .05
Weight Change, kg 0.1 ± 1.4 -0.8 ± 1.5 < .05
BMI at Baseline, kg/m2 27.1 ± 4.2 27.9 ± 4.9 > .05
BMI at the End of Trial, 
kg/m2
27.1 ± 4.3 27.6 ± 4.7 > .05
BMI Change, kg/m2 0.03 ± 0.5 -0.3 ± 0.5 < .05
Table 2. General Characteristics of Study Participants
Data are means ± SD.
1Obtained from independent t-test. 




P = 0.01 P = 0.64































Figure 2. It determined effect of the 12-week supplementation with nano-curcumin or placebo on expression ratio of PPAR- , LDLR, and 
TGF-  gene in PBMCs of patients with diabetes on HD 
(LDLR, low-density lipoprotein receptor; HD, hemodialysis; PBMCs, peripheral blood mononuclear cells; PPAR- , peroxisome proliferator-
activated receptor gamma; TGF- , transforming growth factor beta). 
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levels, HOMA-IR, triglycerides, VLDL-cholesterol, 
total cholesterol, LDL-cholesterol, and total-/
HDL-cholesterol ratio. A meta-analysis showed 
that curcumin intake in subjects with prediabetes 
and T2DM can reduce FPG, but did not change 
HOMA-IR.31 Another study reported that 300 
mg curcumin administration during 3 months to 
patients with (T2DM) significantly decreased FPG 
and HOMA-IR.32 However, Kocher et al.33 reported 
that 294 mg micellar curcumin intake for 6 weeks 
in moderately hyperlipidemic individuals did not 
show any glucose-lowering effect. A recent meta-
analysis suggested that turmeric and curcumin 
in patients with cardiovascular risk factors was 
associated with a significant reduction in total 
cholesterol, LDL-cholesterol, and triglycerides; 
but did not affect HDL-cholesterol levels.34 In 
a clinical study, 1,000 mg curcumin plus 10 mg 
piperine intake during 12 weeks reduced total 
cholesterol; non-HDL-cholesterol, lipoprotein A 
and elevated HDL-cholesterol levels, but failed 
to change LDL-cholesterol and triglycerides levels 
in T2DM patients.35 In contrast to these results, 
an earlier meta-analysis on a heterogeneous 
population reported that curcumin administration 
did not significantly change any lipoproteins.36 
On the other hand, 40 mg nano-curcumin during 
3 months in overweight/obese subjects with non-
alcoholic fatty liver disease (NAFLD) resulted 
in a significant reduction in FPG, HOMA-IR, 
total- and LDL-cholesterol, and triglycerides 
levels as well as an elevation in HDL-cholesterol 
concentrations.30 Several factors including the type 
of the study, curcumin dosage and intervention 
duration may account for these conflicting results 
of different studies. Hyperglycemia is the most 
important factor in the development of DN because 
it increases oxidative stress and inflammation. 
Insulin resistance is an independent predictor for 
cardiovascular disease and mortality in patients 
with CKD. Besides changed glucose, changes in 
plasma lipoproteins are frequent in early stages 
of kidney disease and are more severe in end 
stages.37,38 Curcumin improves hyperglycemia by 
lowering oxidative stress.39 Curcumin can also affect 
-cells function increasing production and secretion 
of insulin.40 The beneficial effect of curcumin on 
insulin resistance is mediated by stimulation of 
glycolysis and inhibition of glyconeogenesis in 
the liver.19 The results of many studies suggested 
that curcumin can influence cholesterol absorption 
and excretion by the bile as well as to decrease 
lipid peroxides.41 Nano-curcumin supplementation 
increased gene expression of PPAR-  and LDLR. 
LDLR is involved in LDL-cholesterol catabolism 
and therefore its increased expression decreases 
plasma LDL-cholesterol levels. Furthermore, 
PPAR-  induction is one of the main mechanisms by 
which glucose-lowering effect of curcumin can be 
explained.42 Since curcumin can upregulate PPAR-  
and LDLR this might explain the improvement of 
lipoproteins and glucose metabolism. 
Effects on Inflammation and Oxidative Stress 
Biomarkers 
The results of our study suggest that Nano-
curcumin during 12 weeks significantly reduced 
hs-CRP and MDA, and increased total nitrite and 
TAC levels, but did not affect GSH levels and 
gene expression of TGF-  in patients with diabetes 
on HD. In a meta-analysis, we have previously 
documented that taking curcumin-containing 
supplements could have anti-inflammatory and 
antioxidant effects which are achieved by a 
significant decrease in IL-6, hs-CRP, and MDA 
concentrations.43 A significant reduction in hs-
CRP, IL-6, and TNF-  concentrations following 
the intake of 1,500 mg/d turmeric for 12 weeks in 
HD patients was seen in another study, but there 
was no significant difference between intervention 
and control groups.44 Short-term therapy with 
curcuminoids (500 mg/d for 4 weeks) resulted 
in suppressing systemic inflammation in subjects 
suffering from sulfur mustard-induced chronic 
pulmonary complications.45 In another study on 
patients with T2DM, 2 g/d turmeric treatment for 4 
weeks significantly reduced MDA concentrations.46 
However, in a meta-analysis; turmeric or curcumin 
intake did not reduce inflammatory cytokines in 
subjects with chronic inflammatory diseases.47 
Discrepancies in might be because of different 
characteristics of study populations, because of 
differences in study design, dosage and kind of 
curcumin-containing supplements used, quality of 
curcumin used and duration of the intervention. 
Earlier studies suggested that different factors, 
including dialysis clearance inflammation and 
oxidative damage are associated with morbidity and 
mortality in HD patients.48,49 High rate of morbidity 
has been correlated with high concentrations of 
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CRP and other inflammatory markers such as IL-1 
or IL-6 in these patients.48,50 Curcumin is a natural 
antioxidant that has protective effects due to both 
increasing biological antioxidant defense system 
and free radical scavenging.51 Curcumin intake 
may also reduce oxidative damage by chelating 
the redox-active metals and suppressing chain 
reactions producing metal ion-induced radicals.52 
This study has some limitations. Due to budget 
restrictions, we did not check complience to Nano-
curcumin intake by a biomarker. We were also 
unable to determine the effects of Nano-curcumin 
administration on other biomarkers of oxidative 
stress and inflammation.
CONCLUSION
We found that nano-curcumin supplementation 
for 12 weeks to patients with diabetes on HD had 
beneficial effects on FPG, insulin levels, HOMA-IR, 
triglycerides, VLDL-cholesterol, total cholesterol, 
LDL-cholesterol, total-/HDL-cholesterol ratio, 
hs-CRP, total nitrite, TAC and MDA, and gene 
expression of PPAR-  and LDLR; but did not affect 
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The Added Value of Trabecular Bone Score in Fracture Risk 
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Introduction. Trabecular Bone Score (TBS) is an index of bone 
microarchitecture independent of Bone Mineral Density (BMD). 
Recently, TBS data has been used to optimize the predictive value 
of the Fracture Risk Assessment Tool (FRAX). The aim of this study 
was to evaluate the clinical value of FRAX adjustment with TBS 
in kidney transplant recipients.
Methods. Seventy post-transplant Iranian kidney recipients were 
included in this study. After the evaluation of BMD and TBS, the 
risk of major osteoporotic fracture (MOF) and hip fracture (HF) 
was assessed once with and once without TBS adjustment. The 
proportion of patients who needed a therapeutic intervention 
was compared before and after TBS adjustment. The association 
between TBS and BMD data was also evaluated.
Results. The mean age of the patients was 54 ± 8.8 years (range: 40 
to 77). The mean TBS of the patients was 1.30 ± 0.12. In multivariate 
analysis, the TBS was significantly associated with the age (P < .05) 
and dialysis period (P < .05). A strong correlation was found between 
the spine BMD and TBS data (r = 0.612, P < .001). A significant 
correlation was found between the MOF and HF of the patients 
before and after adjustment for TBS. The proportion of patients 
needed a therapeutic intervention significantly increased from 
17.1% to 25.7% after TBS adjustment of FRAX.
Conclusion. Adjustment of FRAX with TBS will reclassify the 
treatment decision in a considerable number of kidney transplant 
recipients. This clinical value warrants the adjustment of FRAX 
data with TBS in future workouts. 
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INTRODUCTION
Osteoporosis is a major public health problem 
and a leading cause of fragility fracture.1 Kidney 
transplant recipients are at increased risk of 
osteoporosis as well as fragility fracture.2 It has 
been revealed that bone mineral density (BMD) 
declines by 4% to 10% in the first six months after 
transplantation by several mechanisms such as 
immunosuppression, alterations in the parathyroid 
hormone, changes in mineral metabolism, and 
glucocorticoid administration post-transplant.3 
This bone loss contributes to an increased risk of 
fragility fractures so that nearly 22.5% of kidney 
transplant recipients experience a fracture in the 
first five years after transplantation, an incidence 
that is four times greater than in the general 
population.4 Considering the severe mortality and 
morbidity of fragility fracture and its remarkable 
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health and economic impact, the development of 
new diagnostic techniques for the prevention of 
osteoporotic fragility fractures is of significant 
importance.5
In the general population, low BMD strongly 
reflects the presence of osteoporosis and the risk 
of fragility fracture. However, conflicting results 
are reported in the kidney transplant recipients 
as BMD may be falsely elevated in these patients 
due to aortic calcification, particularly in long-term 
dialysis patients.6-8 Accordingly, the bone quality 
may also be adversely affected besides bone density, 
and if not considered, the fracture risk of kidney 
transplant recipients might be underestimated.9 
Although bone biopsy provides adequate 
information about bone quality, it is an invasive 
test and not suitable for routine workouts.10 Thus, 
more practical approaches are needed for the 
evaluation of bone quality in kidney transplant 
recipients.
Trabecular  bone score  (TBS)  i s  a  novel , 
noninvasive measure of bone quality derived from 
lumbar spine dual-energy X-ray absorptiometry 
(DXA) images. It is a texture measurement that 
quantifies local variations in gray level distribution 
f rom the  DXA image  and  i s  s ign i f i cant ly 
correlated with 3-dimensional parameters of bone 
microarchitecture, independently of BMD. In this 
regard, a higher TBS value is indicative of better 
bone structure, vice versa.11-5 Hence, attempts are 
being made to include TBS data in the fracture 
risk assessment.
Fracture risk assessment tool (FRAX) is a 
supportive software in osteoporosis management 
that provides a 10-year percentage of the risk of 
hip fracture (HF) and major osteoporotic fracture 
(MOF). Before the introduction of TBS, the FRAX 
assessment was based on the BMD information. 
Recently, FRAX data are adjustable with TBS 
information, providing a fracture risk assessment 
based on a combination of TBS and BMD. 
The main goal of this study was to assess the 
association between BMD and TBS data in Iranian 
kidney transplant population as well as to evaluate 
the added value of TBS-adjusted FRAX in the 
reclassification of treatment threshold in these 
patients.
MATERIALS AND METHODS
This study was approved by the review board 
of our institute under the code of 9511402001, and 
written informed consent was obtained from the 
patients before their participation in the research. 
In a cross-sectional study, Iranian kidney transplant 
recipients were recruited from the nephrology 
clinic of Shahid Hashemi Nejad nephrology 
Hospital, Tehran, Iran. The patients were referred 
to the densitometry department for BMD and TBS 
examination providing that they were identified 
as eligible for the study. Inclusion criteria were 
the age of more than 40 years, at least six months 
past the date of transplantation, and a glomerular 
filtration rate (GFR) of more than 30 mL/min. 
Exclusion criteria included the patients undergoing 
osteoporosis treatment within the past two years, 
a history of Cushing’s syndrome, malabsorption 
syndrome, liver failure, or any chronic disorders 
affecting the mineral metabolism. Since TBS can 
solely be computed for patients with a Body Mass 
Index (BMI) ranging from 15 to 37 kg/m2, patients 
with a BMI of less than 15 or higher than 37 were 
also excluded.
BMD of the spine (L1 to L4) and femoral neck 
were assessed by a DXA machine (Hologic Horizon 
WI). The region with the lowest T-score was used 
for the evaluation of osteoporosis. According, 
the patients were categorized into osteoporotic 
(T-score < -2.5), osteopenic (-1 < T-score < -2.5), 
and normal (T-score > -1). 
TBS measurement was performed at the same 
time with BMD evaluation using TBS software 
version 3.0.2.0, which determines the variogram 
of the trabecular bone projected image concerning 
the sum of the squared gray level differences 
between pixels at a specific distance and angle.16 
TBS results were considered degraded if < 1.2, 
partially degraded if 1.2 to 1.35, and normal if > 1.35.
MOF and HF risks were calculated using 
the FRAX calculator defined for the Iranian 
population. According to the guideline of the 
National Osteoporosis Foundation, cutoff values 
of 20% and 3% were considered as high absolute 
ten years risk of fracture for MOF and HF risk, 
respectively.17 The FRAX calculation was done 
once without TBS adjustment and once with TBS 
adjustment (TBS-adjusted FRAX).
Statistical Analysis
SPSS version 16 was used for the statistical 
analysis of the data. Paired data were compared 
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using a paired t-test or its nonparametric counterpart 
(Kruskal-Wallis Test). A comparison of the mean 
value of two independent groups was made 
using an independent t-test or its nonparametric 
equivalent (Mann–Whitney U test). A multiple 
linear regression analysis was used to evaluate 
the association of TBS value with independent 
variables. A chi-square test was used for the 
evaluation of the difference between categorical 
variables. Pearson’s correlation coefficient test was 
used for the evaluation of potential correlations. 
The proportion of patients needing a therapeutic 
intervention before and after TBS adjustment was 
compared using a McNemar’s test. A P value of 
fewer than .05 was considered as statistically 
significant.
RESULTS
A total of 70 kidney transplant recipients were 
identified as eligible for the study. The patient’s 
population included 30 (42.9%) females and 40 
(57.1%) males with the mean age of 54 ± 8.8 years 
(range: 40 to 77 years). The mean glomerular 
filtration rate (GFR) of the patients was 66.3 ± 21.7 
mL/min (range:  30 to 112.1 mL/min).  The 
mean dialysis period before transplantation was 
26.9 ± 31.2 months (range: 0 to 204 months). The 
mean time passed the transplantation date was 
5.1 ± 5.7 years (range: 0.5 to 31 years). The mean 
parathyroid hormone (PTH) of the patients was 
75.8 ± 63.2 pg/mL (range: 13.5 to 356 pg/mL). The 
mean serum vitamin D level was 20.1 ± 13.1 ng/
mL (range: 3 to 75 ng/mL). In 44 (62.8%) patients, 
the kidney was transplanted from a living donor, 
while in 26 (37.2%) cases; it was transplanted 
from a deceased donor. Based on the routine 
protocol of our center, all the patients were under 
prednisolone, mycophenolate mofetil, and CN 
inhibitor medications. Eleven (15.7%) patients 
also were receiving mTOR inhibitors. None of the 
patients were receiving osteoporosis treatment. 
The clinical and demographic characteristics of the 
patients are demonstrated in more detail in Table 1.
The mean femoral neck and spine T-score of 
the patients were -1.49 ± 1.09 and -1.56 ± 1.3, 
respectively. According to the results of BMD 
evaluation, 19 (27.1%) patients were identified as 
osteoporotic, 36 (51.4%) patients were characterized 
as osteopenic, and 15 (21.4%) patients were normal. 
The mean TBS of the patients was 1.296 ± 0.123 
(range: 0.93 to 1.56). Based on the TBS results, 
degraded, partially degraded, and normal bone 
quality was identified in 15 (21.4%), 24 (34.3%), and 
31 (44.3%) patients, respectively. The densitometric 
data of the patients are demonstrated in Table 2.
In bivariate analysis ,  the mean TBS was 
significantly different in two dialysis groups 
P < .05). 
Variables Mean ± SD
Femoral Neck BMD, g/cm2 0.71 ± 0.14
Femoral Neck T-score -1.49 ± 1.09
L1-L4 Spinal BMD, g/cm2) 0.90 ± 0.15
L1-L4 Spinal T-score -1.56 ± 1.3
TBS 1.30 ± 0.12
BMD-based MOF 6.03 ± 4.06
BMD-based HF 2.05 ± 2.89
TBS-adjusted MOF 6.98 ± 7.73
TBS-adjusted HF 2.53 ± 4.32
Table 2. The Densitometric Characteristics of the Kidney 
Transplant Patients
MOF, major osteoporotic fracture; HF, Hip fracture.
Variables Mean ± SDNumber (%) 





























Glomerular Filtration Rate, mL / min  66.3 ± 21.7  
Pre-transplant Dialysis Period, mo  26.9 ± 31.2
Time Past the Transplant, year  5.1 ± 5.7  







 44 (62.8%)  
 26 (37.2%)  
Parathyroid Hormone, pg/mL  75.8 ± 63.2  
Serum Vitamin D, ng/mL  20.1 ± 13.1
ESKD, end-stage kidney disease; ADPKD, autosomal dominant 
polycystic kidney disease.
Table 1. The Demographic, Clinical, and Laboratory Data of 
Kidney Transplant Patients
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Besides, the mean TBS was significantly lower 
in diabetic patients compared with non-diabetic 
patients (P < .05). However, the mean TBS was not 
significantly different in two GFR groups (30 to 60 
mL/min and > 60 mL/min, P > .05). In addition, the 
mean TBS was not significantly different between 
patients who had been transplanted for more than 
five years and those who had been transplanted 
for less than five years (P > .05). Also, the mean 
TBS was not significantly different in patients who 
received mTOR inhibitors and those who did not 
(P > .05). A significant negative correlation was 
also found between the age and TBS of the patients 
(r = -0.381, P < .05).
In multivariate analysis, TBS was still significantly 
associated with the age (P < .05, 95% CI: -0.008 to 
-0.001) and dialysis period (P < .05, 95% CI: -114 to 
-0.005) but not with the GFR (P > .05) and diabetic 
status (P > .05). 
A significant correlation was found between 
the femoral neck BMD and TBS (r = 0.38, P < .05) 
as well as spine BMD and TBS (r = 0.61, P < .001). 
Moreover, a significant association was found 
between the BMD status (osteoporotic, osteopenic, 
and normal) and TBS status (degraded, partially 
degraded, and normal) of the patients (P < .001). 
In this respect, almost half of patients with an 
osteoporotic BMD had a degraded TBS, while the 
majority of patients with a normal BMD also had 
a normal TBS (Table 3). 
The mean MOF of the patients was 6.03 ± 4.06 
before the adjustment with TBS and 6.98 ± 7.73 
after the adjustment with TBS. This difference was 
not statistically significant (P > .05). A significant 
positive correlation was found between the MOF 
of the patients before and after adjustment with 
TBS (r = 0.82, P < .001; Figure A).
The mean HF of the patients was 2.05 ± 2.89 
before the adjustment with TBS and 2.53 ± 4.32 
after  the adjustment with TBS. This difference 
was not statistically significant, as well (P > .05). 
A significant positive correlation was also found 
between the HF of the patients before and after 
adjustment with TBS (r = 0.90, P < .001, Figure B). 



































It shows scatter plots showing the strong correlation of major osteoporotic fracture (A) and hip fracture risk (B) of the kidney transplant 




Degraded Partially Degraded Normal
Osteoporosis 9 (47.4) 9 (47.4) 1 (5.3) 19 (27.1) 
< .001
Osteopenia 5 (13.9) 14 (38.9) 17 (47.2) 36 (51.4) 
Normal 1 (6.7) 1 (6.7) 13 (86.7) 15 (21.4) 
Total 15 (21.4) 24 (34.3) 31 (44.3) 70 (100) 
Table 3. The Association Between BMD and TBS Status of the Kidney Transplant Patients
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Before TBS adjustment, MOF risk of only one 
patient passed the treatment threshold (> 20%). 
After TBS adjustment, the MOF of three other 
patients passed the treatment threshold. Before the 
TBS adjustment, HF of 11 patients was above the 
treatment threshold (> 3%). After TBS adjustment, 
The HF of three additional patients passed the 
treatment threshold. These patients were not the 
same patients who their MOF was reclassified 
after TBS adjustment. Overall, before the TBS 
adjustment, 12 (17.1%) patients needed a therapeutic 
intervention, while after TBS adjustment, 18 (25.7%) 
patients were required therapeutic intervention. 
This difference was statistically significant (P < .05). 
TBS adjustment did not result in the reduction 
of fracture risk below the treatment threshold in 
any patient.
DISCUSSION
In this study, we evaluated the BMD and TBS 
in a series of Iranian kidney transplant recipients.
The effect of TBS adjustment of FRAX on the 
MOF and HF of the patients and the treatment 
strategy was evaluated as well. Based on the result 
of multivariate analysis, TBS was significantly 
months. Besides, TBS was negatively correlated 
with the age of patients. However, TBS was not 
associated with the GFR and diabetic status of the 
patients. A significant positive correlation was 
also found between the TBS and femoral neck/
spine BMD of the patients. The FRAX score of the 
patients revealed a significantly strong correlation 
before and after adjustment with TBS as well. 
Despite this correlation, the treatment decision was 
reclassified in six patients after TBS adjustment 
(three patients based on MOF and three patients 
based on HF). In other words, the FRAX score of 
these six patients crossed the treatment threshold 
after TBS adjustment, indicating a pharmacologic 
osteoporosis treatment. 
Naylor et al. compared the TBS in the kidney 
transplant population with the age and sex-matched 
general population from Manitoba, Canada. Based 
on their results, TBS was significantly lower in 
kidney transplant recipients when compared 
with the general population (1.37 vs. 1.41). 
Moreover, TBS was associated with a fracture 
rate independent of BMD.9 Lower mean TBS was 
also noticed in kidney transplant recipients of the 
study of Pasquali et al. when compared with age-
matched normal control Italian population (1.32 
vs. 1.40).18 Similarly, Bonani et al. observed a lower 
mean TBS in kidney transplant recipients (1.31) in 
comparison with the published reference value in 
a normal control Italian population (range: 1.36 
to 1.47).19 We did not find any previous study 
evaluating the TBS value in either Iranian kidney 
transplant recipient or the general population. 
The mean TBS of the patients in the current series 
was 1.30 that was considerably lower than the 
TBS of the general population in the study of 
Naylor et al., as expected. The mean TBS of the 
present series was also remarkably lower than 
the TBS of kidney transplant recipients in the 
earlier investigations.9,18-9 This difference could be 
attributed to the different characteristics of patients. 
According to the results of the present study, 
factors such as age and dialysis period might affect 
the TBS of the patients. The negative correlation 
between age and TBS has been reported in earlier 
studies.20,21 Lower TBS level in diabetic patients 
has been reported in other investigations.22-3 
In the present study, the diabetic status of the 
patients was significantly associated with TBS 
in the bivariate analysis but not in multivariate 
analysis, suggesting that this association could be 
confounded by other variables. The present study 
revealed a significant negative association between 
the dialysis period and TBS in both bivariate and 
multivariate analyses. By contrast to the present 
study, the study of Shevroja et al. revealed no 
effect of the pre-transplant dialysis period on 
post-transplant TBS.24 Naylor et al. evaluated the 
association between TBS and incident fractures in 
adults with reduced kidney function. Based on 
their results, mean TBS was significantly lower 
in adults with reduced kidney function compared 
with those with normal kidney function (n: 1.28 vs. 
1.30).24 The TBS was not significantly associated 
with GFR of the patients in the current series, either 
in bivariate or in univariate analysis. However, 
it should be noted that the patients’ number was 
markedly higher in the study of Naylor et al. 
The value of TBS in the kidney transplant 
population has been acknowledged in other 
investigations as well.25-7 As a new field of interest in 
osteoporosis, the number of studies on the potential 
optimizing effect of TBS on the predictive value 
of FRAX for fracture (MOF and HF) is increasing. 
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Couraud et al. compared the proportion of patients 
at high fracture risk before and after adjustment 
with TBS in 413 patients hospitalized for a non-
vertebral fracture. Based on their results, the 
before the fracture was similar before and after 
TBS adjustment (24.7% vs. 25.4%). The proportion 
of patients with a risk of MOF above the threshold 
of the therapeutic intervention was significantly 
higher after TBS adjustment for the age categories 
of 60-70years (38.3% vs. 30.9%) and 70 to 80 years 
(31.2% vs. 26.6%).28 
Mirzaei  et  al .  evaluated the effect of TBS 
adjustment  on the FRAX algori thm in 358 
postmenopausal Iranian women. Based on their 
results, the proportion of the women requiring 
a therapeutic intervention remained unchanged 
after FRAX adjustment with TBS. They reported 
no clinical benefit for FRAX-adjustment with TBS 
in postmenopausal women.14
Tamaki et al. aimed to find if TBS improves 
the predictive ability of FRAX for MOF in the 
Japanese population-based osteoporosis cohort 
study. They compared the predictive ability of 
the FRAX model before and after combination 
They identified 67 events of MOF in their cohort 
during a 10-year follow-up period. Based on their 
results, the model incorporating FRAX with TBS 
demonstrated a better fit compared to a model 
consisting of FRAX alone.29 
To the best of our knowledge, no study has 
been performed to evaluate the effect of TBS 
adjustment on the MOF and HF risk of the kidney 
transplant population. Based on the results of the 
current study, the proportion of patients needing 
a therapeutic intervention significantly increased 
from 17.1% to 25.7% after TBS adjustment of FRAX. 
These findings reveal that TBS adjustment of 
FRAX contains valuable clinical utility in kidney 
transplant recipients.
One patient of the current series had normal 
BMD despite fully degraded TBS (Table 3). In 
reviewing her documents, we noticed aortic 
calcification along L1 to L4 lumbar vertebra, which 
could be responsible for misleading normal BMD. 
Aortic calcification in renal transplant patients is 
considered an important predisposing factor for 
falsely elevated bone density in the lumbar spine, 
and adding TBS to the bone evaluation partly 
resolves this problem. This point is highlighted 
in the study of Aleksova et al., which aimed to 
evaluate the association of the TBS with abdominal 
aortic calcification in patients with chronic kidney 
disorders receiving dialysis. They evaluated 146 
patients, of whom 49% had prevalent calcification 
and found an inverse association between TBS to 
vascular calcification.30
The value of TBS in fracture risk assessment 
has also been reported in other diseases such as 
Ankylosing Spondylitis, in which BMD results 
could be falsely elevated by the presence of typical 
syndesmophytes.13
Although mTOR inhibitors have revealed on the 
bone quality,31 no significant association was found 
between the mTOR inhibitors medication and TBS 
of the patients in the present study. However, this 
results could have been adversely affected by the 
small number of patients who were taking mTOR 
inhibitors in the current series. Therefore, further 
studies are required to evaluate the effect of mTOR 
inhibitors on TBS.
The present study was not without weakness. The 
main weakness of this study was the small number 
of patients that could have affected the power of 
statistical analysis. Therefore, future investigations 
with a larger sample size will provide valuable 
complementary information regarding the value 
of TBS in kidney transplant recipients. 
CONCLUSION
TBS was impaired in Iranian kidney transplant 
recipients. Factors such as age and duration 
of dialysis are associated with TBS. Despite a 
significant correlation between MOF and HF 
risk before and after adjustment with TBS, the 
proportion of patients who needed a therapeutic 
intervention significantly increased after FRAX 
adjustment with TBS. These findings highlight the 
complementary role of TBS in kidney transplant 
recipients and suggest TBS adjustment of FRAX 
in future workouts evaluating the bone quality 
of patients after kidney transplant. Moreover, the 
evaluation of TBS beside BMD provides awareness 
regarding the misleading BMD results caused by 
aortic calcification in the kidney transplant recipient.
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The Prevalence of Renal Scars Among Infants Under One 
Year Old With a First UTI With or Without VUR in Qom, Iran, 
2017
Mohsen Akhavan Sepahi,1 Fateme Toloii,2 Shahram Arsang Jang,3 
Bibi Leila Hoseini4
Renal scarring with reflux develops renal nephropathy. The risk 
is higher when it is associated with urinary tract infection (UTI). 
Hence, we investigated the prevalence of renal scars among 
children under one-year-old with the first UTI in Qom, Iran. 
We conducted this retrospective study on 140 infants divided in 
two reflux (n = 70) and non-reflux (n = 70) groups. Participant’s 
records had been analyzed by descriptive and analytic statistics. 
The prevalence of renal scar was 32.12% among all 140 infants. The 
prevalence of renal scars among children with and without reflux, 
was 33 (47.1%), and 12 (17.1%) out of 70 (P < .001); respectively. 
The rate of renal defects increased with higher grades of reflux. 
We found that the rate of renal scar is high in Qom. Therefore, 
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INTRODUCTION
Renal scarring induced by reflux can progress 
to reflux nephropathy. This risk would be higher, 
if vesicoureteral reflux (VUR) is associated with 
urinary tract infection (UTI).1 UTI is one of the 
most common infections among children.2-4 It is 
the first sign in 30% of children with urinary tract 
anomalies.5 Although renal scar can be developed 
by even a single urinary tract infection, but repeated 
infections more probably cause reflux nephropathy.1
VUR is the retrograde urinary flow from the 
bladder to the ureter or kidney.6 It may be familial 
or secondary to distal obstacle of the bladder or 
any other urinary tract anomalies.7 Reflux can lead 
to incomplete urinary evacuation.1 This defect may 
prepare children’s renal infection.8 Although VUR 
is often diagnosed following a UTI, the routine 
ultrasonographic imaging in pregnancy may 
reveal this defect before UTI represented. There 
is no reliable clinical sign to differentiate UTI in 
patients with or without reflux.1
Diagnostic techniques used for urinary tract 
assessment included: Renal ultrasound (RUS), 
voiding cystourethrogram (VCUG), and nuclear 
cystogram (NCG).1,9 Dimercaptosuccinic Acid 
(DMSA) scan is the best way to identify renal scars.10
Any delay in treatment of UTI predisposes 
the children to kidney injuries.4 The long-
term complications of renal scarring include 
hypertension, renal dysfunction and end-stage renal 
disease (ESRD).3,8 VUR is divided into 5 grades 
I–V.7 Surgical intervention is rarely used for under 
one-year-old infants with reflux. It is indicated in 
some cases such as a high-grade reflux, and renal 
Renal Scars Among Infants Under One year Old—Akhavan Sepahi et al
309Iranian Journal of Kidney Diseases | Volume 14 | Number 4 | July 2020
impairment induced by renal nephropathy.11
As mentioned above, children are more likely 
to develop kidney damage following UTI. But the 
risk is highest in young children since ureteral 
bladder reflux is more common in this group. On 
the other hand, one more influencing factor on 
renal scar is genetic predisposibility.3 Although 
several researches had been performed on renal scar 
prevalence, we did not find any study focused on 
children in the first year of life in Qom city. Thus, 
we investigated the rate of renal scars in under 
one-year-old infants with the first UTI affected to 
reflux or not in Qom, Iran in 2017.
MATERIALS AND METHODS
This historical cohort study was conducted in 
Hazrat Masoume hospital, Qom, Iran. This hospital 
has a referral nephrology ward for patients with 
urinary infection. The appropriate sample size was 
139 children. It was calculated based on the statistical 
indices from previous studies and considering the 
probability of type I error 5%, power 80%, patients 
with VUR and abnormal DMSA equal to 75.9%. 
Data were gathered randomly from records of the 
patients admitted in nephrology ward anytime in 
the past till accomplishing the required sample 
size. So, we included all under one-year-old infants 
suffering from UTI. We diagnosed whether each 
infant affected with reflux or not and its severity 
by using VCUG data. The patients with reflux 
were allocated to exposed group, and those in 
unexposed group had no VUR. Both groups had 
been evaluated to detect renal scars by DMSA at 
intervals of 6 months. Some variables including 
age and gender were extracted, too.
The Research Committee of Qom University of 
Medical Sciences (IR.MUQ.REC.1396.124) approved 
this study. All data were gathered, coded, entered 
into a computer, and analyzed. Statistical analysis 
was performed using the STATA version 14. We 
analyzed data by using descriptive statistics and 
Pearson, chi squared tests, as well as logistic 
regression model, ordinal logistic regression 
model. The significance level used was a P value 
of less than .05.
RESULTS
Records of 140 infants affected with the first 
UTI were examined. In each group, 70 children 
were assessed. The average age of the children 
was 10 months. The mean age was 5 and 8 months, 
respectively, in the exposed and unexposed groups.
Of 140, number of 45 patients had abnormal 
DMSA in favor of scars. Thus the prevalence of 
renal scar was 32.12% among infants under one-
year-old with the first urinary tract infection. 
Among them, 8.6% (n = 12) belongs to unexposed 
group; and 23.6% (n = 33) belongs to exposed group. 
The prevalence of renal scars in children with and 
without reflux was 33 (47.1%), and 12 (17.1%) out 
of 70; respectively. The chi - square test showed a 
significant relationship between kidney defects and 
the presence or absence of reflux (P < .001, Figure). 
Odds ratio for scar prevalence in the exposed group 
was 4.31 (95% CI: 1.98 to 9.39) folds comparing the 
unexposed group. The number of girls affected 
It shows frequency distribution of children affected to scar according to exposed and non-exposed groups.
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with scar (n = 9) was higher than the boys (n = 3) 
in the unexposed group. Similar findings were 
observed in the exposed group (n = 25 (girls) vs. 
n = 8 (boys)). Chi-square test showed no significant 
relationship between gender and VUR.
In the exposed group, the number of 33 infants 
affected with scar. Of which, 18 babies had 
moderate and severe reflux (Grade 3, 4, 5), and 15 
had mild reflux (Grade 1, 2). There was a positive 
relationship between renal scarring and VUR grade 
(P < .001, Table). 
DISCUSSION
The present study investigates the prevalence 
of renal scars among infants under one-year-old 
with the first UTI in two groups with and without 
VUR. Of 140 children, 32.12% had renal scar. The 
prevalence of renal scars reported by Warren et al 
was 15.5%.12 This prevalence is nearly half of our 
study. Faust et, al reported the rate of renal defects 
in patients following acute pyelonephritis varied 
from 26.5% (Australia) to 49.0% (Asia).13 It shows 
renal defect in Iran has a better situation compared 
with other countries in the Middle East region.
According to the present findings, 47.1% of 
the babies with reflux and 17.1% of ones without 
reflux had kidney scars. Our findings are nearly 
consistent with this study. Based on Lee et al., the 
first DMSA showed renal damage in 34 (70.8%) 
out of 48 refluxing units and in 13 (27.1%) out of 
48 without reflux (P < .01, OR = 6.54).14 Although 
similar results concluded from these two studies 
based on higher prevalence of scars in patients 
with reflux, the rate of renal scars in our study 
(P < .01, OR = 4.31) is lower than Lee’s study. 
Shaikh et al. reported the prevalence of renal 
scarring 15% in the follow up by DMSA in children 
with the first UTI. This rate is half of our study. 
Since Shaikh’s study was a systematic review, 
which assessed 325 worldwide articles, it could 
be considered as a serious warning for us. Since it 
demonstrates the rate of renal scar in the present 
society is catastrophic in comparison with the 
other places. They also concluded that children 
with reflux are more likely to affect to renal defects 
other than the other group (RR = 2.6 [95% CI: 1.7 
to 3.9]).15 This finding is in consistence with ours.
According to the present study, the rate of kidney 
defects was 83.3% and 34.6%, respectively in high 
and low grades of reflux. According to Nelson, the 
prevalence of renal scars in patients with low-grade 
reflux is 15%, and in patients with high-grade reflux 
is 65%.1 However, according to the present and 
previous studies, the higher the severity of VUR, 
the greater the risk of renal scarring, but the rate 
of our study is more than the others.
Wide variations of renal scars also reported as 
15 to 60% in different studies. Some reasons for 
controversial findings in the mentioned above 
researches can be confounding factors such as 
different sample sizes, race, geographical regions, 
genetic context, age, gender, the presence or absence 
of reflux, and any human mistake in accurate 
diagnosis.3
Some limitations of the present study included: 
hard achievement to data due to lack of electronic 
records, and incomplete records of patients’ 
information. These conditions may increase the 
likelihood of human errors. So, we recommend 
similar studies in different communities for a 
more precise assessment with an experimental, 
etc. methods, esp. with larger and a multi-center 
sample size, and assessing more confounding 
factors influencing on the patients’ prognosis. 
As we know that the prevalence of renal scar in 
patients with vesicoureteral reflux clearly increased, 
it is suggested to conduct studies to evaluate 
appropriate screening tests for UTI in the exposed 
children, too.
CONCLUSION
According to the findings, the rate of renal 
defects in our society is high in comparison with 





n % n % n %
Mild 18 34.6 34 65.4 52 100
< .001Moderate and Sever 15 83.3 3 16.7 18 100
Total 33 47.1 37 52.9 70 100
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with UTI, even those without VUR, are at risk of 
renal scar. As we mentioned before, renal scars 
can lead to irreversible renal injuries. So, we must 
prevent urinary infections in children esp. infants 
under one-year-old. Also, we suggest to apply 
screening methods for early detection of UTI in 
infants to prevent such these complications.
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Proteinuria in Two Sisters with Beaulieu-Boycott-Innes 
Syndrome, A Case Report
Masoud Hassanvand Amouzadeh,1 Mohsen Akhavan Sepahi,2,3 
Ezatollah Abasi4
We report two sisters (13- and 4-year-old) presenting with moderate 
intellectual disability, dysmorphic facial features, intermittent 
hematuria, proteinuria, and dental caries. Their parents and other 
family members were not affected. Whole-exome sequencing was 
performed to screen the underlying genetic cause. These patients 
have been analyzed using Next-Generation Sequencing (NGS) 
method and homozygote variant (c.890delC) has been detected in 
the THOC6 gene. Direct Sanger sequencing confirmed that they are 
homozygote for the pathogenic variant mutations in the THOC6 
gene, which is associated with Beaulieu-Boycott-Innes syndrome 
(BBIS). These patients also had proteinuria and subsequently 
developed hematuria. This is the first report of BBIS in association 
with proteinuria and hematuria without renal defects. Core clinical 
features include low birth weight with subsequent growth failure, 
short stature, and intellectual disability with language delay, 
characteristic faces, cardiac defects, and renal anomalies. The possible 
pathophysiological mechanisms associated with proteinuria and 
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INTRODUCTION
Beaulieu-Boycott-Innes syndrome (BBIS) is an 
autosomal recessive neurodevelopmental disorder 
characterized by delayed development, moderate 
to severe intellectual disability, and dysmorphic 
facial features.1 
Core clinical features include low birth weight 
with subsequent growth failure, short stature, mild 
microcephaly, intellectual disability with language 
delay, characteristic facies and cardiac and renal 
defects. Cryptorchidism in males, submucous 
cleft palate, and corpus callosum dysgenesis, may 
also be present.2 All patients show characteristic 
dysmorphic facial features including a tall forehead 
with high anterior hairline, short and upslanting 
palpebral fissures, deep-set eyes, flat philtrum, and 
dental malocclusion with caries.3-7 The prognosis of 
this syndrome is unknown.5 Anatomic anomalies 
include malformations of the genitourinary system 
(absent and duplicated kidneys), and cardiac defects 
such as ventricular septal defects and persistent 
ductus arteriosus.5 These patients are the first report 
of BBIS in association with transient proteinuria 
and hematuria. 
CASE REPORT
Here, we describe two sisters (13- and 4-year-old) 
with BBIS presented with delayed development, 
severe intellectual disability, and dysmorphic facial 
features (Figure 1 and 2).
No neonatal problems have been described except 
for low birth weight and small head circumference, 
and subsequent growth was slow. Language and 
learning was delayed. On presentation to the 
pediatric nephrology clinic, they weighed 27 kg 
(25th to 50th percentile) and 14 kg (< 25th percentile), 
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respectively. Patients were given a blood sample; 
urine collection cup, a urine container, and the 
parents grasp a written instruction for random 
and 24-hour urine sample collection. They also 
had mild proteinuria and hematuria and venous 
blood gases including PH and bicarbonate levels 
were normal. Figure 3 shows familial pedigree.
Case 1 (Older Sister)
Hemoglobin was 12.7 g/dL, total leucocyte count 
was 6.5 × 109/L (70% neutrophils, 29% lymphocytes, 
and 1% eosinophil) and platelet count was 198 
× 109/L. Blood urea nitrogen was 18.5 mg/L, 
serum creatinine was 19.2 mg/L, serum sodium 
and potassium were 137 mg/dL and 4.5 mg/dL; 
respectively. Our patient had normal levels of lipid 
profile and serum albumin was normal (3.5 g/dL). 
Venous blood gases including PH and bicarbonate 
levels were in normal range. 
She also had normal vital signs but further 
investigation of urine sediment demonstrated mild 
proteinuria and hematuria. Laboratory urine tests 
include the following: urine analysis (PH: 5, WBC: 
1-2, RBC: 8-10, SG: 1.005), urine culture: negative, 
24-hour urine test (protein: 295 mg/dL, Cr: 450 
mg/dL), random urine (Cr: 36 mg/dL, Na: 75 
mg/dL, K: 25 mg/dL).
Case 2 (Younger Sister)
Hemoglobin was 11.5 g/dL, total leucocyte 
count was 5.5 × 109/L (60% neutrophils, 36% 
lymphocytes, and 1% eosinophil) and platelet count 
was 198 × 109, blood urea nitrogen was 19.8 mg/L, 
serum creatinine was 0.52 mg/L, serum sodium 
and potassium were 135 mg/dL and 3.5 mg/dL; 
respectively. Venous blood gases including PH 
and bicarbonate levels were in normal range. Our 
patient had normal levels of lipid profile and her 
serum albumin was normal (3.5 g/dL). She also 
had normal vital signs but further investigation of 
urine sediment demonstrated mild proteinuria and 
transient hematuria. Laboratory urine tests include 
Figure 1. This photo is related to older sister
Figure 2. This photo is belonging to younger sister.
Figure 3. It shows familial pedigree.
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the following: urine analysis (PH: 6, WBC: 1-2, RBC: 
14-16, SG: 1.025), urine culture: negative, 24-hour 
urine test (protein: 195 mg/dL, Cr: 350 mg/dL), 
random urine (Na: 75 mg/dL, K: 25 mg/dL, Cr: 
56.5 mg/dL). The ultrasonographic evaluation of 
kidneys and urinary system was normal. There 
were no signs of fever, edema, lymphadenopathy 
or organomegaly. Results of cardiovascular, 
respiratory and other physical examinations were 
normal. There was no family history of BBIS or 
other syndromic disorders.
DISCUSSION
To date, some patients with BBIS and renal defect 
have been reported. These cases are unusual for 
two reasons. The development of urine sediment 
proteinuria and transient hematuria without renal 
defects is rare in BBIS and there are no similar 
reports in the literature.
Secondly, the patients developed intermittent 
dysuria during the course of this illness; the clinical 
feature was a discomfort in urination for more 
than 5 days. The dysuria rapidly resolved after 
administration of acetaminophen. This convincing 
response to therapy has been considered to represent 
a major diagnostic test for UTI but urine culture 
was negative. These patients have proteinuria 
and subsequently developed hematuria. Although 
all children with proteinuria need laboratory 
examination; treatment is not required in most 
cases.8,9
This is the first report of Beaulieu-Boycott-Innes 
syndrome (BBIS) in association with proteinuria 
and hematuria without renal defects. The possible 
pathophysiological mechanisms are not defined 
but more research is needed to find the reason. 
Regarding to BBIS in association with proteinuria 
and transient hematuria, our study requires kidney 
biopsy and no result was similar to those in other 
parts of the world. We recommended more studies 
on this syndrome especially larger and multi-center 
investigation. 
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Peritoneal Dialysis in Extremely Obese Patient From 
Palestine, A Case Report 
Zakaria Hamdan,1,5 Mahdi Tarabeih,2 Kamel Jebrin,1,5 
Emad Khazneh,1,5 Eman Abusalameh,3 Hanan Nuairat,4 
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Introduction. The incidence of ESRD is increasing dramatically 
and the majority of patients are commenced to hemodialysis 
(HD) or peritoneal dialysis (PD) due to the long waiting time for 
renal transplantation. PD has comparable outcomes with HD but 
many barriers limit its utilization. Obesity is considered among 
the barriers and this was attributed to its related complications.
Case Report. A 50-year-old male patient with ESRD presented to 
our hospital for PD. He was extremely obese (BMI = 44.2 kg/m2). 
The case was discussed between the nephrology, surgical and 
nursing team, and the decision was made to proceed towards PD. 
Conclusion. Obesity should not impede the beneficial effects of PD. 
The obstacles of obesity, which we faced; could be overcome with 
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ABBREVIATIONS
ESRD, end-Stage Renal Disease; CDC, the centers 
for disease control and prevention; PD, peritoneal 
dialysis; HD, hemodialysis; BMI, body mass index; 
PO, per OS; IP, intra-peritoneally; US, united states.
INTRODUCTION
The incidence of end-Stage renal disease (ESRD) 
has increased dramatically, in 1996; the incidence 
in the US was 77,003 (compared with 124,675 in 
2016).1 Hemodialysis (HD) and peritoneal dialysis 
(PD) vary significantly in terms of patient lifestyle, 
employment, and interaction with the healthcare 
system.2 The principles of peritoneal dialysis were 
first described by Popovich and his colleagues in 
1976.4,5 Patients on PD have comparable clinical 
outcomes, and even better; than patients on HD and 
their survival rate is equivalent to the center-based 
HD.4,6,7 However, many barriers limit the utilization 
of PD and Obesity is considered among them.8,9 
One study published in 2003 showed that the most 
nephrologists in the US do not recommend PD 
for ESRD Patients weighing 200 pounds or more.2
This case report presents a patient with ESRD 
with a BMI of 44.2 kg/m2 who underwent successful 
treatment with PD, by collaboration between a 
multidisciplinary team.
CASE REPORT
A 50-year-old man presented to our hospital for 
renal replacement therapy via peritoneal dialysis. 
His past medical history includes type 2 DM and 
HTN. The patient was tolerating moderate exercise 
until 4 months before admission, when he started 
experiencing progressively increasing lower limb 
swelling, nausea, exercise-induced dyspnea as 
well as orthopnea.
Laboratory results at admission: hemoglobin = 8 
g/dL, K = 3.7 mEq/L, PH = 7.10, PCO2 = 26.2 mmHg, 
PO2 = 85 mmHg, HCO3- = 11.3 mEq/L, albumin = 2.9 
g/dL, BUN = 85.8 g/dL, and Cr = 12.4 mg/dL. 
The case was discussed between the nephrologists, 
surgeons, and nurse staff; and the decision was 
made to proceed towards doing PD as a life-saving 
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procedure given that the patient refused HD 
initially. Under local anesthesia, Tenckhoff-swan 
neck curl peritoneal catheter, 62.5 cm in length, 
double cuff was inserted smoothly. Two days 
following the PD catheter insertion, the uremic 
symptoms worsened dramatically and the patient 
became more distressed so the decision was to 
do an urgent session of hemodialysis. After four 
sessions of hemodialysis, patient improved and 
was kept in the peritoneal ward for the whole day 
for educational purposes. 
The patient experienced two episodes of 
peritoneal leak and the PD was discontinued 
for 14 days. After 14 days, the leak stopped and 
the exchanges went smoothly when the patient 
suddenly started complaining of abdominal pain 
and a cloudy fluid coming out with exchanges. A 
diagnosis of peritonitis was established and the 
patient was treated with IP antibiotics for 14 days.
His dry weight was set to 119 kg after 3 months 
with 4 exchanges/d (two with 2.27% dextrose 
and two with 4.5% dextrose). Dwell time was 
considered 4 hours. 
DISCUSSION
Peritoneal dialysis is one of two major modalities 
to treat ESRD patients waiting or not amenable for 
transplantation.2 Despite the wide variety of PD 
use over the world (72% in Hong Kong, 9.7% in 
the US, and 4% in Sudan)4. Contraindications for 
PD include: obesity, severe protein malnutrition, 
polycystic kidney disease, lack of the integrity of the 
abdominal wall, and massive adhesions.8,11 Obesity 
is our main concern. It is thought that obesity and 
increased BMI are associated with increased risk 
of catheter leak, inadequate clearance, infectious 
processes, and peritonitis.11 Many studies have 
reported the paradoxical relationship between 
obesity and mortality among dialysis patients, a 
term referred to as “Obesity Paradox” or “reverse 
epidemiology”.12 According to the CDC, BMI of 
more than 40 Kg/m2 is defined as extreme or 
severe obesity.14
The arguments about the possibility to proceed 
towards PD among obese patients are diverse 
as some studies assumed obesity as a relative 
contraindication to PD,11,16 a barrier to PD8 or not 
a contraindication.15 We have faced most of the 
complications related to obesity but we were able 
to deal with them. 
CONCLUSION
Peritoneal dialysis is a highly valuable modality 
of treatment for end-stage renal disease patients. 
Being overweight should not impede the beneficial 
effects of PD for patients who are willing to do so, 
as it confers them the ability to be engaged deeper 
in the community. The previous recommendations 
that considered obesity as a contraindication for 
PD are attributed to technical problems related to 
catheter insertion and possible future complications 
that can be handled if the patient was transferred 
to a highly qualified center. 
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Late Acute Cellular Rejection After Anakinra Treatment in a 
Kidney Transplant Patient, Is It a Coincidence?
Hasan Haci Yeter,1 Nisa Yetkin,2 Omer Faruk Akcay,1 Ulver Derici,1 
Turgay Arinsoy1
Familial mediterranean fever (FMF) is an autosomal recessive 
auto-inflammatory disorder, which could lead to secondary (AA) 
amyloidosis. Anakinra is an IL-1 receptor blocker and a treatment 
option for patients with FMF. There is no reported rejection episode 
associated with the use of Anakinra in the literature. A forty-
nine years old woman with a history of kidney transplantation 
is described here. Anakinra was initiated in the patients whose 
FMF attacks were exacerbated, and the inflammation could not be 
controlled under the colchicine treatment. After eight months of 
follow up under Anakinra treatment, a moderate but persistent 
increase in serum creatinine level was observed. Allograft biopsy 
was compatible with acute T cell-mediated rejection with BANFF 
type 2A. Data on the use of Anakinra in KTRs is limited. Anti-
drug-antibodies or hapten induced T cell activation may facilitate 
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INTRODUCTION
Familial mediterranean fever (FMF) is an 
autosomal recessive auto-inflammatory disorder 
which is characterized by lifelong recurrent self-
limiting attacks of fever and systemic inflammation.1 
Progressive secondary (AA) amyloidosis is the 
primary cause of mortality and morbidity in patients 
with FMF. Renal amyloidosis leads to proteinuria, 
and end-stage kidney disease develops 2 to 13 
years after the onset of proteinuria.2 Anakinra 
(Kineret;r-metHuIL-1ra) is a recombinant human 
interleukin-1(IL-1) receptor antagonist that inhibits 
the activity of both IL-1  and IL-1  and seems to 
be safe and effective alternative treatment option 
for patients with FMF who do not respond to 
colchicine.1,3 
Here, we report acute T cell-mediated rejection 
(ACR) episode that occurs after Anakinra use in a 
49-year-old woman with kidney transplantation.
CASE REPORT
We present a 49-year-old woman who was 
diagnosed with AA type amyloidosis secondary to 
FMF at the age of twenty. Ten years after diagnosis, 
she started peritoneal dialysis as maintenance 
renal replacement therapy, and two years after 
the first transplantation was done from a living 
related donor. The patient lost his allograft due 
to hyper acute rejection. Then, she continued with 
peritoneal dialysis for seven years until the second 
kidney transplantation was done from a deceased 
donor. The patient and donor were one haplotype 
matched and class 1 and class 2 panel reactive 
antibodies were negative. Her allograft function was 
stable ten years after transplantation, and serum 
creatinine levels were between 0.6 to 0.8 mg/dL 
(Table). Anakinra treatment was started due to the 
resistant disease to colchicine. After eight months 
follow up there was no more attack of FMF, but a 
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moderate and persistent increase in serum creatinine 
level was observed (Figure). As the patient’s 
creatinine level elevated simultaneously with the 
onset of Anakinra, treatment was discontinued, 
and other possible causes of allograft dysfunction 
were examined. Allograft biopsy was performed 
because renal doppler ultrasonography was within 
normal ranges and urine BK PCR, and CMV PCR 
were negative. Allograft biopsy was reported 
as acute T cell-mediated rejection compatible 
with BANFF type 2A. Methylprednisolone was 
started 500 mg/d for six days. Despite high dose 
glucocorticoid therapy, the creatinine level of the 
patient did not decrease; therefore anti-thymocyte 
Variables Before Anakinra After Anakinra (8th Month) 
After Rejection 
Treatment
Hb, g/dL 14.9 12.6 12.3
WBC, 103 u/L 11.16 14.16 10.8
PLT, 109 u/L 364 422 378
BUN, mg/dL 14 38 27
Creatinine, mg/dL 0.64 1.36 1.04
eGFR, mL/m/ 1.73m2 104.8 45.6 63
Sodium, mmol/L 139 139 138
Potassium, mmol/L 4.13 4.41 4.36
CRP, mg/L 23 7.8 1.18
24-h Urine Protein, mg/d 135 134
Tacrolimus Level, ng/mL 5.6 5.7 7.5
BKV PCR - Negative Negative





Hb, Hemoglobin; WBC, white blood cell; PLT, platelet; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; CRP, C-reactive 
protein.


























Time of Anakinra onset
Diagnosis of rejection
It shows serum Cr monitoring of the patient over time.
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globulin (ATG) was initiated 2 mg/kg per dose 
for total dose of 10 mg/kg. After ATG treatment 
serum creatinine level decreased and stabilized 
to 1.04 mg/dL. Prednisolone dose was reduced 
to 5 mg gradually and the patient continued to 
use mycophenolate mofetil and tacrolimus as 
maintenance immunosuppressive therapy. The 
patient is still in follow up, and she is using 
colchicine for FMF. She experienced no FMF attack 
until now.
DISCUSSION
IL-1 blockade is an effective treatment option in 
patients with colchicine resistant FMF. To the best 
of our knowledge, there is no reported rejection 
episode associated with the use of Anakinra in the 
literature. Although, it is challenging to relate ACR 
episode directly to Anakinra use; the deterioration 
of allograft function, which has been stable for ten 
years until Anakinra usage and relatively late period 
for ACR development, makes the case interesting.
Two possible mechanisms could cause this 
association. One of these is that antibodies that 
develop against biological agents named as “anti-
drug antibody” (ADA) may have triggered ACR. 
These antibodies are well defined and responsible 
for the non-response to biological agents and 
hypersensitivity reactions.4 ADA development was 
defined against Infliximab, Etanercept, Canakinumab, 
Tocilizumab, and Anakinra in the literature.5 ADA 
against biological drugs is strongly associated with 
T cell-dependent reaction lymphoid tissue, which 
requires CD40 and CD154 interaction. Therefore, 
antibodies against IL-1 receptor may facilitate the 
development of ACR by causing activation of T cells. 
The other possible mechanism is the hapten 
induced rejection process. Haptens are small non-
protein chemical groups, which could not cause 
antibody stimulation alone but gain antigenic 
structure when coupled to a carrier protein.6 
After binding to the carrier protein, they become 
immunogenic and can cross-link B cell receptors 
and activate T cells.6 Also, there are immunogenetic 
factors defined that could facilitate hapten 
reactions such as HLA-B57, -B15, -B58, -DR4, and 
-DR2 alleles.7,8 It has been shown that the risk of 
drug-related lupus development increases in the 
presence of these alleles.7 Our patient may also be 
susceptible to hapten related reactions because of 
the presence of the HLA DR4 allele.
CONCLUSION
In conclusion, the possible role of Anakinra 
should be considered in cases of acute rejection of 
renal transplantation during the late period. Data 
about the possible side effects of biological agents 
in literature is growing. We informed a situation 
where we observed a possible relationship with 
the use of a biological agent in this report.
ACKNOWLEDGEMENT
Authors declare that they have no conflict of 
interest. This project received no funding support.
REFERENCES
1. Meinzer U, Quartier P, Alexandra J-F, Hentgen V, 
Retornaz F, Koné-Paut I. Interleukin-1 targeting drugs in 
familial Mediterranean fever: a case series and a review of 
the literature. Semin Arthritis Rheum. 2011; 41:265-71.
2. Sohar E, Gafni J, Pras M, Heller H. Familial 
Mediterranean fever: a survey of 470 cases and review of 
the literature. Am J Med. 1967; 43:227-53.
3. van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys 
BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in 
familial Mediterranean fever: a systematic review of the 
literature. Biologics. 2016; 10:75-80.
4. Doeleman MJ, van Maarseveen EM, Swart JF. 
Immunogenicity of biologic agents in juvenile idiopathic 
arthritis: a systematic review and meta-analysis. 
Rheumatology. 2019; 58(10):1839–1849.
5. Wikén M, Hallén B, Kullenberg T, Koskinen LO. 
Development and effect of antibodies to anakinra during 
treatment of severe CAPS: sub-analysis of a long-
term safety and efficacy study. Clin Rheumatol. 2018; 
37:3381-6.
6. Gefen T, Vaya J, Khatib S, et al. The effect of haptens 
on protein-carrier immunogenicity. Immunology. 2015; 
144:116-26.
7. Dunphy J, Oliver M, Rands A, Lovell C, McHugh N. 
Antineutrophil cytoplasmic antibodies and HLA class II 
alleles in minocycline-induced lupus-like syndrome. Br J 
Dermatol. 2000; 142:461-7.
8. Yun J, Adam J, Yerly D, Pichler WJ. Human leukocyte 
antigens (HLA) associated drug hypersensitivity: 
consequences of drug binding to HLA. Allergy. 2012; 
67:1338-46.
Correspondence to: 
Nephrology Department, Gazi University, Ankara, Turkey











Surveillance and Isolation Based Strategies to Prevent 




The possibility of rapid spread of SARS-Cov-2 
infection (COVID-19) via hemodialysis facilities 
should not be ignored. Unavoidable clustering of 
hemodialysis patients and close contact with nursing 
staff would increase the risk of viral transmission. 
In addition, these patients are more likely to be 
old and fragile and have multiple comorbidities. 
Therefore, patients on maintenance hemodialysis 
are more susceptible to COVID-19 and the infection 
might be more severe and complicated.1
Imam Khomeini Hospital Complex (IKHC) 
is a governmental hospital affiliated to Tehran 
University of Medical Sciences. Soon after epidemic 
of COVID-19, IKHC was selected as one of the 
General Recommendations for 
Patients
Abstain from unnecessary personal contacts or public events
Stay at home while off dialysis
Transport by individual vehicle to and from dialysis center
For patients with acceptable residual renal function, two rather than three times per week 
hemodialysis temporarily
At least 6 feet distance between the patients in the dialysis hall
Prohibiting the presence of accompanying personnel in the dialysis ward 
Lockdown Principles
Body temperature measurement before entrance to waiting room
Asking about respiratory symptoms upon arrival 
Screening
Providing alcohol dispenser and surgical masks at the waiting room
Instructing the patients about:
appropriate hand hygiene
use of face mask
disposal of contaminated tissues and materials.
Discourage eating and drinking at the ward
Hygienic Measures
Early referral of suspicious and known cases to the wards allocated for COVID-19 patients 
(Corona Wards)
Complete isolation of Corona Wards from general wards of hospital and the dialysis center
Prohibiting the entrance of suspicious or known cases of COVID-19 to dialysis ward
In cases of acute or chronic kidney diseases who requires renal replacement therapy, 
performing hemodialysis bedside the patient in the Corona Ward
Assigning another dialysis center for hemodialysis patients who discharged from Corona Ward
Suspicious Cases of COVID-19
Providing online educational materials and pamphlets about:
governmental guidelines regarding COVID-19
hand hygiene
appropriate personal protection
Requesting the staff members to inform the head of ward immediately, if they developed 
suggestive symptoms of COVID-19
Standard protection protocol for:
healthcare workers of the dialysis center:
surgical facemask
non-sterile rubber glove
water-repellent gown with long sleeves




Wearing new gloves for each patient
Healthcare Workers
IKHC Guideline for COVID-19 Prevention in Patients and Healthcare Workers of Dialysis Center
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three referral hospitals in Tehran for COVID-19 
admission. Thus, IKHC played a dual role during 
epidemic of COVID-19; it should manage referral 
cases of COVID-19 while providing routine medical 
services for other patients.
Maintaining the activity of dialysis center of 
IKHC during the outbreak of COVID-19 necessitates 
adopting appropriate preventive strategies to 
protect medical staff and patients.2 Previous 
experiences from MERS-CoV revealed that strict 
patient surveillance and proper isolation practice 
would prevent secondary viral transmission.3
To provide a comprehensive guideline for 
COVID-19 prevention in dialysis center of IKHC, 
we reviewed interim additional guidance released 
by Center for Disease Control and Prevention 
and other guidelines and recommendations.4,5 
Considering our limitations and resources, we 
customized an appropriate guideline for COVID-19 
prevention in healthcare workers and dialysis 
patients. Our recommendations were oriented in 
three main categories: general recommendations 
for hemodialysis  patients,  instructions for 
suspicious and known cases of COVID-19 and 
recommendations to protect healthcare workers. 
Table 1 represents our guideline briefly.
In conclusion, preventive managements would 
play a key role in breaking the chain of viral 
transmission and containment of COVID-19 
pandemic in hemodialysis centers. Our strategy 
for COVID-19 prevention in the dialysis center 
of IKHC was mainly based on surveillance and 
isolation of otherwise healthy hemodialysis patients 
from suspicious cases of COVID-19. By adopting 
such strategies, we encountered very few cases of 
COVID-19 in healthcare workers and hemodialysis 
patients of our center. So, it seems that strategies 
based on surveillance and isolation would be very 
effective in prevention of COVID-19, as it was 
shown in similar setting of MERS-CoV outbreak 
previously.3
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Comment: Newly Diagnosed Glomerulonephritis During 
COVID-19 Infection Undergoing Immunosuppression 
Therapy, a Case Report
IJKD 2020;14:323-5
www.ijkd.org
We read with great interest the case report 
article by Moeinzadeh  et al,  entitled “newly 
diagnosed glomerulonephritis during COVID-19 
infection undergoing immunosuppression therapy” 
published in a recent issue of IJKD.1 The authors 
presented a case of a 25-year-old male with no 
known co-morbidities who presented with weakness 
and arthralgia to coronavirus clinic. Initial work up 
revealed severe anemia (hemoglobin [Hb] of 5.2 g/
dL) and renal impairment (serum creatinine [SCr] 
of 3.7 mg/dL). He was admitted to the hospital, 
where further investigations showed worsening of 
renal function (SCr 4.2 mg/dL) with active urinary 
sediment and a further decline in Hb concentration 
(4.5 g/dL). High-resolution computed tomography 
(HRCT) of the chest demonstrated ground glass 
opacities (GGO) with a differential of diffuse 
alveolar hemorrhage and possible coronavirus 
infection. Patient received three days pulse of steroid 
[1 gram of Methylprednisolone/day] with presumed 
diagnosis of rapidly progressive Glomerulonephritis 
(RPGN). Serology and secondary work up were 
sent out and renal biopsy was obtained. The 
patient subsequently underwent plasmapheresis 
and three doses of intravenous immunoglobulin 
(IVIG), 20 g each time for alveolar hemorrhage. 
Renal biopsy was later reported as diffuse crescentic 
GN. Meanwhile, his coronavirus test was found to 
be positive and hydroxychloroquine in addition 
of levofloxacin was initiated. 
The above case adds yet another dimension to the 
expanding spectrum of renal pathological lesions 
seen in patients of COVID-19 disease, particularly 
one based on renal histopathology. We would like 
to take this opportunity to highlight some points 
pertaining to kidney involvement in COVID-19, in 
general, and in this particular case. Clarification 
of the following items by the authors will further 
improve the understanding of the kidney pathology 
in this disease.
1- The data of kidney involvement in COVID-19 
infection has started to accumulate but the 
results are conflicting.2 Renal involvement in 
COVID-19 is common and has been shown to 
correlate with in-hospital deaths.3 However, 
biopsy based studies are scarce.4 Most reports 
suggest tubulointerstitial involvement in this 
disease, but more recently, a number of case 
reports have reported glomerular involvement, 
particularly, collapsing glomerulopathy (CG), 
especially in persons of African ancestry.5-7 
This suggests a possible role of APOL1 high 
risk alleles in predisposing these patients to 
the development of CG in COVID-19 infection, 
and the viral illness serving as second-hit in its 
pathogenesis.8-10
2- The case presented by Moeinzadeh et al was 
diagnosed and treated in the lines of primary 
GN coexisting with COVID-19 infection. The 
patient was treated for both conditions and 
there is also some overlap in the treatment of 
COVID-19 disease and primary GN. The major 
cause of morbidity in this case, according to 
authors, seems to be autoantibody-mediated 
vasculitis, manifesting as pulmonary renal 
syndrome. However, lack of any respiratory 
symptoms with this degree of involvement in 
vasculitis is unusual. Regarding renal biopsy 
findings, it is important to note that renal 
biopsy was obtained on completion of induction 
treatment of RPGN and no detailed pathology 
description was given. The authors only provided 
representative images of one or two abnormal 
glomeruli. All the three images show segmental 
obliteration of capillary lumina with segmental 
collapse of capillary loops and associated florid 
extracapillary proliferation of cells, which appear 
to be visceral epithelial cells (podocytes). These 
cells either surround the segmentally sclerosed 
Letter
324 Iranian Journal of Kidney Diseases | Volume 14 | Number 4 | July 2020
tuft (with a cleft-like space between the parietal 
epithelial cell layer) or fill the urinary space 
resembling a cellular crescent (pseudo-crescent). 
There is focal vacuolization and a few hyaline 
droplets in the cytoplasm of some of these 
proliferating cells. No evidence of glomerular 
necrosis, such as influx of leukocytes, necrotic 
cell debris or accumulation of fibrin is visible. 
No immunofluorescence or electron microscopy 
findings are given. A right approach would 
have been to consider both pseudo-crescents 
and true crescents in the differential diagnosis. 
All the features noted above, in our view, favor 
pseudo-crescents and hence CG should have been 
considered in the differential. It is well known that 
sometimes it is difficult to differentiate among 
these two forms of extracapillary proliferative GN 
and this case represents one of those examples. 
We take the liberty to illustrate this point in 
Figure 1, where preliminary view shows striking 
homology between the two conditions; however, 
more critical review shows tangible differences 
between these. The authors could utilize some 
immunohistochemical markers or electron 
microscopic study to differentiate between the 
two. Additionally, other known causes of CG, 
such as HIV status, parvovirus B19 infection, 
and others should be considered and clinically 
ruled out. If it turns out to be CG, this will be a 
significant finding as almost all previous cases 
of CG in association with COVID-19 infection 
have been reported in African Americans.
3- The results of the primary and many subsequent 
investigations were not correctly presented. 
His hemoglobin (Hb) is stated to be 5.2 g/L at 
presentation, which should be in g/dL. Similarly, 
SCr is given as 3.7 g/dL, which should be 3.7 
mg/dL. C-reactive protein (CRP) is given as 
2+, which is not a correct presentation of this 
result. Titer of c-ANCA given as 1/50 (positive) 
is incomprehensible. What method of ANCA 
testing was used? 
4- The authors state that they discharged the 
patient with stable creatinine value of 5.5 mg/dl. 
With just one value of SCr, how can they claim 
that the function was stable, when all previous 
readings showed a continued rise? 
5- The authors also did not establish definitive 
recovery from COVID-19 in this case according 
to Iran Ministry of Health and Medical Education 
COVID-19 guidelines. The reason put forward 
was the critical condition of the patient. This is 
It shows morphological features of true crescent and pseudo-crescent. A) Medium-power view of a glomerulus showing collapse of two 
tufts with overlying podocyte hyperplasia and hypertrophy forming focal pseudocrescents over the involved tufts (arrows). Note: There 
are numerous protein resorption droplets in the cytoplasm of podocytes. These also show cytoplasmic vacuolization (asterisk). There is 
no fibrin or capillary wall rupture. Moreover, an irregular cleft-like space (arrowhead) separates this mass of proliferating podocytes from 
parietal epithelial layer (Jones silver stain, ×200). B) A glomerulus with focal true crescent formation (arrow). Note the rupture of capillary 
walls of the tuft at 5 O’clock position with exudation of fibrin into the Bowman’s space and nuclear debris (asterisk). Note that the 
proliferating cells in the extracapillary space are originating from the parietal epithelium, which is showing a mitotic figure (arrowhead). 
There is no space between true crescent and parietal epithelium in this case. (Jones silver stain, ×200).
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contradictory with their subsequent statement, 
in which, they claim that the patient was 
discharged healthy.
In summary, the authors need commendation 
on presenting the above case for increasing the 
awareness of nephrology and pathology community 
regarding expanding spectrum of pathological 
lesions in COVID-19 disease. We think this critique 
will further improve the understanding of many 
aspects of this interesting case.
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Response to Comment on; Newly Diagnosed 
Glomerulonephritis During COVID-19 Infection Undergoing 




I have read the article entitled “Comment 
on;  Newly Diagnosed Glomerulonephri t is 
D u r i n g  C O V I D - 1 9  I n f e c t i o n  U n d e r g o i n g 
Immunosuppression Therapy, a Case Report.” By 
Mubarak et al., I want to congratulate the authors 
for this successful editorial letter, and make some 
contributions.
In this comment Mubarak et al. have been noted 
some point that we clarify them in the following:
1- Mubarak et al. mentioned that our case did 
not have any respiratory symptoms related to 
glomerulonephritis (GN), but it is notable that 
our case had diffuse alveolar hemorrhage in 
his computed tomography report and it could 
related to systemic vasculitis.1 
2- It is a reality that differentiation between these 
two entities (crescent & pseudocrescent) can be 
very hard and challenging, but not in our case 
which reveals clear crescentic features of gloms 
in figures. 
 The term crescent is used for a lesion consisting 
of extracapillary hypercellularity, composed of 
a variable mixture of cells. Fibrin and fibrous 
matrix may be present; 10% or more of the 
circumference of Bowman’s capsule should be 
involved.2 In our case parietal epithelial cells 
show proliferation and make cellular crescent, 
although in some glom’s podocyte hyperplasia 
is seen also and it’s not in conflict with the 
diagnosis of crescentic GN.
 True crescents and pseudocrescents even may 
coexist in the same glomerulus.3
 The presence of fibrinoid necrosis, karyorrhexis, 
glomerular basement membrane rupture and red 
blood cell casts to be helpful indicators of crescent 
formation while the absence of these findings 
with the presence of protein resorption droplets 
admixed with the hypertrophied and hyperplastic 
podocytes, significant tubular intracytoplasmic 
protein resorption drops, microcystic tubular 
dilatation, thyroid type tubular atrophy and a 
predominance of solidified or disappearing-type 
global glomerulosclerosis suggests collapsing 
glomerulopathy.4
 In contrast with your comment, there were no 
protein resorption droplets in our pictures and 
also cellular vacuolation was not specific for 
pseudocrescent formation.
 The glomeruli in the case also show capsular 
rapture (Figure 1A), fibrinoid necrosis (Figure 1B), 
and karyorrhexis (Figure 1C); which define the 
diagnosis of crescentic GN.
 Collapsing lesions are more commonly global 
than segmental and are often accompanied by 
severe tubulointerstitial injury with microcysts 
and hypertrophic tubular epithelial cells swollen.5 
 Many various IHC markers like CD68, CK, 
Nestin, CD44, WT1, and ki67 can be helpful 
in challenging case for differentiation between 
crescent and pseudo crescent,3,4,6 but in this 
case the diagnosis was clear by morphology 
and IHC study just achieved for responding 
your comment and as expected, confirmed our 
diagnosis.
 In collapsing glomerulopathy, hyperplastic 
podocytes showed complete loss of normal 
podocyte phenotype utilizing known markers 
of podocytes (CALLA, GLEPP1, Podocalyxin, 
Synaptopodin,  WT1,  P27,  and p57)  were 
decreased while Cyclin D1, Cyclin E, Cyclin 
A, Ki-67, Desmin, Cytokeratin, and CD68 were 
increased.4,7
 We use the markers of cytokeratin, CD68, and 
Ki67 (Figure 2) and no accentuated staining 
compatible for hyperplastic podocytes was seen.
 Usually in true crescents, no cell expresses 
cytokeratin and numerous CD68-positive 
hyperplastic dysregulated podocytes in a 
glomerulus showing a pattern of collapsing GN.3 
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Figure 1. It shows true crescents with a) capsular rupture (Jones 
staining × 400); b) fibrinoid necrosis (Jones staining × 400); and 




Figure 2. It demonstrates true crescents; IHC staining, 
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It should be mentioned that contrary to previous 
reports, podocytes are indeed involved in human 
crescentic GN too and therefore interpretation 
of IHC study for differentiating crescent from 
pseudocrescent should be done by cautious.3
 Unfortunately, we don’t have access to electron 
microscopy at our center. Immunofluorescence 
study was negative in the case, but didn’t prepare 
photos and as you know IF staining is not stable 
for long time and now, we can’t send you the 
IF photos.
3- It was noted that renal biopsy was given 
on completion of  induction treatment of 
rapidly  progress ive  g lomerulonephri t i s 
(RPGN), but in our case; renal biopsy was 
given before intravenous immunoglobulin or 
cyclophosphamide administration. 
4- It was correctly mentioned that hemoglobin 
should have been reported in g/dL. It was a 
mistake. It also noted that C-reactive protein 
(CRP) is given in qualitative form, which is not 
a correct presentation of this result. We should 
mention that In this case CRP is reported as 
qualitative result in that situation.
5- We tested antineutrophil cytoplasmic antibodies 
(ANCA) with ELISA and the titration was 50.
6- It is notable that the creatinine level of our 
case was stable around 5.5 mg/dL during 
hospitalization. There was no significant change 
in creatinine to report in our article.
7- In this case, the importance of receiving a 
strong immunosuppressive drug despite 
COVID-19 was considered. Despite receiving 
immunosuppressive agents, the patient did not 
progress respiratory failure caused by COVID-19. 
Therefore, this condition considered as health 
during COVID-19 infection. His renal disease 
condition will be determined over time.
In the last several weeks, there have been 
numerous concerns not just from patients but also 
from other nephrologists on the most effective 
way to treat immunosuppression in today’s 
environment.  Will  patients with GN could 
their doses of immunosuppression or avoid the 
treatment altogether?8 When evaluating the effect 
of immunosuppression on COVID-19 outcomes, 
nephrologists must take into consideration the 
possible influence of avoiding immunosuppression 
on the kidney outcomes at the same time. It still 
recommended that patients who are at high risk 
of progression to kidney disease without prompt 
treatment, initiate regular immunosuppression 
regimens.8,9 There is evidence that cyclophosphamide-
based regimens is an important immunosuppressive 
drug for induction therapy in these patients. 
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Erratum information (IJKD_V14_No3): 
On page 184, the name of Elahe Sanei should be added as 5th 
author with following affiliation “Mashhad University of Medical 
Sciences, Mashhad, Iran”. 
On Page 215, Table 2; Alpha Koloto must be changed to Alpha 
Klotho.
On Page 215, Figure explanation must be read as “ It shows 
comparison of alpha klotho levels in exercise and control patients 
(alpha 1: before, alpha 2: after study, darman: exercise)”.
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